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ABSTRACT
PEGylation Stabilizes the Conformation of Proteins and the
Noncovalent Interactions Within Them
Steven R. E. Draper
Department of Chemistry and Biochemistry, BYU
Doctor of Philosophy
PEGylation has been used for decades to enhance the pharmacokinetic properties of
protein therapeutics. This method has been effective at increasing the serum half-life of these
drugs, but the mechanism of how it does this is unclear.
Chapter 1 is an introduction to the methods of PEGylation. In chapter 2 we show that the
effect of PEGylation on the conformational stability of the WW domain differs based on amino
acid linker and conjugation site. We show that all positions in the WW domain that were tested
can be stabilized by at least one amino acid linker. The rate of proteolysis is proportional to the
degree of conformational stability. Chapter 3 shows that PEG-based desolvation can increase the
strength of the interaction between two salt bridge residues, though the effect of structural
context is unclear. A crystal structure shows that PEG occupies the space between the PEGylation
site and the salt bridge, displacing water. In Chapter 4 we discuss the effect that PEGylation has
on the interaction strength of a solvent exposed hydrophobic patch. When the c Log P of the
hydrophobic patch increases, PEG increases the conformational stability of the WW domain
more dramatically. Chapter 5 is about the effect of PEG based desolvation on the strength of an
NH-π hydrogen bond in the WW domain between Trp11 and Asn26. When Trp11 is mutated to
Phe, Tyr and naphthylalanine (Nal), the melting temperatures correlate with the calculated
interaction energies between the sidechain arene of the hydrogen bond acceptor and formamide.
When Asn26 is PEGylated in the presence of each of these amino acids, the effect that PEG has
on the conformational stability of the WW domain correlates with the melting temperature of
the nonPEGylated variants, the calculated interaction energies, the arene molecular polarizability,
and the arene molar volume.

Keywords: PEG, PEGylation, conformational stability, protein therapeutics, desolvation,
noncovalent interactions
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1 INTRODUCTION
Proteins are attractive targets to use as therapeutics for various diseases.1-3 Proteins have been
used as drugs with success, but they are subject to the body’s natural mechanisms for recycling
and expelling proteins (such as proteolysis, antibody recognition and renal filtration) which shorten
the half-life of the drug significantly.4-9 This results in patients having to inject these protein
therapeutics frequently.10 PEGylation, the conjugation of polyethylene glycol (PEG), was
developed in the 1970s and has been used since to increase the pharmacokinetic properties of
protein therapeutics and combat their negative side effects.4, 5
Polyethylene glycol (PEG) is a polymer made from the anionic ring opening of ethylene oxide
and terminated with a hydroxyl group (yielding a diol PEG) or and ethylene oxide group (yielding
a hydroxy methyl PEG). PEG is soluble in organic and aqueous solvents and, on average, adsorbs
2-3 water molecules per ethylene oxide unit.6, 11 PEG increases the solubility of protein drugs6 and
its water adsorption properties increases its hydrodynamic radius, making it appear as if it is up to
10 times larger than a protein of a comparable molecular weight.6, 11 This conjugation increases
the hydrodynamic radius and solubility of the PEG-protein conjugate which can increase
proteolytic resistance, decrease antibody recognition, protect from aggregation and decrease renal
clearance,4-8, 12 all of which increase the circulation half-life of the protein drug. The impact of
PEGylation on the pharmacokinetic properties of proteins has been reviewed extensively
elsewhere.13, 14
Many previous reviews of protein PEGylation contrast first-generation nonspecific methods
with second-generation site-specific methods.6,

11, 15-17

In a recent publication Levine et al.18

suggested that PEGylation methods can be grouped according to their reliance on intrinsic vs
1

extrinsic amino acid reactivity; we have followed their approach in this review. Intrinsic reactivity
comprises the inherent nucleophilicity of the unmodified proteinogenic amino acids (e.g., the Cys
thiol; the Lys ε-amine, etc.). In contrast, extrinsic reactivity must be incorporated into proteins
from an exogenous source, typically a non-proteinogenic amino acid with a unique bioorthogonal
functional group that can participate in a reaction not available to the canonical proteinogenic
amino acids.
PEGylation methods that take advantage of intrinsic amino acid reactivity can be nonspecific,
site-directed, or site-specific; methods that depend on extrinsic amino acid reactivity are typically
site-directed or site-specific. Nonspecific methods involve PEGylation reagents that are reactive
to more than one kind of protein side-chain or backbone nucleophile. Site-directed and site-specific
methods both rely on PEGylation reagents with a strong preference for a particular reactive
functional group. However, site-specific methods involve proteins with just one instance of this
group vs. multiple instances for site-directed methods.
1.1 Intrinsic Amino Acid Reactivity
As described above, proteinogenic amino acids have many functional groups with potential
nucleophilicity, including the Cys thiol; the Lys ε-amine; the Ser, Thr, or Tyr alcohols; the Asp
and Glu carboxylates; the Trp indole and His imidazole nitrogens; and the Asn and Glu amides.
Nonspecific, site-directed, and site-specific PEGylation methods for targeting these nucleophilic
groups are summarized in the following sections.
1.1.1 Nonspecific Conjugation: One of the first PEGylation strategies was developed by
Abuchowski et al.4,

5

and it involved introducing a PEG dichlorotriazine to the protein.
2

Figure 1. Depiction of nonspecific PEGylation methods by intrinsic reactivity. A) Nonspecific PEGylation with
dichlorotriazine-PEG. This method conjugates to lysine, serine, tyrosine, cysteine, and histidine. B) Nonspecific
PEGylation with a PEG-tresylates reagent. C) Nonspecific PEGylation with succinimidyl carbonate-PEG. This
method reacts with lysine, tyrosine, and histidine.

Dichlorotriazine (Figure 1A) is a good electrophile and attaches to any respectable nucleophile on
the surface of a protein, such as lysine, serine, threonine, tyrosine, cysteine, and histidine.
Abuchowski et al.5 used this method to PEGylate Bovine serum albumin (BSA). The resulting
PEG-BSA conjugate (modified at an undetermined subset of an estimated 60 possible sites) was
not immunogenic in rabbits, unlike its non-PEGylated counterpart.5 In another study, the same
authors attached PEG to 43% of the amino groups in bovine liver catalase using dichlorotriazine.
The enzyme retained most of its activity and was resistant to proteases.4
Other nonspecific PEG electrophiles include PEG-tresylates (Figure 1B), which react
preferentially with amies but do not generally distinguish between the N-terminal α-amine vs. the
Lys ε-amine19, 20 and succinimidyl carbonate (Figure 1C), which reacts preferentially with lysine
to form a carbamate linkage but can also react with tyrosine and histidine.11, 21

3

These nonspecific methods generally result in heterogeneous mixtures of PEGylated isoforms
that differ in the number and location of conjugation sites. Most nonspecifically PEGylated
proteins have decreased immunogenicity and increased proteolytic stability and serum half-life
relative to their non-PEGylated counterparts. However, nonspecific PEGylation frequently
decreases in vitro activity, presumably due to PEGylation events within or near active sites or
because the large hydrodynamic radii of the conjugated PEGs limit access to substrates or binding
partners. Chemists have begun to address this problem by developing site-directed and site-specific
conjugation PEGylation methods (summarized below) that can exercise greater control over the
number and location of conjugation sites.
1.1.2 Site-Directed vs. Site-Specific Conjugation: Cysteine is the most frequently targeted
amino acid for intrinsic PEGylation methods; the soft nucleophilicity of the Cys thiol makes it
reactive toward PEGylation reagents that are not reactive toward harder nucleophiles like the Lys
ε-amine. Cys-PEGylation methods can be site-specific or site-directed, depending on whether the
protein of interest has more than one Cys. Because Cys is incorporated into proteins with much
lower frequency (~1%) than the other 19 proteinogenic amino acids,22 many proteins have no Cys
residues; many others have only one. Proteins with only one Cys can be PEGylated sitespecifically; mutagenesis to introduce a single Cys into a protein with no native Cys residues is
usually trivial.11, 15 In contrast, efforts to PEGylate a protein with multiple cysteines typically rely
on the increased accessibility of surface vs. buried Cys residues. Alternatively, others have
engineered proteins with multiple Cys residues by removing undesired Cys conjugation sites.

4

Figure 2. Depiction of site-directed PEGylation methods by intrinsic reactivity. A) Site-directed PEGylation with
PEG-maleimide. This method is selective for cysteine. B) Site-directed PEGylation with a PEG-acrylate. This method
is selective for cysteine. C) Mechanism for site-directed PEGylation of a disulfide bridge with dithiomaleimide-PEG.
This is selective towards disulfide bridges. D) Another example of site-directed PEGylation of a disulfide bridge. E)
Site-directed acylation of primary amines. Site directed toward the N-terminus at low pH. F) Site directed reductive
amination to alkylate primary amines. Selective toward the N-terminus at low pH.

The most common Cys-PEGylation method is conjugate addition of the Cys thiol to a PEG5

maleimide (Figure 2A). Pan et al.23 used this approach to PEGylate tumor necrosis factor-related
apoptosis-inducing ligand (TRAIL) by incorporating Cys in place of a native Asn residue at a
potential glycosylation site. The resulting Cys-PEGylated TRAIL had a longer half-life and better
anti-tumor activity than N-terminally PEGylated (see the N-terminal PEGylation section below).
Qiu et al.24 used the maleimide strategy to modify human thyroid hormone (HTH) with PEG chains
of varying length. The activity of the resulting PEG-HTH conjugates decreased with increasing
PEG length, whereas circulation half-life increased. Maleimide-based Cys-PEGylation similarly
increased the half-lives of Glucagon-like peptide 125 and of a bispecific single-domain antibodylinked Fab.26
A related Cys-PEGylation method involves conjugate addition to a PEG-acrylate (Figure 2B).
In one study, the authors used a PEG-acrylate to PEGylate HIV-1 fusion inhibitors based off of
the HR2 region of gp41.27 The inhibitors form a six-helix bundle with the HIV-1 binding proteins,
competing for binding with the proteins on the cell. They introduced Cys residues into their
therapeutic peptide at non-interacting surface exposed positions of the six-helix bundle. They
found that PEGylation at these sites decreased in vitro activity, but not as much as PEGylation at
the N-terminus, C-terminus, or at interacting positions of the helix bundle.
Cysteine PEGylation can be very effective and can be made site-specific through mutagenesis,
as mentioned above. This can have negative effects on protein folding. Introducing a non-native
free Cys into a peptide can induce disulfide scrambling with existing disulfide bonds or cause
protein dimerization between the introduced free Cys.15 Even with these potential pitfalls, this
method has shown to be effective.

6

Disulfide PEGylation is a type of Cys PEGylation but it involves the bridging of the two
disulfide residues with a single bis-electrophile PEGylation reagent. This forms a non-reduceable
disulfide surrogate. This strategy eliminates the need to mutate in non-native Cys residues, thereby
reducing the chances of intermolecular disulfide formation and/or disulfide scrambling.15 Balan et
al.28 reduced the disulfide within L-asparaginase, and then alkylated the resulting free Cys thiols
using a PEGylated α,β-unsaturated β′-monosulfone. (Figure 2C). Schumacher et al.29 reduced the
disulfide bridge in somatostatin with TCEP and then alkylated the resulting free Cys thiols with a
PEG-dithiomaleimide (Figure 2D). The resulting PEG-protein conjugate retained bioactivity.
Robin et al.30 took advantage of the fluorescent properties of dithiomaleimide to simultaneously
PEGylate and fluorescently label salmon calcitonin.
Lysine can be targeted rather specifically but has a much higher frequency than Cys (~6%),
with many proteins containing multiple Lys residues.15, 22 This often results in multiple PEGylation
events occurring at different positions in the same protein, making Lys PEGylation a site-directed
method. This method can become site-specific by reducing the amount of Lys residues in a protein.
Lys can be PEGylated using methoxy-PEG-succinimidyl propionate (PEG-NHS, Figure 2E).31,
32

Narimatsu et al.31 used saturation mutagenesis and phage display to create a library of Lys-

deficient variants of lymphotoxin-α. After several rounds of selection, they eventually found a
variant that contained only one lysine and maintained the same bioactivity as the wild-type variant.
They PEGylated that Lys residue using PEG-NHS and found that their site-directed PEGylation
only reduced the activity by 50% whereas nonspecific PEGylation reduced it to 10%. Morishige
et al.

32

PEGylated a tumor necrosis factor superfamily member (LIGHT), a potential protein

7

candidate for cancer therapy, using the same method. The resulting PEG-protein had identical in
vitro activity to non-PEGylated LIGHT.
The N-terminal ammonium group of a protein has a pKa of 7.8, whereas the ε-ammonium on
lysine has a pKa of 10.1. At low pH, the lysine groups are charged while the N-terminal amine is
not.15 Chemists have taken advantage of these properties to preferentially modify the N-terminus,
giving a mono-PEGylated product with yields from 30-90%33-35 In many cases, a substantial
amount of bis-PEGylated protein is also observed, presumably due to the inadvertent PEGylation
of a Lys residue. Kinstler et al.34 used acylation (Figure 2E) and alkylation (Figure 2F) to
preferentially PEGylate the N-terminus of recombinant human granulocyte colony stimulating
factor. They wanted to assess the impact of charge at the PEGylation site (the alkylation product
is charged while the acylation product is not) on the properties of the resulting PEG-protein
conjugates. They saw less aggregation with alkylation, potentially because the retention of the
charged ammonium at the N-terminus increases solubility.
Transglutaminase is an enzyme that catalyzes the transamidation reaction between an amino
group on a lysine residue from one protein and an amide group on a glutamine from another protein
via an amide bond.36 In the food industry this enzyme is called “meat glue” because the
crosslinking reaction causes liquified meat to thicken.37 The substrate scope of transglutaminases
is not limited to Lys: transglutaminase has been used to PEGylate proteins with a primary PEGamine, though multiple PEGylation events can occur if there are multiple glutamines in the protein.
Glutamine is incorporated into proteins with a frequency of 4% (lower than Lys but greater than
Cys). This raises the potential for Gln-PEGylation to be site-specific rather than site-directed,
especially since transglutaminase appears to preferentially modify Gln residues within flexible
8

regions of proteins.38 For example, only Gln 91 was PEGylated in apomyoglobin even though
there are many Gln residues in the protein (presumably because Gln 91 is in a flexible region).38
PEGylation by transglutaminase has shown many of the positive effects of other PEGylation
methods, such as decrease in antigenicity39 and increase in serum half-life.10
Researchers have recently started exploring the possibility of noncovalent PEGylation. The
method usually entails attaching a functional group to PEG that elicits a strong noncovalent
interaction with specific residues or regions of a protein. Though the interactions are transient,
noncovalent PEGylation retains many of the benefits of conventional PEGylation while avoiding
permanent chemical changes to the protein.
One approach is to target histidine. Many proteins have a poly-histidine tag on their N- or Cterminus for purification with Ni-NTA resin after overexpression. Recently, Kim et al.40 used a
PEG chain with Ni-NTA moieties to noncovalently PEGylate a histidine tag on tumor necrosis
factor-related apoptosis inducing ligand (TRAIL). They found that PEG attached to the His tag
best when the PEG chain had two Ni-NTA groups. The resulting PEG-TRAIL conjugate was less
prone to aggregation but had lower in vitro activity. In addition, the circulation half-life of their
PEGylated drug increased relative to the non-PEGylated drug in a rat model. Histidine has about
a 2% frequency in proteins, making this a promising site-directed PEGylation method.

9

Figure 3. Site-specific PEGylation using Ser/Thr ligation techniques. Yields a native peptide bond and a native
Ser/Thr residue after cleaving with TFA.

Others have used cation-anion interactions to noncovalently PEGylate proteins. Kurinomaru
et al.41 PEGylated densely negatively charged L-Asparaginase using a PEG chain that was
functionalized with positive charges. PEG bound to the protein without decreasing solubility and
the PEG-protein conjugate had increased proteolytic resistance. Another lab42 attached PEG to a
negatively charged macrocycle (sulfonatocalix[4]arene). The resulting molecule bound to
positively charged residues of a model protein.
Many native chemical ligation techniques have been developed to connect peptide fragments
by a native peptide bond, most of which involve N-terminal Cys residues and C-terminal
thioesters. Marsac et al.43 used a PEG-thioester to PEGylate a protein with an N-terminal cysteine.
The thioester undergoes reversible transthioesterification with the Cys thiol, which places the Nterminal amine close enough to the thioester to rearrange for irreversible S- to N-acyl transfer. This
reaction

is

site-specific

to

N-terminal

Cys

residues

because

potential

competing

transthioesterification reactions with internal Cys residues are reversible.
Native chemical ligation is also possible with N-terminal serine or threonine residues.44 Levine
et al.18 used Ser/Thr ligation to site-specifically PEGylate the N-terminus of a protein fragment of
biologically expressed bovine pancreatic ribonuclease A using a PEG-salicylaldehyde ester
10

(Figure 3). This approach results in irreversible N-terminal PEGylation via a native peptide bond
along with an unmodified Ser/Thr side chain after cleavage with TFA.
1.2 Extrinsic Amino Acid Reactivity
PEGylation by extrinsic reactivity is accomplished by incorporating a non-proteinogenic
amino acid or selectively changing a functional group in the protein to elicit chemoselective
bioorthogonal reactivity that is not available to the canonical proteinogenic amino acids.
PEGylation methods that depend on extrinsic reactivity are typically site-directed or site-specific.
Incorporating non-proteinogenic amino acids into proteins can be challenging; selected approaches
are discussed below; a more comprehensive treatment is available in several recent reviews.45, 46
1.2.1 Site-Directed Conjugation: Auxotrophic bacterial strains cannot synthesize one or more
of the 20 proteinogenic amino acids.47,

48

In some cases, feeding these bacteria an unnatural

analogue in place of the amino acid they cannot synthesize results in proteins where the unnatural
analogue replaces its proteinogenic counterpart. For instance, azidohomoalanine and
homopropargyl glycine can be incorporated into proteins as methionine surrogates in Metauxotrophic bacteria and subsequently functionalized via the chemoselective reactions discussed
below. This approach generally replaces all instances of Met with the unnatural analogue, meaning
this method can be site-specific or site-directed depending on the presence of one vs. many native
Met residues.
Schoffelen et al.49 used autotrophic expression to incorporate azidohomoalanine (Aha) in place
of two Met residues within Candida antarctica Lipase B. Copper-catalyzed azide-alkyne
cycloaddition (CuAAC) with a PEG-alkyne functionalized only the surface-exposed Aha (Figure
11

Figure 4. Depiction of site-directed PEGylation methods by extrinsic reactivity. A) Site-directed PEGylation with
azidohomoalanine. It is usually incorporated via auxotrophic expression as a methionine surrogate and functionalized
with a PEG-alkyne using copper-catalyzed azide/alkyne cycloaddition (CuAAC). B) Site-directed PEGylation with
azidohomoalanine and PEGylated using Staudinger ligation. C) Site-directed PEGylation with homopropargylglycine.
It is usually incorporated via auxotrophic expression as a methionine surrogate and functionalized with an iodoarylPEG using palladium as a catalyst.

4A); presumably the buried Aha remained inaccessible during the reaction. Cazalis et al.

50

incorporated Aha into a protein via the same method, but used the Staudinger ligation between the
Aha azide and a triarylphosphine−PEG reagent to form an amide linkage (Figure 4B). The
triarylphosphine in this methods oxidizes and there is some evidence that suggests that phosphine
oxides are toxic;51 their impact should be explored further before this method is used more broadly.
Li et al.52 incorporated homopropargylglycine (Hpg) into ubiquitin as a methionine surrogate
using auxotrophic expression. They conjugated PEG to their protein by reacting the alkyne on Hpg
with an iodoaryl-PEG using a Pd-catalyzed Sonogashira cross-coupling reaction (Figure 4C).
12

Figure 3. Depiction of site-specific PEGylation methods by extrinsic reactivity. A) Intein ligation using hydrazine to
capture the thioester intermediate. B) Intein ligation using a thiol to capture the thioester intermediate to give a
thioacid.

1.2.2 Site-Specific Conjugation: Inteins are proteins that catalyze their own splicing
reaction.53 This reaction happens via a thioester intermediate, which can be intercepted by an
exogenous nucleophile, resulting in a C-terminally modified protein that can be further
functionalized.54 Thom et al.55 captured the thioester intermediate with hydrazine. They then used
a pyruvyl functionalized PEG to PEGylate via a hydrazone linkage (Figure 5A). Another study56
uses intein thioester cleaving conditions that leave a thioacid on the C-terminus. They then
PEGylate with a sulfonamide functionalized PEG (Figure 5B).
Amber suppression is a method that hijacks the molecular machinery of a cell to incorporate
nonproteinogenic amino acids into proteins.46, 57, 58 This is done by acylating the cognate tRNA of
the amber codon (a stop codon in E. coli) with a nonproteinogenic amino acid; the resulting aminoacyl tRNA then delivers the non-proteinogenic amino acid to the ribosome, where it is incorporated

13

Figure 4. Depiction of site-specific PEGylation methods by extrinsic reactivity. A) Site-specific PEGylation with pacetylphenylalanine incorporated by amber suppression and PEGylated with a PEG-oxyamine. B) Site-specific
PEGylation with Pyrroline−carboxylysine incorporated by amber suppression and PEGylated via reductive amination.
C) Site-specific PEGylation with p-iodophenylalanine incorporated by amber suppression and PEGylated via SuzukiMiyaura coupling. D) Site-specific PEGylation with azido-phenylalanine incorporated via amber suppression and
PEGylated via CuAAC and a PEG-alkyne. E) Site-specific PEGylation with propargyloxy phenylalanine incorporated
via amber suppression and PEGylated via CuAAC and a PEG-azide. F) Site-specific PEGylation with
propargylglycine incorporated via solid phase peptide synthesis (SPPS) and PEGylated via CuAAC using a PEGazide.

into the nascent polypeptide wherever the amber codon appears in the mRNA transcript. The
14

original strategy involved chemical tRNA acylation followed by injection of the amino-acyl tRNA
into cells.46, 57 Now this process can be done completely within E. coli using an engineered aminoacyl-tRNA synthetase to charge the amber tRNA with a specific nonproteinogenic amino acid.
Bacteria equipped with these tools can obtain the nonproteinogenic amino acid in their expression
media, allowing site-specific incorporation into proteins, though often in low yields.58, 59
p-Acetylphenylalanine (pAcF) can be incorporated into proteins via amber suppression and
subsequently functionalized with a PEG-oxyamine via an oxime linkage (Figure 6A).60, 61 Cho et
al.60 PEGylated human growth hormone at position 35 using this method. In a clinical study, they
found that it had greater potency than the non-PEGylated variant and required a lower injection
frequency to be effective in patients. Another study61 showed that half-life of PEGylated Fibroblast
growth factor 21 increased when the pAcF-PEGylation site was remote from the active site.
Pyrroline−carboxylysine (PyrLys) and p-iodophenylalanine (pIF) can also be incorporated into
proteins via amber suppression. PyrLys can be modified with PEG-linked 2-aminobenzaldehyde
or a 2-aminobenzophenone via a ring-formation/condensation reaction that forms a tertiary amine
upon reduction (Figure 6B).62 pIF can be modified with a PEG-linked boronic acid via a Pdcatalyzed Suzuki-Miyaura coupling reaction (Figure 6C).63
Wilding et al.64 used amber suppression in a cell-free expression system to generate six T4
lysozyme variants in which a p-azidophenylalanine (pAzF) residue was incorporated at one of six
possible PEGylation sites; the resulting variants were modified with a PEG alkyne via CuAAC
(Figure 6D). They found that the effects of PEGylation on the thermal stability of their protein
varied from site to site in ways that they were not able to predict.

15

The most strait forward method to incorporate a nonproteinogenic amino acid into a protein
site-specifically is via solid-phase peptide synthesis (SPPS). Jølck et al.65 used SPPS to incorporate
propargyl glycine into a protein, which they subsequently functionalized with a PEG-azide via
CuAAC (Figure 6E). This method is not as practical for larger proteins, as the increase in size of
the protein increases the difficulty of the synthesis.
1.3 The Effect of PEGylation on Noncovalent Interactions
Proteins with high conformational stability are less susceptible to proteolysis, aggregation, and
recognition by antibodies. PEG has been shown to increase the conformational stability of proteins
leading to an increase in resistance to these negative pharmacokinetic properties.66, 67 Predicting
sites where PEGylation increases conformational stability (and therefore, the pharmacokinetics of
the protein) has proven to be a difficult endeavor, and generally remains an empirical matter of
trial and error. Understanding how PEGylation effects noncovalent interactions could be an
important step to predicting favorable PEGylation sites. Chapters 3, 4 and 5 of this work discusses
this matter in further detail, but here we give a brief review of what is known about the effect of
PEGylation on noncovalent interactions.
Jain et al.68 performed molecular simulations that suggest that PEG can interact with the
ammonium groups of Lysine residues and stabilize the helical conformation of their simulated
peptide. Hamed et al.69 also show by molecular dynamic simulations that PEG can affect
noncovalent interactions. Their data suggests that PEG is close enough to the surface of the model
system, 1CW, for the oxygen atoms to interact with lysine residues. The PEG molecule also shields
hydrophobic surface area from water, increasing the strength of the interaction between the
hydrophobic residues.
16

Inspired by this molecular dynamics study, Pandey et al.70 used a PEG maleimide to PEGylate
1CW, and hopefully increase conformational stability. They found that the interactions proposed
by Hamed et al.69 were not energetically significant; however, they did find that there is a favorable
three-way interaction between PEG maleimide and two flanking lysine residues. They postulate
that it is because of a favorable interaction between two Lys residues and the maleimide moiety.
They did not confirm that PEG was affecting this interaction, but a triple mutant cycle analysis
experiment using a Cys conjugated maleimide as a control for the PEG-maleimide would reveal
the answer.
1.4 Conclusion and Goals
Here we have discussed the various methods of PEGylation and the classes in which they can
be organized. Researchers have done much work to develop methods to PEGylate specific amino
acids, incorporate non-proteinogenic amino acids for conjugation, and PEGylate specific sites.
With all these techniques, one thing that remains consistent is the inconsistency. While it is true
that PEGylation generally increases solubility and circulation half-life, the effect on activity varies
on a case-by-case basis. Mu et al.61 have shed light on this by showing that the effect of PEGylation
on activity varies based on the PEGylation site, but the current method to identify the optimum
site is still an empirical matter of trial and error. We wondered whether there are structure or
sequenced based criteria to select favorable PEGylation sites, so we have turned to a study of
protein conformational stability to help solve this problem.
Conformational stability is related to the circulation half-life and activity of protein drugs.
Some of the major pathways by which proteins are removed from circulation are through
proteolysis and aggregation. These negative effects are reduced when the protein has increased
17

conformational stability.71-77 The folded structure of a protein is also related directly to activity
since the shape of a protein is what gives it function. It is known that PEGylation can increase,
decrease, or have no effect on protein conformational stability, but there are no clear guidelines on
how to predict these effects. Our goal in the Price lab is to develop these guidelines so that we can
predict favorable PEGylation sites. We hypothesize that optimal sites will be those where PEG
enhances conformational stability; this enhancement will compound the already beneficial effects
of PEGylation.
In this work we will look at the effects of PEGylation on the conformational stability of various
model peptide systems. Chapter 2 discusses the effect that PEGylation has on the WW domain
when it is conjugated to different positions using various conjugation methods. Chapters 3, 4 and
5 explore the mechanism of PEG-based increases in conformational stability. We do this by
analyzing how PEG-based desolvation affects the strength of salt bridges (Chapter 3), hydrophobic
interactions (Chapter 4), and NH-π hydrogen bonds (Chapter 5).
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2 POLYETHYLENE GLYCOL BASED CHANGES TO Β‑SHEET PROTEIN
CONFORMATIONAL AND PROTEOLYTIC STABILITY DEPEND ON
CONJUGATION STRATEGY AND LOCATION
*Reproduced with permission from Bioconjugate Chem. 2017, 28, 10, 2507–2513 Copyright 2017 American
Chemical Society.
*Paul Lawrence and Steven Draper contributed equally to the work in this chapter. Paul Lawrence synthesized
all the PEGylated amino acids and synthesized and collected the Thermal CD data for the PEGylated and
nonPEGylated variants for Asn–PEG, Aha–PEG and PrF–PEG. Steven Draper synthesized and collected the
thermal CD data for the Gln–PEG peptide variants and collected all the proteolysis data.

2.1 Introduction
We recently showed that modifying the side-chain amide nitrogen of an Asn residue at certain
positions within the WW domain of the human protein Pin 1 with a 190 Da monomethoxyPEG
(i.e., four ethylene oxide units) substantially increases WW conformational and proteolytic
stability, with optimal increases in proteolytic stability correlated with large increases in protein
conformational stability.1 We chose the WW domain as a model system because its wellcharacterized two-state folding behavior facilitates detailed analysis of its thermodynamic
properties.2-4 Based on a scan of this PEGylated Asn residue at other positions within WW, we
developed a set of structure-based guidelines for identifying stabilizing PEGylation sites and used
these guidelines successfully to identify a stabilizing PEGylation site within a second β-sheet
protein (i.e., the Src SH3 domain).5 However, we subsequently found that using alternative
PEGylation strategies at position 19 can dramatically alter the impact of PEG on WW
conformational stability, depending on the identity of the PEG-protein linker. For example,
modifying a propargyloxyphenylalanine residue (PrF) at position 19 with a PEG azide via the
copper-catalyzed azide−alkyne cycloaddition only slightly stabilizes WW relative to the nonPEGylated variant. In contrast, the PEGylation of azidohomoalanine (Aha) with the corresponding
29

PEG alkyne or of Gln with the corresponding PEG amine is substantially more stabilizing (ΔΔGf
= −0.29 ± 0.03 or −0.40 ± 0.02 kcal/mol, respectively), although neither imparts the same level of
stabilization as does Asn-PEGylation.1
Table 1. Sequences, Melting Temperatures, Folding Free Energies, and Apparent Proteolysis Rate Constants for
PEGylated WW Variants vs Their Non-PEGylated Counterpartsa
Peptide
Sequence
Tm (°C)
ΔΔGf (kcal/mol)
H2N-KLPPGWEKRMQRSSGRVYYFNHITNASQFERPSG-COOH 56.6 ± 0.1
16Q
H2N-KLPPGWEKRMQRSSGRVYYFNHITNASQFERPSG-COOH 63.5 ± 0.1
16Qp
-0.67 ± 0.02
H2N-KLPPGWEKRMXRSSGRVYYFNHITNASQFERPSG-COOH 52.8 ± 0.3
16X
H2N-KLPPGWEKRMXRSSGRVYYFNHITNASQFERPSG-COOH 56.9 ± 0.3
16Xp
-0.39 ± 0.04
H2N-KLPPGWEKRMZRSSGRVYYFNHITNASQFERPSG-COOH 60.3 ± 0.2
16Z
H2N-KLPPGWEKRMZRSSGRVYYFNHITNASQFERPSG-COOH 59.6 ± 0.5
16Zp
0.07 ± 0.05
H2N-KLPPGWEKRMNRSSGRVYYFNHITNASQFERPSG-COOH 50.6 ± 0.2
16N
H2N-KLPPGWEKRMNRSSGRVYYFNHITNASQFERPSG-COOH 60.7 ± 0.3
16Np
-0.90 ± 0.04
H2N-KLPPGWEKRMNRSSGRVYYFNHITNASQFERPSG-COOH 70.3 ± 0.1
16Nbp
-1.70 ± 0.03
H2N-KLPPGWEKRMSRQSGRVYYFNHITNASQFERPSG-COOH 58.5 ± 0.2
18Q
H2N-KLPPGWEKRMSRQSGRVYYFNHITNASQFERPSG-COOH 59.8 ± 0.2
18Qp
-0.12 ± 0.02
H2N-KLPPGWEKRMSRXSGRVYYFNHITNASQFERPSG-COOH 56.1 ± 0.1
18X
H2N-KLPPGWEKRMSRXSGRVYYFNHITNASQFERPSG-COOH 56.1 ± 0.2
18Xp
0.00 ± 0.02
H2N-KLPPGWEKRMSRZSGRVYYFNHITNASQFERPSG-COOH 52.9 ± 0.2
18Z
H2N-KLPPGWEKRMSRZSGRVYYFNHITNASQFERPSG-COOH 53.5 ± 0.4
18Zp
-0.05 ± 0.04
H2N-KLPPGWEKRMSRNSGRVYYFNHITNASQFERPSG-COOH 57.5 ± 0.1
18N
H2N-KLPPGWEKRMSRNSGRVYYFNHITNASQFERPSG-COOH 58.3 ± 0.1
18Np
-0.08 ± 0.02
H2N-KLPPGWEKRMSRNSGRVYYFNHITNASQFERPSG-COOH 57.1 ± 0.1
18Nbp
0.03 ± 0.01
H2N-KLPPGWEKRMSRSQGRVYYFNHITNASQFERPSG-COOH 54.2 ± 0.2
19Q
H2N-KLPPGWEKRMSRSQGRVYYFNHITNASQFERPSG-COOH 58.7 ± 0.2
19Qp
-0.40 ± 0.02
H2N-KLPPGWEKRMSRSXGRVYYFNHITNASQFERPSG-COOH 54.0 ± 0.2
19X
H2N-KLPPGWEKRMSRSXGRVYYFNHITNASQFERPSG-COOH 57.7 ± 0.2
19Xp
-0.29 ± 0.03
H2N-KLPPGWEKRMSRSZGRVYYFNHITNASQFERPSG-COOH 52.3 ± 0.3
19Z
H2N-KLPPGWEKRMSRSZGRVYYFNHITNASQFERPSG-COOH 53.7 ± 0.2
19Zp
-0.13 ± 0.04
H2N-KLPPGWEKRMSRSNGRVYYFNHITNASQFERPSG-COOH 56.1 ± 0.2
19N
H2N-KLPPGWEKRMSRSNGRVYYFNHITNASQFERPSG-COOH 63.8 ± 0.1
19Np
-0.69 ± 0.02
H2N-KLPPGWEKRMSRSNGRVYYFNHITNASQFERPSG-COOH 68.1 ± 0.1
19Nbp
-1.19 ± 0.03
H2N-KLPPGWEKRMSRSSGRVQYFNHITNASQFERPSG-COOH 39.4 ± 0.2
23Q
H2N-KLPPGWEKRMSRSSGRVQYFNHITNASQFERPSG-COOH 34.5 ± 0.3
23Qp
0.23 ± 0.04
H2N-KLPPGWEKRMSRSSGRVXYFNHITNASQFERPSG-COOH 44.7 ± 0.3
23X
H2N-KLPPGWEKRMSRSSGRVXYFNHITNASQFERPSG-COOH 39.5 ± 0.9
23Xp
0.43 ± 0.16
H2N-KLPPGWEKRMSRSSGRVZYFNHITNASQFERPSG-COOH 52.1 ± 0.2
23Z
H2N-KLPPGWEKRMSRSSGRVZYFNHITNASQFERPSG-COOH 55.6 ± 0.2
23Zp
-0.29 ± 0.03
H2N-KLPPGWEKRMSRSSGRVNYFNHITNASQFERPSG-COOH 27.7 ± 0.3
23N
H2N-KLPPGWEKRMSRSSGRVNYFNHITNASQFERPSG-COOH 20.5 ± 0.2
23Np
0.47 ± 0.11
H2N-KLPPGWEKRMSRSSGRVNYFNHITNASQFERPSG-COOH 24.9 ± 0.3
23Nbp
0.18 ± 0.10
a
N = Asn−PEG; = N = Asn−bPEGPEG; Q = Gln−PEG; X = Aha; X = Aha−PEG; Z = PrF; Z = PrF−PEG. Melting
temperatures were determined by variable-temperature circular dichroism (CD) experiments at 50 μM protein
concentration in 20 mM sodium phosphate buffer at pH 7, except for 16N, 16Np, 16Nbp, 18N, 18Np, 18Nbp, 32N,
32Np, and 32Nbp, which were performed at 100 μM protein concentration. PEG-based differences in folding free
energy are given at the melting temperature of the corresponding non-PEGylated protein. The apparent proteolysis
rate constants k and rate constant ratios r were derived from a high-performance liquid chromatography based
proteolysis assay at room temperature, as described in section 2.4.
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Table 2. Sequences, Melting Temperatures, Folding Free Energies, and Apparent Proteolysis Rate Constants for
PEGylated WW Variants vs Their Non-PEGylated Counterpartsa
Peptide
Sequence
Tm (°C) ΔΔGf (kcal/mol)
H2N-KLPPGWEKRMSRSSGRVYYFNQITNASQFERPSG-COOH
27Q
56.4 ± 0.2
H2N-KLPPGWEKRMSRSSGRVYYFNQITNASQFERPSG-COOH
27Qp
53.1 ± 0.1
0.27 ± 0.02
H2N-KLPPGWEKRMSRSSGRVYYFNXITNASQFERPSG-COOH
27X
60.7 ± 0.4
H2N-KLPPGWEKRMSRSSGRVYYFNXITNASQFERPSG-COOH
27Xp
52.1 ± 0.2
0.68 ± 0.04
H2N-KLPPGWEKRMSRSSGRVYYFNZITNASQFERPSG-COOH
27Z
52.0 ± 0.2
H2N-KLPPGWEKRMSRSSGRVYYFNZITNASQFERPSG-COOH
27Zp
59.8 ± 0.3
-0.62 ± 0.03
H2N-KLPPGWEKRMSRSSGRVYYFNNITNASQFERPSG-COOH
27N
54.9 ± 0.1
H2N-KLPPGWEKRMSRSSGRVYYFNNITNASQFERPSG-COOH
27Np
52.6 ± 0.2
0.20 ± 0.02
H2N-KLPPGWEKRMSRSSGRVYYFNNITNASQFERPSG-COOH
27Nbp
41.5 ± 0.3
1.26 ± 0.06
H2N-KLPPGWEKRMSRSSGRVYYFNHIQNASQFERPSG-COOH
29Q
45.3 ± 0.5
H2N-KLPPGWEKRMSRSSGRVYYFNHIQNASQFERPSG-COOH
29Qp
43.3 ± 0.3
0.16 ± 0.06
H2N-KLPPGWEKRMSRSSGRVYYFNHIXNASQFERPSG-COOH
29X
47.6 ± 0.3
H2N-KLPPGWEKRMSRSSGRVYYFNHIXNASQFERPSG-COOH
29Xp
42.2 ± 0.9
0.32 ± 0.07
H2N-KLPPGWEKRMSRSSGRVYYFNHIZNASQFERPSG-COOH
29Z
41.1 ± 0.2
H2N-KLPPGWEKRMSRSSGRVYYFNHIZNASQFERPSG-COOH
29Zp
43.1 ± 0.2
-0.17 ± 0.06
H2N-KLPPGWEKRMSRSSGRVYYFNHINNASQFERPSG-COOH
29N
50.0 ± 0.1
H2N-KLPPGWEKRMSRSSGRVYYFNHINNASQFERPSG-COOH
29Np
56.8 ± 0.1
-0.57 ± 0.01
H2N-KLPPGWEKRMSRSSGRVYYFNHINNASQFERPSG-COOH
29Nbp
58.0 ± 0.1
-0.67 ± 0.02
H2N-KLPPGWEKRMSRSSGRVYYFNHITNAQQFERPSG-COOH
32Q
58.3 ± 0.2
H2N-KLPPGWEKRMSRSSGRVYYFNHITNAQQFERPSG-COOH
32Qp
63.0 ± 0.2
-0.44 ± 0.02
H2N-KLPPGWEKRMSRSSGRVYYFNHITNAXQFERPSG-COOH
32X
62.9 ± 0.3
H2N-KLPPGWEKRMSRSSGRVYYFNHITNAXQFERPSG-COOH
32Xp
62.8 ± 0.3
0.01 ± 0.03
H2N-KLPPGWEKRMSRSSGRVYYFNHITNAZQFERPSG-COOH
32Z
58.8 ± 0.2
H2N-KLPPGWEKRMSRSSGRVYYFNHITNAZQFERPSG-COOH
32Zp
63.8 ± 0.3
-0.33 ± 0.03
H2N-KLPPGWEKRMSRSSGRVYYFNHITNANQFERPSG-COOH
32N
45.1 ± 0.2
H2N-KLPPGWEKRMSRSSGRVYYFNHITNANQFERPSG-COOH
32Np
50.3 ± 0.2
-0.45 ± 0.03
H2N-KLPPGWEKRMSRSSGRVYYFNHITNANQFERPSG-COOH
32Nbp
55.2 ± 0.1
-0.93 ± 0.03
a
N = Asn−PEG; = N = Asn−bPEGPEG; Q = Gln−PEG; X = Aha; X = Aha−PEG; Z = PrF; Z = PrF−PEG. Melting
temperatures were determined by variable-temperature circular dichroism (CD) experiments at 50 μM protein
concentration in 20 mM sodium phosphate buffer at pH 7, except for 16N, 16Np, 16Nbp, 18N, 18Np, 18Nbp, 32N,
32Np, and 32Nbp, which were performed at 100 μM protein concentration. PEG-based differences in folding free
energy are given at the melting temperature of the corresponding non-PEGylated protein. The apparent proteolysis
rate constants k and rate constant ratios r were derived from a high-performance liquid chromatography based
proteolysis assay at room temperature, as described in section 2.4.

Despite their inferiority to Asn-PEG at position 19, Gln-PEG, Aha-PEG, and PrF-PEG are
more straightforward to incorporate into expressed proteins than Asn-PEG because their nonPEGylated counterparts are encodable (Gln without any reengineering of cellular translational
machinery6 and PrF via amber suppression7 or can be incorporated in lieu of existing amino acids
in auxotrophic strains (Aha is a methionine surrogate).8 Moreover, Gln, Aha, and PrF can be
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functionalized with PEG in the context of a native unprotected protein via well-known
chemoselective strategies (i.e., transglutaminase chemistry for Gln10,6 and azide-alkyne
cycloaddition for Aha and PrF).1 We investigated whether Gln-PEG, Aha-PEG, and PrF-PEG
would have a similarly smaller impact on WW stability relative to Asn-PEG at other prospective
sites within WW and whether our structure-based guidelines for identifying stabilizing AsnPEGylation sites in WW would be useful in the context of these alternative PEGylation methods.
2.2 Results and Discussion
We prepared several WW variants in which we incorporated Gln versus Gln-PEG, Aha versus
Aha-PEG, and PrF versus PrF-PEG at positions 16, 18, 23, 27, 29, or 32 (locations where we
previously incorporated Asn versus Asn-PEG;5 see Figure 1). The names and amino acid
sequences of these WW variants appear in Table 1 and 2. For example, Gln and Gln-PEG occupy
position 16 in variants 16Q and 16Qp, respectively; Aha and Aha-PEG occupy position 16 in
variants 16X and 16Xp, respectively; whereas PrF and PrF−PEG occupy position 16 in variants
16Z and 16Zp. Variants in which each of these residues occupy positions 18, 19, 23, 27, 29, and
32 are named via analogous conventions (variants at position 19 were prepared and characterized
previously).1
We used variable-temperature circular dichroism (CD) experiments to assess the
conformational stability of each variant relative to its non-PEGylated counterpart. The results of
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this analysis appear in Table 1 and 2, which
lists the melting temperatures (Tm) of each
variant and folding free energy (ΔΔGf) of
each PEGylated variant relative to its nonPEGylated counterpart at the melting
temperature of the non-PEGylated protein.
To assess how well Gln-, Aha-, and PrFPEGylation mimic the impact of AsnPEGylation on WW stability, we plotted the
ΔΔGf associated with Gln-, Aha-, and PrFPEGylation versus the ΔΔGf associated
with Asn-PEGylation at each of the
positions described above using leastsquares regression to fit each data set to a
linear equation. The results of this analysis
are shown in Figure 2.
The impact of Gln-PEGylation on WW
stability correlates relatively well with that
Figure 5. Structures of PEG-protein linkages involving Asn,
Gln, azidohomoalanine (Aha), and propargyloxyphenylalanine
(PrF) incorporated at the indicated sites within WW.

of Asn-PEGylation (R2 = 0.62 with slope =
0.59 ± 0.21 and intercept = 0.03 ± 0.11),
though Gln−PEGylation is moderately less

stabilizing than Asn-PEGylation. The impact of Aha-PEGylation on WW stability correlates
33

similarly

well

with

that

of

Asn-

PEGylation (R2 = 0.63, with slope = 0.62
± 0.21 and intercept = 0.29 ± 0.11),
although as with Gln-PEGylation, AhaPEGylation is less stabilizing than AsnPEGylation. In contrast, the impact of PrFPEGylation

correlates

weakly

and

inversely with that of Asn-PEGylation (R2
= 0.40 with slope = −0.28 ± 0.15 and
intercept = −0.30 ± 0.08). Despite the poor
correlation

between

PrF-

and

Asn-

PEGylation, it is interesting that PrFPEGylation substantially stabilizes WW at
positions 23 (ΔΔGf = −0.29 ± 0.03
Figure 6. Plots of the impact (ΔΔGf) of Gln-, Aha-, and PrFPEGylation vs the impact of Asn-PEGylation (ΔΔGf) on the
conformational stability of WW at positions 16, 18, 19, 23, 27,
29, and 32.

kcal/mol) and 27 (ΔΔGf = −0.62 ± 0.03
kcal/mol),

locations

where

Asn-

PEGylation was substantially destabilizing (ΔΔGf = 0.47 ± 0.11 kcal/mol at position 23; 0.20 ±
0.02 kcal/mol at position 27). Indeed, it is encouraging that for each position we investigated, at
least one option among Gln-, Aha-, or PrF-PEGylation is substantially stabilizing, suggesting that
matching the appropriate linker to a given site could result in PEG-based stabilization at most
positions in WW and perhaps in other proteins as well.
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Another important determinant of PEG-based stabilization is the structure of the PEG
oligomer. We recently found that the stabilizing impact of Asn-PEGylation of WW at position 19
increases as the PEG oligomer lengthens from one to four ethylene oxide units; increasing PEG
length beyond this point does not substantially change the observed PEG-based stabilization.9
However, alkylating the side-chain amide nitrogen in Asn-PEG with a second four-unit PEG (i.e.,
branched PEGylation) results in a branched PEG-Asn conjugate (i.e., Asn-bPEG, Figure 1) that
has a much more stabilizing impact on WW at position 19 than its linear Asn−PEGylated
counterpart.1 We wondered whether branched Asn-bPEG would have a similarly enhanced effect
on WW conformational stability at the other positions we investigated previously for linear AsnPEG (i.e., positions 16, 18, 23, 27, 29, and 32).
To explore this possibility, we prepared
variants 16Nbp, 18Nbp, 23Nbp, 27Nbp,
29Nbp, and 32Nbp, in which Asn-bPEG
occupies positions 16, 18, 23, 27, 29, and 32,
respectively (variant 19Nbp was prepared and
characterized

previously).1

Melting

temperatures and folding free energies relative
to the corresponding non-PEGylated compound
Figure 7. Plot of the impact of branched AsnbPEGylation vs linear Asn-PEGylation on the
conformational stability of WW at positions 16, 18, 19,
23, 27, 29, and 32.

are shown in Table 1 and 2. The correlation
between the ΔΔGf associated with Asn-bPEG

versus the ΔΔGf associated with Asn-PEG is strong (R2 = 0.77 with slope = 1.8 ± 0.4; Figure 3),
indicating that Asn-bPEG generally has a more pronounced effect on WW stability than does Asn35

PEG. At locations where Asn-PEG is stabilizing, Asn-bPEG is substantially more stabilizing; at
locations where Asn-PEG is destabilizing, Asn-bPEG is substantially more destabilizing.
We previously showed that linear Asn-PEGylation at one or more positions better protects
WW from proteolysis when it also increases protein conformational stability.5 We wondered
whether the same would be true for Gln-, Aha-, PrF-, and branched Asn−PEGylation. To explore
this possibility, we used high-performance liquid chromatography (HPLC) to monitor the amount
of each WW variant remaining in solution after being exposed to proteinase K. We fit the resulting
data for each variant to a monoexponential function, from which we extracted the apparent
proteolysis rate constants (k, s−1). The apparent proteolytic rate constant for each variant is related
to half-life (t1/2, s) according to the following relationship: t1/2 = (ln 2)/k. Consequently, WW
variants with smaller apparent proteolytic rate constants have correspondingly higher half-lives
(i.e., they survive longer in the presence of proteinase K). In general, we find that WW variants
with higher melting temperatures have lower proteolysis rate constants (Figure 4), independent of
whether or not they are PEGylated, suggesting that conformational stability is the major
determinant the proteolytic stability of each WW variant in the presence of proteinase K.
We compared the apparent proteolytic rate constant of each PEGylated WW variant (k) to that
of its non-PEGylated counterpart (k°) using the dimensionless rate constant ratio r (defined as r =
k/k°). PEGylation accelerates proteolysis when r is greater than 1 (i.e., k > k°) and slows proteolysis
when r is less than 1 (i.e., k < k°). We originally envisioned exploring the relationship between r
and the observed PEG-based changes in conformational stability (ΔΔGf) for each sequenced
matched pair of PEGylated versus non-PEGylated WW variants. However, rate constants (and rate
constant ratios) generally have a logarithmic relationship with changes in free energy; ΔΔGf should
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Figure 9. Relationship between apparent proteolysis rate constants and melting temperatures for the PEGylated WW
variants described above, along with their non-PEGylated counterparts, across all positions investigated.

Figure 8. Plots of the natural logarithm of r (i.e., the ratio of apparent proteolysis rate constants for PEGylated vs nonPEGylated WW variants) vs PEG-based changes in WW conformational stability (ΔΔGf) for (A) all linker types, and
for each individual linker type, including (B) linear Asn-PEGylation, (C) branched Asn-PEGylation, (D) GlnPEGylation, (E) Aha-PEGylation, and (F) PrF-PEGylation.
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be more directly related to ln(r) than to r. Therefore, we used ln(r) as an alternative indicator of
the proteolytic stability of each PEGylated variant relative to its non-PEGylated counterpart:
PEGylation increases proteolytic stability when ln(r) is negative and decreases proteolytic stability
when ln(r) is positive.
Figure 5A shows the combined ln(r) versus ΔΔGf data for all PEGylation sites and methods
described above. We fit these combined data to a linear equation via least-squares regression; the
resulting slopes and intercepts are given ± standard error in Figure 5A, with R2, F, and p values as
indicated. The negative y-intercept from this combined analysis suggests that PEGylation
generally enhances WW proteolytic stability by a small baseline amount even when ΔΔGf = 0.
However, the extent of this favorable baseline change in proteolytic stability varies substantially
from one PEGylation method to another (see Figure 5B−F, in which the ln(r) versus ΔΔGf data for
each PEGylation method are analyzed separately). In some cases, baseline changes in proteolytic
stability are unfavorable or are indistinguishable from zero (note the large standard errors and
unacceptably high p values for the y-intercepts in Figure 5B,E,F). For example, PrF-PEGylation
at position 16 accelerates proteolysis by a factor of 3.6, even though it has almost no impact on
WW conformational stability (ΔΔGf = −0.07 ± 0.05 kcal/mol; compare 16Z and 16Zp in Table 1).
The slope for the combined ln(r) versus ΔΔGf data set is positive (Figure 5A); ln(r) tends to
be negative when ΔΔGf is negative and positive when ΔΔGf is positive, indicating that PEG-based
changes in WW conformational and proteolytic stability are tightly coupled. We observer greater
PEG-based increases to proteolytic stability in tandem with larger increases in conformational
stability. For example, branched Asn-PEGylation at position 16 stabilizes WW by −1.70 ± 0.03
kcal/mol (compare 16Nbp and 16N in Table 1) and slows proteolysis by a factor of 10, the highest
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level of proteolytic protection we have observed. In contrast, linear Asn-PEGylation at the same
position only stabilizes WW by −0.90 ± 0.04 kcal/mol (compare 16Np and 16N in Table 1); the
associated increase in proteolytic stability is correspondingly smaller. PEG-based decreases in
conformational stability and proteolytic stability are similarly coupled: branched Asn-PEGylation
at position 27 destabilizes WW by 1.26 ± 0.06 kcal/mol (compare 27Nbp and 27N in Table 2)and
accelerates proteolysis by a factor of 2.8. Slopes obtained from separate analyses of the ln(r) versus
ΔΔGf data for each PEGylation method lead to qualitatively similar conclusions, although the
small number of points and the substantial variability within each data set make quantitative
comparisons impossible (see Figure 5B−F).
2.3 Conclusions
We have shown here that the impacts of Aha-, Gln-, and branched Asn-PEGylation on WW
conformational stability are correlated reasonably well with that of linear Asn-PEGylation,
suggesting that the structure-based criteria developed previously for identifying stabilizing linear
Asn-PEGylation sites5 should be useful for identifying stabilizing Aha-, Gln-, and branched AsnPEGylation sites. In contrast, the impact of PrF-PEGylation on WW conformational stability does
not correlate well with that of Asn-PEGylation. However, we note with interest that two
destabilizing Asn-PEGylation sites are substantially stabilized by PrF-PEGylation, suggesting the
intriguing possibility that most prospective PEGylation sites can experience PEG-based increases
to conformational stability when matched with the appropriate PEG-protein linker.
We have also shown that the impact of PEGylation on the proteolytic stability of each WW
variant depends strongly on how PEG affects conformational stability for each PEG-protein linker
explored here. The largest PEG-based reductions in proteolysis rate are strongly associated with
39

the largest PEG-based increases in conformational stability. These results demonstrate that
choosing the appropriate PEGylation site and PEG-protein linker is critical for attaining optimal
PEG-based increases to conformational and proteolytic stability in the model protein WW,
highlighting the continuing need for predictive structure-based tools to guide such choices. Efforts
to apply this knowledge to proteins of therapeutic interest are underway.
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2.4 Supporting Information

2.4.1 Protein Synthesis, Purification, and Characterization: Proteins 16N, 16Np, 18N,
18Np, 19Q, 19Qp, 19X, 19Xp, 19Z, 19Zp, 19N, 19Np, 19Nbp, 23N, 23Np, 27N, 27Np, 29N,
29Np, 32N, and 32Np (sequences shown in Table S1) were synthesized previously.1,

5

The

remaining WW variants shown in Table 1 were synthesized as C-terminal acids by Fmoc-based
microwave-assisted solid-phase peptide synthesis as described previously,1 using the following
reagents: Fmoc-Gly-loaded Novasyn Wang resin (EMD Biosciences); standard Fmoc-protected αamino acids with acid-labile side-chain protecting groups (EMD Biosciences or Advanced
ChemTech);

previously

synthesized

Fmoc-L-GlnPEG4-OH

[18-((((9H-fluoren-9-

yl)methoxy)carbonyl)amino)-15-oxo-2,5,8,11-tetraoxa-14-azanonadecan-19-oic acid],1 used to
prepare proteins 16Qp, 18Qp, 23Qp, 27Qp, 29Qp, and 32Qp; commercially available Fmoc-L4-azidohomoalanine, used to prepare proteins 16X, 18X, 23X, 27X, 29X, and 32X; previously
synthesized PEG-alkyne 2,5,8,11-tetraoxatetradec-13-yne10 used to prepare 16Xp, 18Xp, 23Xp,
27Xp, 29Xp, and 32Xp from proteins 16X, 18X, 23X, 27X, 29X, and 32X via the copper (I)
catalyzed azide-alkyne cycloaddition1; previously synthesized Fmoc-L-PrF-OH N-[(9H-Fluoren9-ylmethoxy)-O-2-propyn-1yl-L-tyrosine11, used to prepare proteins 16Z, 18Z, 23Z, 27Z, 29Z,
and 32Z; commercially available PEG-azide 13-azido-2,5,8,11-tetraoxatridecane, used to prepare
proteins 16Zp, 18Zp, 23Zp, 27Zp, 29Zp, and 32Zp from proteins 18Z, 23Z, 27Z, 29Z, and 32Z
via the copper (I) catalyzed azide-alkyne cycloaddition1; previously synthesized Fmoc-L(AsnPEG4)2-OH

[(S)-17-((((9H-fluoren-9-yl)methoxy)carbonyl)amino)-15-oxo-14-(2,5,8,11-

tetraoxatridecan-13-yl)-2,5,8,11-tetraoxa-14-azaoctadecan-18-oic acid],1 used to prepare proteins
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16Nbp, 18Nbp, 23Nbp, 27Nbp, 29Nbp, and 32Nbp; 2-(1H-benzotriazole-1-yl)-1,1,3,3tetramethyluronium hexafluorophosphate (HBTU) and N-hydroxybenzotriazole hydrate (HOBt)
from Advanced ChemTech for amino acid activation; 20% piperidine in N,N-dimethylformamide
for removal of the Fmoc protecting group from the N-terminal α-amine; a solution of a solution of
phenol (0.0625 g), water (62.5 μL), thioanisole (62.5 μL), ethanedithiol (31 μL) and
triisopropylsilane (12.5 μL) in trifluoroacetic acid (TFA, 1 mL) for cleaving the protein from resin
and globally removing acid-labile side-chain protecting groups. Proteins were precipitated from
the TFA solution by addition of diethyl ether (~40 mL). Following centrifugation, the ether was
decanted, and the pellet was dissolved in ~40mL 1:1 H2O/MeCN, then flash frozen over dry ice in
acetone and lyophilized to remove volatile impurities. The resulting powder was stored at -20°C
until purification.
Proteins were purified by preparative reverse-phase high performance liquid chromatography
(HPLC) on a C18 column using a linear gradient of water in acetonitrile with 0.1% v/v TFA.
Fractions containing the desired protein product were pooled, frozen, and lyophilized. Proteins
were identified by electrospray ionization time of flight mass spectrometry (ESI-TOF); expected
and observed exact masses mass spectra appear in Table S1 and spectra appear in Figures S1–S41.
Protein purity was assessed by Analytical HPLC (traces are shown in Figures S42–S86).
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Table S1. Sequences for WW variants, along with expected and observed exact masses from ESI-TOF MS
experiments.

a

Peptide

Sequence

z

16Q
16Qp
16X
16Xp
16Z
16Zp
16Nbp
18Q
18Qp
18X
18Xp
18Z
18Zp
18Nbp
23Q
23Qp
23X
23Xp
23Z
23Zp
23Nbp
27Q
27Qp
27X
27Xp
27Z
27Zp
27Nbp
29Q
29Qp
29X
29Xp
29Z
29Zp
29Nbp
32Q
32Qp
32X
32Xp
32Z
32Zp
32Nbp

H2N-KLPPGWEKRMQRSSGRVYYFNHITNASQFERPSG-COOH
H2N-KLPPGWEKRMQRSSGRVYYFNHITNASQFERPSG-COOH
H2N-KLPPGWEKRMXRSSGRVYYFNHITNASQFERPSG-COOH
H2N-KLPPGWEKRMXRSSGRVYYFNHITNASQFERPSG-COOH
H2N-KLPPGWEKRMZRSSGRVYYFNHITNASQFERPSG-COOH
H2N-KLPPGWEKRMZRSSGRVYYFNHITNASQFERPSG-COOH
H2N-KLPPGWEKRMNRSSGRVYYFNHITNASQFERPSG-COOH
H2N-KLPPGWEKRMSRQSGRVYYFNHITNASQFERPSG-COOH
H2N-KLPPGWEKRMSRQSGRVYYFNHITNASQFERPSG-COOH
H2N-KLPPGWEKRMSRXSGRVYYFNHITNASQFERPSG-COOH
H2N-KLPPGWEKRMSRXSGRVYYFNHITNASQFERPSG-COOH
H2N-KLPPGWEKRMSRZSGRVYYFNHITNASQFERPSG-COOH
H2N-KLPPGWEKRMSRZSGRVYYFNHITNASQFERPSG-COOH
H2N-KLPPGWEKRMSRNSGRVYYFNHITNASQFERPSG-COOH
H2N-KLPPGWEKRMSRSQGRVYYFNHITNASQFERPSG-COOH
H2N-KLPPGWEKRMSRSQGRVYYFNHITNASQFERPSG-COOH
H2N-KLPPGWEKRMSRSXGRVYYFNHITNASQFERPSG-COOH
H2N-KLPPGWEKRMSRSXGRVYYFNHITNASQFERPSG-COOH
H2N-KLPPGWEKRMSRSZGRVYYFNHITNASQFERPSG-COOH
H2N-KLPPGWEKRMSRSZGRVYYFNHITNASQFERPSG-COOH
H2N-KLPPGWEKRMSRSNGRVYYFNHITNASQFERPSG-COOH
H2N-KLPPGWEKRMSRSSGRVQYFNHITNASQFERPSG-COOH
H2N-KLPPGWEKRMSRSSGRVQYFNHITNASQFERPSG-COOH
H2N-KLPPGWEKRMSRSSGRVXYFNHITNASQFERPSG-COOH
H2N-KLPPGWEKRMSRSSGRVXYFNHITNASQFERPSG-COOH
H2N-KLPPGWEKRMSRSSGRVZYFNHITNASQFERPSG-COOH
H2N-KLPPGWEKRMSRSSGRVZYFNHITNASQFERPSG-COOH
H2N-KLPPGWEKRMSRSSGRVNYFNHITNASQFERPSG-COOH
H2N-KLPPGWEKRMSRSSGRVYYFNQITNASQFERPSG-COOH
H2N-KLPPGWEKRMSRSSGRVYYFNQITNASQFERPSG-COOH
H2N-KLPPGWEKRMSRSSGRVYYFNXITNASQFERPSG-COOH
H2N-KLPPGWEKRMSRSSGRVYYFNXITNASQFERPSG-COOH
H2N-KLPPGWEKRMSRSSGRVYYFNZITNASQFERPSG-COOH
H2N-KLPPGWEKRMSRSSGRVYYFNZITNASQFERPSG-COOH
H2N-KLPPGWEKRMSRSSGRVYYFNNITNASQFERPSG-COOH
H2N-KLPPGWEKRMSRSSGRVYYFNHIQNASQFERPSG-COOH
H2N-KLPPGWEKRMSRSSGRVYYFNHIQNASQFERPSG-COOH
H2N-KLPPGWEKRMSRSSGRVYYFNHIXNASQFERPSG-COOH
H2N-KLPPGWEKRMSRSSGRVYYFNHIXNASQFERPSG-COOH
H2N-KLPPGWEKRMSRSSGRVYYFNHIZNASQFERPSG-COOH
H2N-KLPPGWEKRMSRSSGRVYYFNHIZNASQFERPSG-COOH
H2N-KLPPGWEKRMSRSSGRVYYFNHINNASQFERPSG-COOH

4
4
3
3
4
4
4
4
4
3
3
4
4
4
4
4
3
4
4
4
3
4
4
4
4
4
4
3
4
4
3
3
4
4
3
4
4
4
3
4
4
4

Expected
[M+z·H+]/z
1006.76
1054.29
1341.51
1408.72
1025.02
1083.30
1098.32
1006.76
1054.29
1341.34
1408.72
1025.02
1083.30
1098.32
987.72
1035.28
1316.00
1037.78
1006.01
1418.72
1438.74
994.25
1041.78
993.75
1044.28
1012.51
1070.79
1447.41
1003.26
1050.79
1336.67
1404.04
1021.51
1079.80
1459.41
1006.76
1054.29
1006.26
1408.72
1025.02
1083.30
1098.32

Observed
[M+ z·H+]/z
1006.74
1054.29
1341.34
1408.71
1025.03
1083.30
1098.31
1006.75
1054.29
1341.33
1408.70
1025.00
1083.30
1098.31
987.75
1035.28
1315.99
1037.78
1005.99
1418.74
1438.77
994.25
1041.80
993.75
1044.28
1012.50
1070.78
1447.44
1003.25
1050.79
1336.67
1404.04
1021.52
1079.82
1459.42
1006.76
1054.29
1006.25
1408.69
1025.03
1083.30
1098.31

N = Asn-PEG; N = Asn-branched PEG; Q = Gln-PEG; X = Aha; X = Aha-PEG; Z = PrF; Z = PrF-PEG.
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Figure S1. ESI-TOF spectrum for WW variant 16Q.

Figure S2. ESI-TOF spectrum for WW variant 16Qp.

Figure S3. ESI-TOF spectrum for WW variant 18Q.
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Figure S4. ESI-TOF spectrum for WW variant 18Qp.

Figure S5. ESI-TOF spectrum for WW variant 23Q.
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Figure S6. ESI-TOF spectrum for WW variant 23Qp.

Figure S7. ESI-TOF spectrum for WW variant 27Q.
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Figure S8. ESI-TOF spectrum for WW variant 27Qp.

Figure S9. ESI-TOF spectrum for WW variant 29Q.
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Figure S10. ESI-TOF spectrum for WW variant 29Qp.

Figure S11. ESI-TOF spectrum for WW variant 32Q.
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Figure S12. ESI-TOF spectrum for WW variant 32Qp.

Figure S13. ESI-TOF spectrum for WW variant 16X.
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Figure S14. ESI-TOF spectrum for WW variant 16Xp.

Figure S15. ESI-TOF spectrum for WW variant 18X.
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Figure S16. ESI-TOF spectrum for WW variant 18Xp.

Figure S17. ESI-TOF spectrum for WW variant 23X.

Figure S18. ESI-TOF spectrum for WW variant 23Xp.
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Figure S1910. ESI-TOF spectrum for WW variant 27X.

Figure S20. ESI-TOF spectrum for WW variant 27Xp.
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Figure S20. ESI-TOF spectrum for WW variant 29X.

Figure S21. ESI-TOF spectrum for WW variant 29Xp.
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Figure S22. ESI-TOF spectrum for WW variant 32X.

Figure S23. ESI-TOF spectrum for WW variant 32Xp.

Figure S24. ESI-TOF spectrum for WW variant 16Z.
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Figure S25. ESI-TOF spectrum for WW variant 16Zp.

Figure S26. ESI-TOF spectrum for WW variant 18Z.
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Figure S27. ESI-TOF spectrum for WW variant 18Zp.

Figure S28. ESI-TOF spectrum for WW variant 23Z.

Figure S29. ESI-TOF spectrum for WW variant 23Zp.
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Figure S30. ESI-TOF spectrum for WW variant 27Z.

Figure S31. ESI-TOF spectrum for WW variant 27Zp.
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Figure S32. ESI-TOF spectrum for WW variant 29Z.

Figure S33. ESI-TOF spectrum for WW variant 29Zp.
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Figure S34. ESI-TOF spectrum for WW variant 32Z.

Figure S35. ESI-TOF spectrum for WW variant 32Zp.
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Figure S36. ESI-TOF spectrum for WW variant 16Nbp.

Figure S37. ESI-TOF spectrum for WW variant 18Nbp.

Figure S38. ESI-TOF spectrum for WW variant 23Nbp.
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Figure S39. ESI-TOF spectrum for WW variant 27Nbp.

Figure S40. ESI-TOF spectrum for WW variant 29Nbp.

61

Figure S41. ESI-TOF spectrum for WW variant 32Nbp.

Figure S42. Analytical HPLC Data for WW variant 16Q. Protein solution was injected onto a C18 analytical
column and eluted using a linear gradient of 10-60% B (A=H2O, 0.1% TFA; B= MeCN, 0.1% TFA) over 50
minutes, followed by a 10 minute rinse (95% B), and a 10 minute column re-equilibration (10% B) with a
flow rate of 1 mL/min.
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Figure S43. Analytical HPLC Data for WW variant 16Qp. Protein solution was injected onto a C18 analytical
column and eluted using a linear gradient of 10-60% B (A=H2O, 0.1% TFA; B= MeCN, 0.1% TFA) over 50
minutes, followed by a 10 minute rinse (95% B), and a 10 minute column re-equilibration (10% B) with a
flow rate of 1 mL/min.

Figure S44. Analytical HPLC Data for WW variant 16X. Protein solution was injected onto a C18 analytical
column and eluted using a linear gradient of 10-60% B (A=H2O, 0.1% TFA; B= MeCN, 0.1% TFA) over 50
minutes, followed by a 10 minute rinse (95% B), and a 10 minute column re-equilibration (10% B) with a
flow rate of 1 mL/min.
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Figure S45. Analytical HPLC Data for WW variant 16Xp. Protein solution was injected onto a C18 analytical
column and eluted using a linear gradient of 10-60% B (A=H2O, 0.1% TFA; B= MeCN, 0.1% TFA) over 50
minutes, followed by a 10 minute rinse (95% B), and a 10 minute column re-equilibration (10% B) with a
flow rate of 1 mL/min.

Figure S46. Analytical HPLC Data for WW variant 16Z. Protein solution was injected onto a C18 analytical
column and eluted using a linear gradient of 10-60% B (A=H2O, 0.1% TFA; B= MeCN, 0.1% TFA) over 50
minutes, followed by a 10 minute rinse (95% B), and a 10 minute column re-equilibration (10% B) with a
flow rate of 1 mL/min
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Figure S47. Analytical HPLC Data for WW variant 16Zp. Protein solution was injected onto a C18 analytical
column and eluted using a linear gradient of 10-60% B (A=H2O, 0.1% TFA; B= MeCN, 0.1% TFA) over 50
minutes, followed by a 10 minute rinse (95% B), and a 10 minute column re-equilibration (10% B) with a
flow rate of 1 mL/min.

Figure S48. Analytical HPLC Data for WW variant 16Nbp. Protein solution was injected onto a C18
analytical column and eluted using a linear gradient of 10-60% B (A=H2O, 0.1% TFA; B= MeCN, 0.1% TFA)
over 50 minutes, followed by a 10 minute rinse (95% B), and a 10 minute column re-equilibration (10% B)
with a flow rate of 1 mL/min.
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Figure S49. Analytical HPLC Data for WW variant 18Q. Protein solution was injected onto a C18 analytical
column and eluted using a linear gradient of 10-60% B (A=H2O, 0.1% TFA; B= MeCN, 0.1% TFA) over 50
minutes, followed by a 10 minute rinse (95% B), and a 10 minute column re-equilibration (10% B) with a
flow rate of 1 mL/min.

Figure S50. Analytical HPLC Data for WW variant 18Qp. Protein solution was injected onto a C18 analytical
column and eluted using a linear gradient of 10-60% B (A=H2O, 0.1% TFA; B= MeCN, 0.1% TFA) over 50
minutes, followed by a 10 minute rinse (95% B), and a 10 minute column re-equilibration (10% B) with a
flow rate of 1 mL/min.
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Figure S51. Analytical HPLC Data for WW variant 18X. Protein solution was injected onto a C18 analytical
column and eluted using a linear gradient of 10-60% B (A=H2O, 0.1% TFA; B= MeCN, 0.1% TFA) over 50
minutes, followed by a 10 minute rinse (95% B), and a 10 minute column re-equilibration (10% B) with a
flow rate of 1 mL/min.

Figure S52. Analytical HPLC Data for WW variant 18Xp. Protein solution was injected onto a C18 analytical
column and eluted using a linear gradient of 10-60% B (A=H2O, 0.1% TFA; B= MeCN, 0.1% TFA) over 50
minutes, followed by a 10 minute rinse (95% B), and a 10 minute column re-equilibration (10% B) with a
flow rate of 1 mL/min.
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Figure S53. Analytical HPLC Data for WW variant 18Z. Protein solution was injected onto a C18 analytical
column and eluted using a linear gradient of 10-60% B (A=H2O, 0.1% TFA; B= MeCN, 0.1% TFA) over 50
minutes, followed by a 10 minute rinse (95% B), and a 10 minute column re-equilibration (10% B) with a
flow rate of 1 mL/min.

Figure S54. Analytical HPLC Data for WW variant 18Zp. Protein solution was injected onto a C18 analytical
column and eluted using a linear gradient of 10-60% B (A=H2O, 0.1% TFA; B= MeCN, 0.1% TFA) over 50
minutes, followed by a 10 minute rinse (95% B), and a 10 minute column re-equilibration (10% B) with a
flow rate of 1 mL/min.
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Figure S55. Analytical HPLC Data for WW variant 18Nbp. Protein solution was injected onto a C18
analytical column and eluted using a linear gradient of 10-60% B (A=H2O, 0.1% TFA; B= MeCN, 0.1% TFA)
over 50 minutes, followed by a 10 minute rinse (95% B), and a 10 minute column re-equilibration (10% B)
with a flow rate of 1 mL/min.

Figure S57. Analytical HPLC Data for WW variant 23Q. Protein solution was injected onto a C18 analytical
column and eluted using a linear gradient of 10-60% B (A=H2O, 0.1% TFA; B= MeCN, 0.1% TFA) over 50
minutes, followed by a 10 minute rinse (95% B), and a 10 minute column re-equilibration (10% B) with a
flow rate of 1 mL/min.
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Figure S58. Analytical HPLC Data for WW variant 23Qp. Protein solution was injected onto a C18
analytical column and eluted using a linear gradient of 10-60% B (A=H2O, 0.1% TFA; B= MeCN, 0.1% TFA)
over 50 minutes, followed by a 10 minute rinse (95% B), and a 10 minute column re-equilibration (10%
B) with a flow rate of 1 mL/min.

Figure S60. Analytical HPLC Data for WW variant 23X. Protein solution was injected onto a C18 analytical
column and eluted using a linear gradient of 10-60% B (A=H2O, 0.1% TFA; B= MeCN, 0.1% TFA) over 50
minutes, followed by a 10 minute rinse (95% B), and a 10 minute column re-equilibration (10% B) with a
flow rate of 1 mL/min.
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Figure S61. Analytical HPLC Data for WW variant 23Xp. Protein solution was injected onto a C18 analytical
column and eluted using a linear gradient of 10-60% B (A=H2O, 0.1% TFA; B= MeCN, 0.1% TFA) over 50
minutes, followed by a 10 minute rinse (95% B), and a 10 minute column re-equilibration (10% B) with a
flow rate of 1 mL/min.

Figure S62. Analytical HPLC Data for WW variant 23Z. Protein solution was injected onto a C18 analytical
column and eluted using a linear gradient of 10-60% B (A=H2O, 0.1% TFA; B= MeCN, 0.1% TFA) over 50
minutes, followed by a 10 minute rinse (95% B), and a 10 minute column re-equilibration (10% B) with a
flow rate of 1 mL/min.
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Figure S63. Analytical HPLC Data for WW variant 23Zp. Protein solution was injected onto a C18 analytical
column and eluted using a linear gradient of 10-60% B (A=H2O, 0.1% TFA; B= MeCN, 0.1% TFA) over 50
minutes, followed by a 10 minute rinse (95% B), and a 10 minute column re-equilibration (10% B) with a
flow rate of 1 mL/min.

Figure S64. Analytical HPLC Data for WW variant 23Nbp. Protein solution was injected onto a C18
analytical column and eluted using a linear gradient of 10-60% B (A=H2O, 0.1% TFA; B= MeCN, 0.1% TFA)
over 50 minutes, followed by a 10 minute rinse (95% B), and a 10 minute column re-equilibration (10% B)
with a flow rate of 1 mL/min.
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Figure S65. Analytical HPLC Data for WW variant 27Q. Protein solution was injected onto a C18 analytical
column and eluted using a linear gradient of 10-60% B (A=H2O, 0.1% TFA; B= MeCN, 0.1% TFA) over 50
minutes, followed by a 10 minute rinse (95% B), and a 10 minute column re-equilibration (10% B) with a
flow rate of 1 mL/min.

Figure S66. Analytical HPLC Data for WW variant 27Qp. Protein solution was injected onto a C18 analytical
column and eluted using a linear gradient of 10-60% B (A=H2O, 0.1% TFA; B= MeCN, 0.1% TFA) over 50
minutes, followed by a 10 minute rinse (95% B), and a 10 minute column re-equilibration (10% B) with a
flow rate of 1 mL/min.
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Figure S67. Analytical HPLC Data for WW variant 27X. Protein solution was injected onto a C18 analytical
column and eluted using a linear gradient of 10-60% B (A=H2O, 0.1% TFA; B= MeCN, 0.1% TFA) over 50
minutes, followed by a 10 minute rinse (95% B), and a 10 minute column re-equilibration (10% B) with a
flow rate of 1 mL/min.

Figure S69. Analytical HPLC Data for WW variant 27Xp. Protein solution was injected onto a C18 analytical
column and eluted using a linear gradient of 10-60% B (A=H2O, 0.1% TFA; B= MeCN, 0.1% TFA) over 50
minutes, followed by a 10 minute rinse (95% B), and a 10 minute column re-equilibration (10% B) with a
flow rate of 1 mL/min.
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Figure S70. Analytical HPLC Data for WW variant 27Z. Protein solution was injected onto a C18 analytical
column and eluted using a linear gradient of 10-60% B (A=H2O, 0.1% TFA; B= MeCN, 0.1% TFA) over 50
minutes, followed by a 10 minute rinse (95% B), and a 10 minute column re-equilibration (10% B) with a
flow rate of 1 mL/min.

Figure S71. Analytical HPLC Data for WW variant 27Zp. Protein solution was injected onto a C18
analytical column and eluted using a linear gradient of 10-60% B (A=H2O, 0.1% TFA; B= MeCN, 0.1% TFA)
over 50 minutes, followed by a 10 minute rinse (95% B), and a 10 minute column re-equilibration (10%
B) with a flow rate of 1 mL/min.
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Figure S72. Analytical HPLC Data for WW variant 27Nbp. Protein solution was injected onto a C18
analytical column and eluted using a linear gradient of 10-60% B (A=H2O, 0.1% TFA; B= MeCN, 0.1% TFA)
over 50 minutes, followed by a 10 minute rinse (95% B), and a 10 minute column re-equilibration (10%
B) with a flow rate of 1 mL/min.

Figure S73. Analytical HPLC Data for WW variant 29Q. Protein solution was injected onto a C18 analytical
column and eluted using a linear gradient of 10-60% B (A=H2O, 0.1% TFA; B= MeCN, 0.1% TFA) over 50
minutes, followed by a 10 minute rinse (95% B), and a 10 minute column re-equilibration (10% B) with a
flow rate of 1 mL/min.
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Figure S74. Analytical HPLC Data for WW variant 29Qp. Protein solution was injected onto a C18 analytical
column and eluted using a linear gradient of 10-60% B (A=H2O, 0.1% TFA; B= MeCN, 0.1% TFA) over 50
minutes, followed by a 10 minute rinse (95% B), and a 10 minute column re-equilibration (10% B) with a
flow rate of 1 mL/min.

Figure S75. Analytical HPLC Data for WW variant 29X. Protein solution was injected onto a C18 analytical
column and eluted using a linear gradient of 10-60% B (A=H2O, 0.1% TFA; B= MeCN, 0.1% TFA) over 50
minutes, followed by a 10 minute rinse (95% B), and a 10 minute column re-equilibration (10% B) with a
flow rate of 1 mL/min.
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Figure S76. Analytical HPLC Data for WW variant 29Xp. Protein solution was injected onto a C18 analytical
column and eluted using a linear gradient of 10-60% B (A=H2O, 0.1% TFA; B= MeCN, 0.1% TFA) over 50
minutes, followed by a 10 minute rinse (95% B), and a 10 minute column re-equilibration (10% B) with a
flow rate of 1 mL/min.

Figure S77. Analytical HPLC Data for WW variant 29Z. Protein solution was injected onto a C18 analytical
column and eluted using a linear gradient of 10-60% B (A=H2O, 0.1% TFA; B= MeCN, 0.1% TFA) over 50
minutes, followed by a 10 minute rinse (95% B), and a 10 minute column re-equilibration (10% B) with a
flow rate of 1 mL/min.
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Figure S78. Analytical HPLC Data for WW variant 29Zp. Protein solution was injected onto a C18 analytical
column and eluted using a linear gradient of 10-60% B (A=H2O, 0.1% TFA; B= MeCN, 0.1% TFA) over 50
minutes, followed by a 10 minute rinse (95% B), and a 10 minute column re-equilibration (10% B) with a
flow rate of 1 mL/min.

Figure S79. Analytical HPLC Data for WW variant 29Nbp. Protein solution was injected onto a C18
analytical column and eluted using a linear gradient of 10-60% B (A=H2O, 0.1% TFA; B= MeCN, 0.1% TFA)
over 50 minutes, followed by a 10 minute rinse (95% B), and a 10 minute column re-equilibration (10%
B) with a flow rate of 1 mL/min.
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Figure S80. Analytical HPLC Data for WW variant 32Q. Protein solution was injected onto a C18 analytical
column and eluted using a linear gradient of 10-60% B (A=H2O, 0.1% TFA; B= MeCN, 0.1% TFA) over 50
minutes, followed by a 10 minute rinse (95% B), and a 10 minute column re-equilibration (10% B) with a
flow rate of 1 mL/min.

Figure S81. Analytical HPLC Data for WW variant 32Qp. Protein solution was injected onto a C18 analytical
column and eluted using a linear gradient of 10-60% B (A=H2O, 0.1% TFA; B= MeCN, 0.1% TFA) over 50
minutes, followed by a 10 minute rinse (95% B), and a 10 minute column re-equilibration (10% B) with a
flow rate of 1 mL/min.
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Figure S82. Analytical HPLC Data for WW variant 32X. Protein solution was injected onto a C18 analytical
column and eluted using a linear gradient of 10-60% B (A=H2O, 0.1% TFA; B= MeCN, 0.1% TFA) over 50
minutes, followed by a 10 minute rinse (95% B), and a 10 minute column re-equilibration (10% B) with a
flow rate of 1 mL/min.

Figure S83. Analytical HPLC Data for WW variant 32Xp. Protein solution was injected onto a C18 analytical
column and eluted using a linear gradient of 10-60% B (A=H2O, 0.1% TFA; B= MeCN, 0.1% TFA) over 50
minutes, followed by a 10 minute rinse (95% B), and a 10 minute column re-equilibration (10% B) with a
flow rate of 1 mL/min.
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Figure S84. Analytical HPLC Data for WW variant 32Z. Protein solution was injected onto a C18 analytical
column and eluted using a linear gradient of 10-60% B (A=H2O, 0.1% TFA; B= MeCN, 0.1% TFA) over 50
minutes, followed by a 10 minute rinse (95% B), and a 10 minute column re-equilibration (10% B) with a
flow rate of 1 mL/min.

Figure S85. Analytical HPLC Data for WW variant 32Zp. Protein solution was injected onto a C18 analytical
column and eluted using a linear gradient of 10-60% B (A=H2O, 0.1% TFA; B= MeCN, 0.1% TFA) over 50
minutes, followed by a 10 minute rinse (95% B), and a 10 minute column re-equilibration (10% B) with a
flow rate of 1 mL/min.
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Figure S86. Analytical HPLC Data for WW variant 32Nbp. Protein solution was injected onto a C18
analytical column and eluted using a linear gradient of 10-60% B (A=H2O, 0.1% TFA; B= MeCN, 0.1% TFA)
over 50 minutes, followed by a 10 minute rinse (95% B), and a 10 minute column re-equilibration (10%
B) with a flow rate of 1 mL/min.

2.4.2 Biophysical Characterization of WW Variants: Measurements were made with an
Aviv 420 Circular Dichroism Spectropolarimeter, using quartz cuvettes with a path length of 0.1
cm. Protein solutions were prepared in 20 mM sodium phosphate buffer, pH 7, and protein
concentrations were determined spectroscopically based on tyrosine and tryptophan absorbance at
280 nm in 6 M guanidine hydrochloride + 20 mM sodium phosphate (εTrp = 5690 M-1cm-1, εTyr =
1280 M-1cm-1).12 CD spectra of 30 μM solutions were obtained from 260 to 200 nm at 25°C.
Variable temperature CD data were obtained at least in triplicate by monitoring the molar
ellipticity at 222 nm of 30 µM solutions each protein variant (30 μM) in 20 mM sodium phosphate
(pH 7) from 1 to 95°C at 2 °C intervals, with 120 s equilibration time between data points and 30
s averaging time.
Triplicate variable temperature CD data for each WW variant and their individual variants
were fit globally to a two-state model for thermally-induced unfolding of a monomeric proteins as
shown in equations S1–S3:
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,

(S1)

where [θ] is molar ellipticity; T is temperature in Kelvin; D0 is the y-intercept and D1 is the
slope of the post-transition baseline; N0 is the y-intercept and N1 is the slope of the pre-transition
baseline; and Kf is the temperature-dependent folding equilibrium constant. Kf is related to the
temperature-dependent free energy of folding ΔGf(T) according to the following equation:

,

(S2)

where R is the universal gas constant (0.0019872 kcal/mol/K). ΔGf(T) was fit to the following
equation:
∆Gf =

∆H(Tm )∙(Tm -T)
Tm

T

+ ∆Cp ∙ (T-Tm -T ∙ ln �T �)
m

(S3)

where the fit parameters are Tm (the midpoint of the unfolding transition; the temperature at
which ΔGf = 0); ΔH(Tm), the change in enthalpy upon folding at Tm; and ΔCp, the change in heat
capacity upon folding. The parameters for equations S1-S3 were used to calculate the values of
the folding free energy ΔGf for WW variants in the main text. Far-UV CD spectra and variable
temperature CD data for these compounds are shown below in Figures S87-S116.
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Figure S87. CD spectra (50 µM) and variable temperature CD data (50 µM) for WW variant 16Q in 20
mM sodium phosphate, pH 7. Fit parameters appear in the table, along with standard errors.

Figure S88. CD spectra (50 µM) and variable temperature CD data (50 µM) for WW variant 16Qp in 20
mM sodium phosphate, pH 7. Fit parameters appear in the table, along with standard errors.

85

Figure S89. CD spectra (50 µM) and variable temperature CD data (50 µM) for WW variants 16X
(black) and 16Xp (red) in 20 mM sodium phosphate, pH 7. Fit parameters appear in the table, along with
standard errors.
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Figure S90. CD spectra (50 µM) and variable temperature CD data (50 µM) for WW variants 16Z
(black) and 16Zp (red) in 20 mM sodium phosphate, pH 7. Fit parameters appear in the table, along with
standard errors.
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Figure S91. CD spectra (50 µM) and variable temperature CD data (50 µM) for WW variant 16NBp in
20 mM sodium phosphate, pH 7. Fit parameters appear in the table, along with standard errors.

Figure S92. CD spectra (50 µM) and variable temperature CD data (50 µM) for WW variant 18Q in 20
mM sodium phosphate, pH 7. Fit parameters appear in the table, along with standard errors.
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Figure S93. CD spectra (50 µM) and variable temperature CD data (50 µM) for WW variant 18Qp in 20
mM sodium phosphate, pH 7. Fit parameters appear in the table, along with standard errors.

Figure S94. CD spectra (50 µM) and variable temperature CD data (50 µM) for WW variants 18X
(black) and 18Xp (red) in 20 mM sodium phosphate, pH 7. Fit parameters appear in the table, along with
standard errors.
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Figure S95. CD spectra (50 µM) and variable temperature CD data (50 µM) for WW variants 18Z
(black) and 18Zp (red) in 20 mM sodium phosphate, pH 7. Fit parameters appear in the table, along with
standard errors.
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Figure S96. CD spectra (50 µM) and variable temperature CD data (50 µM) for WW variant 18NBp in
20 mM sodium phosphate, pH 7. Fit parameters appear in the table, along with standard errors.

Figure S97. CD spectra (50 µM) and variable temperature CD data (50 µM) for WW variant 23Q in 20
mM sodium phosphate, pH 7. Fit parameters appear in the table, along with standard errors.
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Figure S98. CD spectra (50 µM) and variable temperature CD data (50 µM) for WW variant 23Qp in 20
mM sodium phosphate, pH 7. Fit parameters appear in the table, along with standard errors.

Figure S99. CD spectra (50 µM) and variable temperature CD data (50 µM) for WW variants 23X
(black) and 23Xp (red) in 20 mM sodium phosphate, pH 7. Fit parameters appear in the table, along with
standard errors.

92

Figure S100. CD spectra (50 µM) and variable temperature CD data (50 µM) for WW variants 23Z
(black) and 23Zp (red) in 20 mM sodium phosphate, pH 7. Fit parameters appear in the table, along with
standard errors.
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Figure S101. CD spectra (50 µM) and variable temperature CD data (50 µM) for WW variant 23NBp in
20 mM sodium phosphate, pH 7. Fit parameters appear in the table, along with standard errors.

Figure S102. CD spectra (50 µM) and variable temperature CD data (50 µM) for WW variant 27Q in 20
mM sodium phosphate, pH 7. Fit parameters appear in the table, along with standard errors.
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Figure S103. CD spectra (50 µM) and variable temperature CD data (50 µM) for WW variant 27Qp in
20 mM sodium phosphate, pH 7. Fit parameters appear in the table, along with standard errors.

Figure S104. CD spectra (50 µM) and variable temperature CD data (50 µM) for WW variants 27X
(black) and 27Xp (red) in 20 mM sodium phosphate, pH 7. Fit parameters appear in the table, along with
standard errors.
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Figure S105. CD spectra (50 µM) and variable temperature CD data (50 µM) for WW variants 27Z
(black) and 27Zp (red) in 20 mM sodium phosphate, pH 7. Fit parameters appear in the table, along with
standard errors.
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Figure S106. CD spectra (50 µM) and variable temperature CD data (50 µM) for WW variant 27NBp in
20 mM sodium phosphate, pH 7. Fit parameters appear in the table, along with standard errors.

Figure S107. CD spectra (50 µM) and variable temperature CD data (50 µM) for WW variant 29Q in 20
mM sodium phosphate, pH 7. Fit parameters appear in the table, along with standard errors.
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Figure S108. CD spectra (50 µM) and variable temperature CD data (50 µM) for WW variant 29Qp in
20 mM sodium phosphate, pH 7. Fit parameters appear in the table, along with standard errors.

Figure S109. CD spectra (50 µM) and variable temperature CD data (50 µM) for WW variants 29X
(black) and 29Xp (red) in 20 mM sodium phosphate, pH 7. Fit parameters appear in the table, along with
standard errors.
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Figure S110. CD spectra (50 µM) and variable temperature CD data (50 µM) for WW variants 29Z
(black) and 29Zp (red) in 20 mM sodium phosphate, pH 7. Fit parameters appear in the table, along with
standard errors.
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Figure S111. CD spectra (50 µM) and variable temperature CD data (50 µM) for WW variant 29NBp in
20 mM sodium phosphate, pH 7. Fit parameters appear in the table, along with standard errors.

Figure S112. CD spectra (50 µM) and variable temperature CD data (50 µM) for WW variant 32Q in 20
mM sodium phosphate, pH 7. Fit parameters appear in the table, along with standard errors.
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Figure S113. CD spectra (50 µM) and variable temperature CD data (50 µM) for WW variant 32Qp in
20 mM sodium phosphate, pH 7. Fit parameters appear in the table, along with standard errors.
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Figure S114. CD spectra (50 µM) and variable temperature CD data (50 µM) for WW variants 32X
(black) and 32Xp (red) in 20 mM sodium phosphate, pH 7. Fit parameters appear in the table, along with
standard errors.
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Figure S115. CD spectra (50 µM) and variable temperature CD data (50 µM) for WW variants 32Z
(black) and 32Zp (red) in 20 mM sodium phosphate, pH 7. Fit parameters appear in the table, along with
standard errors.
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Figure S116. CD spectra (50 µM) and variable temperature CD data (50 µM) for WW variant 32NBp in
20 mM sodium phosphate, pH 7. Fit parameters appear in the table, along with standard errors.

2.4.3 Proteolysis: 50 μM protein solutions in 20 mM sodium phosphate buffer (pH 7) were
incubated at ambient temperature with 17 μg/mL proteinase K respectively for up to 90 minutes.
At each of the time points, the proteolysis reaction was quenched by adding 150 μL of aqueous
trifluoroacetic acid (1% v/v) to 50 uL of the reaction mixture. The quenched mixture was then
analyzed in triplicate by reverse phase HPLC analytical column, monitored by a UV-Vis detector
at 220 nm. The degradation of the proteins was assessed using the integrated HPLC peak area to
account for how much of the full-length protein remained at each time point. The protein half-lives
were calculated by fitting the integrated peak areas as a function of time to a monoexponential
decay equation:
Area(t) = A0 • exp [-t / τ],
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where t is time in minutes, A0 is a constant corresponding to relative integrated peak area at t = 0,
and τ is the decay time, which is related to the protein half-life t1/2 (t1/2 = τ ln 2). Decay traces for
proteins 16Q, 16Qp, 18Q, 18Qp, 23Q, 23Qp, 27Q, 27Qp, 29Q, 29Qp, 32Q, 32Qp, 16X, 16Xp,
18X, 18Xp, 23X, 23Xp, 27X, 27Xp, 29X, 29Xp, 32X, 32Xp, 16Z, 16Zp, 18Z, 18Zp, 23Z, 23Zp,
27Z, 27Zp, 29Z, 29Zp, 32Z, 32Zp, 16N, 16Np, 16Nbp, 18N, 18Np, 18Nbp, 23N, 23Np, 23Nbp,
27N, 27Np, 27Nbp, 29N, 29Np, 29Nbp and 32N, 32Np and 32Nbp are shown in Figures S117–
S (Data for asparagine and asparagine mono-PEG variants were collected previously, but were
collected again to account for differences in enzyme activity due to preparation).

Figure S117. (t1/2 = 1.29 ± 0.03 min) Proteolysis of 16Q (50 μM protein concentration in 20 mM sodium
phosphate buffer, pH 7) by proteinase K (10 mg/mL), as monitored by HPLC. Data points are shown as
black circles with error bars, and each represents the average of three replicate experiments. The solid red
line represents the fit of the data to a monoexponential decay function, which was used to calculate the
indicated half-lives.
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Figure S118. (t1/2 = 3.58 ± 0.22 min) Proteolysis of 16Qp (50 μM protein concentration in 20 mM
sodium phosphate buffer, pH 7) by proteinase K (10 mg/mL), as monitored by HPLC. Data points are
shown as black circles with error bars, and each represents the average of three replicate experiments. The
solid red line represents the fit of the data to a monoexponential decay function, which was used to
calculate the indicated half-lives.

Figure S119. (t1/2 = 1.48 ± 0.08 min) Proteolysis of 18Q (50 μM protein concentration in 20 mM sodium
phosphate buffer, pH 7) by proteinase K (10 mg/mL), as monitored by HPLC. Data points are shown as
black circles with error bars, and each represents the average of three replicate experiments. The solid red
line represents the fit of the data to a monoexponential decay function, which was used to calculate the
indicated half-lives.
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Figure S120. (t1/2 = 1.91 ± 0.17 min) Proteolysis of 18Qp (50 μM protein concentration in 20 mM
sodium phosphate buffer, pH 7) by proteinase K (10 mg/mL), as monitored by HPLC. Data points are
shown as black circles with error bars, and each represents the average of three replicate experiments. The
solid red line represents the fit of the data to a monoexponential decay function, which was used to
calculate the indicated half-lives.

Figure S121. (t1/2 = 0.40 ± 0.04 min) Proteolysis of 19Q (50 μM protein concentration in 20 mM sodium
phosphate buffer, pH 7) by proteinase K (10 mg/mL), as monitored by HPLC. Data points are shown as
black circles with error bars, and each represents the average of three replicate experiments. The solid red
line represents the fit of the data to a monoexponential decay function, which was used to calculate the
indicated half-lives.
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Figure S122. (t1/2 = 1.59 ± 0.08 min) Proteolysis of 19Qp (50 μM protein concentration in 20 mM
sodium phosphate buffer, pH 7) by proteinase K (10 mg/mL), as monitored by HPLC. Data points are
shown as black circles with error bars, and each represents the average of three replicate experiments. The
solid red line represents the fit of the data to a monoexponential decay function, which was used to
calculate the indicated half-lives.

Figure S123. (t1/2 = 0.25 ± 0.03 min) Proteolysis of 23Q (50 μM protein concentration in 20 mM sodium
phosphate buffer, pH 7) by proteinase K (10 mg/mL), as monitored by HPLC. Data points are shown as
black circles with error bars, and each represents the average of three replicate experiments. The solid red
line represents the fit of the data to a monoexponential decay function, which was used to calculate the
indicated half-lives.
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Figure S124. (t1/2 = 0.23 ± 0.01 min) Proteolysis of 23Qp (50 μM protein concentration in 20 mM
sodium phosphate buffer, pH 7) by proteinase K (10 mg/mL), as monitored by HPLC. Data points are
shown as black circles with error bars, and each represents the average of three replicate experiments. The
solid red line represents the fit of the data to a monoexponential decay function, which was used to
calculate the indicated half-lives.

Figure S125. (t1/2 = 1.07 ± 0.02 min) Proteolysis of 27Q (50 μM protein concentration in 20 mM sodium
phosphate buffer, pH 7) by proteinase K (10 mg/mL), as monitored by HPLC. Data points are shown as
black circles with error bars, and each represents the average of three replicate experiments. The solid red
line represents the fit of the data to a monoexponential decay function, which was used to calculate the
indicated half-lives.
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Figure S126. (t1/2 = 0.82 ± 0.05 min) Proteolysis of 27Qp (50 μM protein concentration in 20 mM
sodium phosphate buffer, pH 7) by proteinase K (10 mg/mL), as monitored by HPLC. Data points are
shown as black circles with error bars, and each represents the average of three replicate experiments. The
solid red line represents the fit of the data to a monoexponential decay function, which was used to
calculate the indicated half-lives.

Figure S127. (t1/2 = 0.24 ± 0.01 min) Proteolysis of 29Q (50 μM protein concentration in 20 mM sodium
phosphate buffer, pH 7) by proteinase K (10 mg/mL), as monitored by HPLC. Data points are shown as
black circles with error bars, and each represents the average of three replicate experiments. The solid red
line represents the fit of the data to a monoexponential decay function, which was used to calculate the
indicated half-lives.
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Figure S128. (t1/2 = 0.31 ± 0.02 min) Proteolysis of 29Qp (50 μM protein concentration in 20 mM
sodium phosphate buffer, pH 7) by proteinase K (10 mg/mL), as monitored by HPLC. Data points are
shown as black circles with error bars, and each represents the average of three replicate experiments. The
solid red line represents the fit of the data to a monoexponential decay function, which was used to
calculate the indicated half-lives.

Figure S129. (t1/2 = 1.44 ± 0.05 min) Proteolysis of 32Q (50 μM protein concentration in 20 mM sodium
phosphate buffer, pH 7) by proteinase K (10 mg/mL), as monitored by HPLC. Data points are shown as
black circles with error bars, and each represents the average of three replicate experiments. The solid red
line represents the fit of the data to a monoexponential decay function, which was used to calculate the
indicated half-lives.
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Figure S130. (t1/2 = 4.36 ± 0.38 min) Proteolysis of 32Qp (50 μM protein concentration in 20 mM
sodium phosphate buffer, pH 7) by proteinase K (10 mg/mL), as monitored by HPLC. Data points are
shown as black circles with error bars, and each represents the average of three replicate experiments. The
solid red line represents the fit of the data to a monoexponential decay function, which was used to
calculate the indicated half-lives.

Figure S131. (t1/2 = 1.23 ± 0.06 min) Proteolysis of 16N (50 μM protein concentration in 20 mM sodium
phosphate buffer, pH 7) by proteinase K (10 mg/mL), as monitored by HPLC. Data points are shown as
black circles with error bars, and each represents the average of three replicate experiments. The solid red
line represents the fit of the data to a monoexponential decay function, which was used to calculate the
indicated half-lives.
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Figure S132. (t1/2 = 3.09 ± 0.38 min) Proteolysis of 16Np (50 μM protein concentration in 20 mM
sodium phosphate buffer, pH 7) by proteinase K (10 mg/mL), as monitored by HPLC. Data points are
shown as black circles with error bars, and each represents the average of three replicate experiments. The
solid red line represents the fit of the data to a monoexponential decay function, which was used to
calculate the indicated half-lives.

Figure S133. (t1/2 = 13.30 ± 0.75 min) Proteolysis of 16Nbp (50 μM protein concentration in 20 mM
sodium phosphate buffer, pH 7) by proteinase K (10 mg/mL), as monitored by HPLC. Data points are
shown as black circles with error bars, and each represents the average of three replicate experiments. The
solid red line represents the fit of the data to a monoexponential decay function, which was used to
calculate the indicated half-lives.
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Figure S134. (t1/2 = 3.11 ± 0.88 min) Proteolysis of 18N (50 μM protein concentration in 20 mM sodium
phosphate buffer, pH 7) by proteinase K (10 mg/mL), as monitored by HPLC. Data points are shown as
black circles with error bars, and each represents the average of three replicate experiments. The solid red
line represents the fit of the data to a monoexponential decay function, which was used to calculate the
indicated half-lives.

Figure S135. (t1/2 = ± min) Proteolysis of 18Np (50 μM protein concentration in 20 mM sodium
phosphate buffer, pH 7) by proteinase K (10 mg/mL), as monitored by HPLC. Data points are shown as
black circles with error bars, and each represents the average of three replicate experiments. The solid red
line represents the fit of the data to a monoexponential decay function, which was used to calculate the
indicated half-lives.
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Figure S136. (t1/2 = ± min) Proteolysis of 18Nbp (50 μM protein concentration in 20 mM sodium
phosphate buffer, pH 7) by proteinase K (10 mg/mL), as monitored by HPLC. Data points are shown as
black circles with error bars, and each represents the average of three replicate experiments. The solid red
line represents the fit of the data to a monoexponential decay function, which was used to calculate the
indicated half-lives.

Figure S137. (t1/2 = 1.06 ± 0.19 min) Proteolysis of 19N (50 μM protein concentration in 20 mM sodium
phosphate buffer, pH 7) by proteinase K (10 mg/mL), as monitored by HPLC. Data points are shown as
black circles with error bars, and each represents the average of three replicate experiments. The solid red
line represents the fit of the data to a monoexponential decay function, which was used to calculate the
indicated half-lives.
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Figure S138. (t1/2 = 6.22 ± 0.44 min) Proteolysis of 19Np (50 μM protein concentration in 20 mM
sodium phosphate buffer, pH 7) by proteinase K (10 mg/mL), as monitored by HPLC. Data points are
shown as black circles with error bars, and each represents the average of three replicate experiments. The
solid red line represents the fit of the data to a monoexponential decay function, which was used to
calculate the indicated half-lives.

Figure S139. (t1/2 = 10.45 ± 1.12 min) Proteolysis of 19Nbp (50 μM protein concentration in 20 mM
sodium phosphate buffer, pH 7) by proteinase K (10 mg/mL), as monitored by HPLC. Data points are
shown as black circles with error bars, and each represents the average of three replicate experiments. The
solid red line represents the fit of the data to a monoexponential decay function, which was used to
calculate the indicated half-lives.
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Figure S140. (t1/2 = 0.010 ± 0.001 min) Proteolysis of 23N (50 μM protein concentration in 20 mM
sodium phosphate buffer, pH 7) by proteinase K (10 mg/mL), as monitored by HPLC. Data points are
shown as black circles with error bars, and each represents the average of three replicate experiments. The
solid red line represents the fit of the data to a monoexponential decay function, which was used to
calculate the indicated half-lives.

Figure S141. (t1/2 = 0.19 ± 0.03 min) Proteolysis of 23Np (50 μM protein concentration in 20 mM
sodium phosphate buffer, pH 7) by proteinase K (10 mg/mL), as monitored by HPLC. Data points are
shown as black circles with error bars, and each represents the average of three replicate experiments. The
solid red line represents the fit of the data to a monoexponential decay function, which was used to
calculate the indicated half-lives.
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Figure S142. (t1/2 = 0.90 ± 0.06 min) Proteolysis of 23Nbp (50 μM protein concentration in 20 mM
sodium phosphate buffer, pH 7) by proteinase K (10 mg/mL), as monitored by HPLC. Data points are
shown as black circles with error bars, and each represents the average of three replicate experiments. The
solid red line represents the fit of the data to a monoexponential decay function, which was used to
calculate the indicated half-lives.

Figure S143. (t1/2 = 1.38 ± 0.30 min) Proteolysis of 27N (50 μM protein concentration in 20 mM sodium
phosphate buffer, pH 7) by proteinase K (10 mg/mL), as monitored by HPLC. Data points are shown as
black circles with error bars, and each represents the average of three replicate experiments. The solid red
line represents the fit of the data to a monoexponential decay function, which was used to calculate the
indicated half-lives.
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Figure S144. (t1/2 = 1.61 ± 0.11 min) Proteolysis of 27Np (50 μM protein concentration in 20 mM
sodium phosphate buffer, pH 7) by proteinase K (10 mg/mL), as monitored by HPLC. Data points are
shown as black circles with error bars, and each represents the average of three replicate experiments. The
solid red line represents the fit of the data to a monoexponential decay function, which was used to
calculate the indicated half-lives.

Figure S145. (t1/2 = 0.50 ± 0.02 min) Proteolysis of 27Nbp (50 μM protein concentration in 20 mM
sodium phosphate buffer, pH 7) by proteinase K (10 mg/mL), as monitored by HPLC. Data points are
shown as black circles with error bars, and each represents the average of three replicate experiments. The
solid red line represents the fit of the data to a monoexponential decay function, which was used to
calculate the indicated half-lives.
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Figure S146. (t1/2 = 0.30 ± 0.04 min) Proteolysis of 29N (50 μM protein concentration in 20 mM sodium
phosphate buffer, pH 7) by proteinase K (10 mg/mL), as monitored by HPLC. Data points are shown as
black circles with error bars, and each represents the average of three replicate experiments. The solid red
line represents the fit of the data to a monoexponential decay function, which was used to calculate the
indicated half-lives.

Figure S147. (t1/2 = 0.81 ± 0.17 min) Proteolysis of 29Np (50 μM protein concentration in 20 mM
sodium phosphate buffer, pH 7) by proteinase K (10 mg/mL), as monitored by HPLC. Data points are
shown as black circles with error bars, and each represents the average of three replicate experiments. The
solid red line represents the fit of the data to a monoexponential decay function, which was used to
calculate the indicated half-lives.
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Figure S148. (t1/2 = 2.24± 0.06 min) Proteolysis of 29Nbp (50 μM protein concentration in 20 mM
sodium phosphate buffer, pH 7) by proteinase K (10 mg/mL), as monitored by HPLC. Data points are
shown as black circles with error bars, and each represents the average of three replicate experiments. The
solid red line represents the fit of the data to a monoexponential decay function, which was used to
calculate the indicated half-lives.

Figure S149. (t1/2 = 0.36± 0.03 min) Proteolysis of 32N (50 μM protein concentration in 20 mM sodium
phosphate buffer, pH 7) by proteinase K (10 mg/mL), as monitored by HPLC. Data points are shown as
black circles with error bars, and each represents the average of three replicate experiments. The solid red
line represents the fit of the data to a monoexponential decay function, which was used to calculate the
indicated half-lives.
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Figure S150. (t1/2 = 0.72± 0.01 min) Proteolysis of 32Np (50 μM protein concentration in 20 mM sodium
phosphate buffer, pH 7) by proteinase K (10 mg/mL), as monitored by HPLC. Data points are shown as
black circles with error bars, and each represents the average of three replicate experiments. The solid red
line represents the fit of the data to a monoexponential decay function, which was used to calculate the
indicated half-lives.

Figure S151. (t1/2 = 1.54 ± 0.16 min) Proteolysis of 32Nbp (50 μM protein concentration in 20 mM
sodium phosphate buffer, pH 7) by proteinase K (10 mg/mL), as monitored by HPLC. Data points are
shown as black circles with error bars, and each represents the average of three replicate experiments. The
solid red line represents the fit of the data to a monoexponential decay function, which was used to
calculate the indicated half-lives.
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Figure S152. (t1/2 = 0.77 ± 0.09 min) Proteolysis of 16X (50 μM protein concentration in 20 mM sodium
phosphate buffer, pH 7) by proteinase K (10 mg/mL), as monitored by HPLC. Data points are shown as
black circles with error bars, and each represents the average of three replicate experiments. The solid red
line represents the fit of the data to a monoexponential decay function, which was used to calculate the
indicated half-lives.

Figure S153. (t1/2 = 1.52 ± 0.12 min) Proteolysis of 16Xp (50 μM protein concentration in 20 mM
sodium phosphate buffer, pH 7) by proteinase K (10 mg/mL), as monitored by HPLC. Data points are
shown as black circles with error bars, and each represents the average of three replicate experiments. The
solid red line represents the fit of the data to a monoexponential decay function, which was used to
calculate the indicated half-lives.
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Figure S154. (t1/2 = 1.46 ± 0.02 min) Proteolysis of 18X (50 μM protein concentration in 20 mM sodium
phosphate buffer, pH 7) by proteinase K (10 mg/mL), as monitored by HPLC. Data points are shown as
black circles with error bars, and each represents the average of three replicate experiments. The solid red
line represents the fit of the data to a monoexponential decay function, which was used to calculate the
indicated half-lives.

Figure S155. (t1/2 = 1.71 ± 0.12 min) Proteolysis of 18Xp (50 μM protein concentration in 20 mM
sodium phosphate buffer, pH 7) by proteinase K (10 mg/mL), as monitored by HPLC. Data points are
shown as black circles with error bars, and each represents the average of three replicate experiments. The
solid red line represents the fit of the data to a monoexponential decay function, which was used to
calculate the indicated half-lives.
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Figure S156. (t1/2 = 0.90 ± 0.02 min) Proteolysis of 19X (50 μM protein concentration in 20 mM sodium
phosphate buffer, pH 7) by proteinase K (10 mg/mL), as monitored by HPLC. Data points are shown as
black circles with error bars, and each represents the average of three replicate experiments. The solid red
line represents the fit of the data to a monoexponential decay function, which was used to calculate the
indicated half-lives.

Figure S157. (t1/2 = 1.30 ± 0.01 min) Proteolysis of 19Xp (50 μM protein concentration in 20 mM
sodium phosphate buffer, pH 7) by proteinase K (10 mg/mL), as monitored by HPLC. Data points are
shown as black circles with error bars, and each represents the average of three replicate experiments. The
solid red line represents the fit of the data to a monoexponential decay function, which was used to
calculate the indicated half-lives.
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Figure S158. (t1/2 = 0.20 ± 0.01 min) Proteolysis of 23X (50 μM protein concentration in 20 mM sodium
phosphate buffer, pH 7) by proteinase K (10 mg/mL), as monitored by HPLC. Data points are shown as
black circles with error bars, and each represents the average of three replicate experiments. The solid red
line represents the fit of the data to a monoexponential decay function, which was used to calculate the
indicated half-lives.

Figure S159. (t1/2 = 0.28 ± 0.02 min) Proteolysis of 23Xp (50 μM protein concentration in 20 mM
sodium phosphate buffer, pH 7) by proteinase K (10 mg/mL), as monitored by HPLC. Data points are
shown as black circles with error bars, and each represents the average of three replicate experiments. The
solid red line represents the fit of the data to a monoexponential decay function, which was used to
calculate the indicated half-lives.
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Figure S160. (t1/2 = 0.75 ± 0.04 min) Proteolysis of 27X (50 μM protein concentration in 20 mM sodium
phosphate buffer, pH 7) by proteinase K (10 mg/mL), as monitored by HPLC. Data points are shown as
black circles with error bars, and each represents the average of three replicate experiments. The solid red
line represents the fit of the data to a monoexponential decay function, which was used to calculate the
indicated half-lives.

Figure S161. (t1/2 = 0.42 ± 0.05 min) Proteolysis of 27X (50 μM protein concentration in 20 mM sodium
phosphate buffer, pH 7) by proteinase K (10 mg/mL), as monitored by HPLC. Data points are shown as
black circles with error bars, and each represents the average of three replicate experiments. The solid red
line represents the fit of the data to a monoexponential decay function, which was used to calculate the
indicated half-lives.
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Figure S162. (t1/2 = 0.24 ± 0.01 min) Proteolysis of 29X (50 μM protein concentration in 20 mM sodium
phosphate buffer, pH 7) by proteinase K (10 mg/mL), as monitored by HPLC. Data points are shown as
black circles with error bars, and each represents the average of three replicate experiments. The solid red
line represents the fit of the data to a monoexponential decay function, which was used to calculate the
indicated half-lives.

Figure S163. (t1/2 = 0.31 ± 0.02 min) Proteolysis of 29Xp (50 μM protein concentration in 20 mM
sodium phosphate buffer, pH 7) by proteinase K (10 mg/mL), as monitored by HPLC. Data points are
shown as black circles with error bars, and each represents the average of three replicate experiments. The
solid red line represents the fit of the data to a monoexponential decay function, which was used to
calculate the indicated half-lives.
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Figure S164. (t1/2 = 1.33 ± 0.02 min) Proteolysis of 32X (50 μM protein concentration in 20 mM sodium
phosphate buffer, pH 7) by proteinase K (10 mg/mL), as monitored by HPLC. Data points are shown as
black circles with error bars, and each represents the average of three replicate experiments. The solid red
line represents the fit of the data to a monoexponential decay function, which was used to calculate the
indicated half-lives.

Figure S165. (t1/2 = 1.67 ± 0.04 min) Proteolysis of 32Xp (50 μM protein concentration in 20 mM
sodium phosphate buffer, pH 7) by proteinase K (10 mg/mL), as monitored by HPLC. Data points are
shown as black circles with error bars, and each represents the average of three replicate experiments. The
solid red line represents the fit of the data to a monoexponential decay function, which was used to
calculate the indicated half-lives.
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Figure S166. (t1/2 = 5.48 ± 1.86 min) Proteolysis of 16Z (50 μM protein concentration in 20 mM sodium
phosphate buffer, pH 7) by proteinase K (10 mg/mL), as monitored by HPLC. Data points are shown as
black circles with error bars, and each represents the average of three replicate experiments. The solid red
line represents the fit of the data to a monoexponential decay function, which was used to calculate the
indicated half-lives.

Figure S167. (t1/2 = 1.67 ± 0.04 min) Proteolysis of 16Zp (50 μM protein concentration in 20 mM
sodium phosphate buffer, pH 7) by proteinase K (10 mg/mL), as monitored by HPLC. Data points are
shown as black circles with error bars, and each represents the average of three replicate experiments. The
solid red line represents the fit of the data to a monoexponential decay function, which was used to
calculate the indicated half-lives.

130

Figure S167. (t1/2 = 0.97 ± 0.16 min) Proteolysis of 18Z (50 μM protein concentration in 20 mM sodium
phosphate buffer, pH 7) by proteinase K (10 mg/mL), as monitored by HPLC. Data points are shown as
black circles with error bars, and each represents the average of three replicate experiments. The solid red
line represents the fit of the data to a monoexponential decay function, which was used to calculate the
indicated half-lives.

Figure S168. (t1/2 = 1.01 ± 0.15 min) Proteolysis of 18Zp (50 μM protein concentration in 20 mM
sodium phosphate buffer, pH 7) by proteinase K (10 mg/mL), as monitored by HPLC. Data points are
shown as black circles with error bars, and each represents the average of three replicate experiments. The
solid red line represents the fit of the data to a monoexponential decay function, which was used to
calculate the indicated half-lives.
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Figure S169. (t1/2 = 0.66 ± 0.01 min) Proteolysis of 19Z (50 μM protein concentration in 20 mM sodium
phosphate buffer, pH 7) by proteinase K (10 mg/mL), as monitored by HPLC. Data points are shown as
black circles with error bars, and each represents the average of three replicate experiments. The solid red
line represents the fit of the data to a monoexponential decay function, which was used to calculate the
indicated half-lives.

Figure S170. (t1/2 = 1.93 ± 0.2 min) Proteolysis of 19Zp (50 μM protein concentration in 20 mM sodium
phosphate buffer, pH 7) by proteinase K (10 mg/mL), as monitored by HPLC. Data points are shown as
black circles with error bars, and each represents the average of three replicate experiments. The solid red
line represents the fit of the data to a monoexponential decay function, which was used to calculate the
indicated half-lives.
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Figure S171. (t1/2 = 1.47 ± 0.03 min) Proteolysis of 23Z (50 μM protein concentration in 20 mM sodium
phosphate buffer, pH 7) by proteinase K (10 mg/mL), as monitored by HPLC. Data points are shown as
black circles with error bars, and each represents the average of three replicate experiments. The solid red
line represents the fit of the data to a monoexponential decay function, which was used to calculate the
indicated half-lives.

Figure S172. (t1/2 = 1.95 ± 0.06 min) Proteolysis of 23Zp (50 μM protein concentration in 20 mM
sodium phosphate buffer, pH 7) by proteinase K (10 mg/mL), as monitored by HPLC. Data points are
shown as black circles with error bars, and each represents the average of three replicate experiments. The
solid red line represents the fit of the data to a monoexponential decay function, which was used to
calculate the indicated half-lives.
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Figure S173. (t1/2 = 4.24 ± 1.16 min) Proteolysis of 27Z (50 μM protein concentration in 20 mM sodium
phosphate buffer, pH 7) by proteinase K (10 mg/mL), as monitored by HPLC. Data points are shown as
black circles with error bars, and each represents the average of three replicate experiments. The solid red
line represents the fit of the data to a monoexponential decay function, which was used to calculate the
indicated half-lives.

Figure S174. (t1/2 = 5.60 ± 1.09 min) Proteolysis of 27Zp (50 μM protein concentration in 20 mM
sodium phosphate buffer, pH 7) by proteinase K (10 mg/mL), as monitored by HPLC. Data points are
shown as black circles with error bars, and each represents the average of three replicate experiments. The
solid red line represents the fit of the data to a monoexponential decay function, which was used to
calculate the indicated half-lives.
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Figure S175. (t1/2 = 0.24 ± 0.01 min) Proteolysis of 29Z (50 μM protein concentration in 20 mM sodium
phosphate buffer, pH 7) by proteinase K (10 mg/mL), as monitored by HPLC. Data points are shown as
black circles with error bars, and each represents the average of three replicate experiments. The solid red
line represents the fit of the data to a monoexponential decay function, which was used to calculate the
indicated half-lives.

Figure S176. (t1/2 = 0.26 ± 0.04 min) Proteolysis of 29Zp (50 μM protein concentration in 20 mM
sodium phosphate buffer, pH 7) by proteinase K (10 mg/mL), as monitored by HPLC. Data points are
shown as black circles with error bars, and each represents the average of three replicate experiments. The
solid red line represents the fit of the data to a monoexponential decay function, which was used to
calculate the indicated half-lives.
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Figure S177. (t1/2 = 1.99 ± 0.33 min) Proteolysis of 32Z (50 μM protein concentration in 20 mM sodium
phosphate buffer, pH 7) by proteinase K (10 mg/mL), as monitored by HPLC. Data points are shown as
black circles with error bars, and each represents the average of three replicate experiments. The solid red
line represents the fit of the data to a monoexponential decay function, which was used to calculate the
indicated half-lives.

Figure S178. (t1/2 = 2.27 ± 0.28 min) Proteolysis of 32Zp (50 μM protein concentration in 20 mM
sodium phosphate buffer, pH 7) by proteinase K (10 mg/mL), as monitored by HPLC. Data points are
shown as black circles with error bars, and each represents the average of three replicate experiments. The
solid red line represents the fit of the data to a monoexponential decay function, which was used to
calculate the indicated half-lives.
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3. INFLUENCE OF PEGYLATION ON THE STRENGTH OF PROTEIN SURFACE
SALT BRIDGES
*Reproduced with permission from ACS Chem. Biol. 2019, 14, 1652–1659 Copyright 2019 American Chemical Society.
*Qiang Xiao and Steven Draper are co-first author in this publication and both contributed to the work in this chapter. Qiang
Xiao performed the Asn-PEG scan in GCN4 and synthesized and collected data for the GCN4, 1CW, and one of the WW
triple mutant cycles. Steven Draper performed the other WW triple mutant cycle and crystalized and solved the crystal
structures in this work.

3.1 Introduction
We previously hypothesized that optimal PEGylation sites will be characterized by the
increased conformational stability of the PEG-protein conjugate relative to its non-PEGylated
counterpart.1, 2 The rationale for this hypothesis is that proteolysis, aggregation, and recognition
by neutralizing antibodies are generally more severe for unfolded proteins than for folded
proteins.3 Consequently, we have explored the impact of PEGylation on the conformational
stability of peptide and protein model systems in search of structure- or sequence-based criteria
for identifying conformationally stabilizing PEGylation sites. We found that PEG can increase
conformational stability, but the extent of stabilization depends strongly the location of the
PEGylation site2 and the chemistry used to connect PEG and protein.4, 5 Detailed thermodynamic
analyses and computational simulations suggest that the stabilizing impact of PEGylation derives
from an entropic effect, likely because PEG allows some first-shell water molecules to be released
to bulk solvent.2 We wondered whether such localized desolvation might increase the strength of
non-covalent interactions in the immediate vicinity of the PEGylation site; this possibility seemed
reasonable in light of several recent reports linking the strength of a salt bridge or of a hydrogen
bond to the polarity of its immediate microenvironment and its exposure to solvent.6-10
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Figure 1. (A) Ribbon diagram of dimeric helix bundle formed by peptide GCN4-p1 (PDB ID: 2ZTA) with side
chains shown as sticks. Positions where we incorporated Asn vs. AsnPEG are numbered and highlighted in gray.
(B) Structures of Asn vs. AsnPEG; Gln vs. GlnPEG; and PrF vs. PrFPEG. (C)–(H) Summary of triple mutant box
analysis of PEGylation sites and nearby salt bridges (highlighted in orange and gray, respectively) within peptides
based on α-helical coiled-coil dimer GCN4 (PDB ID: 2ZTA): (C) 2α4 vs. p2α4 and (D) 2α18 vs. p2α18; α-helical
coiled-coil trimer 1CW (PDB ID: 1COI): (E) 3α1 vs p3α1 and (F) 3α6 vs. p3α6; and two closely related variants of
β-sheet protein WW (PDB IDs: 2F21 and 1PIN): (G) β18 vs. pβ18 and (H) β23 vs. pβ23. Impact of PEGylation on
salt bridge strength (ΔΔΔΔGf) is indicated below each figure ± standard error in kcal/mol.

3.2 Results and Discussion
We explored this possibility in the context of dimeric helix-bundle peptide GCN4-p1 (Figure
1A).11 As with other helix bundles, the primary sequence of GCN4-p1 is characterized by a sevenresidue repeating pattern in which non-polar residues occupy positions a and d of an abcdefg
heptad, with polar and/or charged residues predominantly occupying the other positions. Such an
arrangement aligns the non-polar a- and d-position along the same side of the peptide in the αhelical conformation; burial of these residues at the interface between the two helices provides the
driving force for helix-bundle formation.12 In contrast, residues at the other five positions are
solvent-exposed and are therefore ideal locations for probing the impact of PEG-based desolvation
on the strength of non-covalent interactions at the protein surface. Accordingly, Qiang Xiao
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prepared GCN4-p1 variants p2α1, p2α3, p2α4, p2α6, p2α7, p2α10, p2α14, p2α18, p2α21, p2α25,
and p2α28, in which we incorporated an asparagine-linked monomethoxy-PEG (i.e., AsnPEG,
Table 1. Sequences, melting temperatures and folding free energies of GCN4-p1 variants 2α1, 2α3, 2α4, 2α6, 2α7,
2α10, 2α14, 2α18, 2α21, 2α25, 2α28 and their PEGylated counterparts.a
Sequence
Tm (°C) ΔGf (kcal/mol)
ΔΔGf b (kcal/mol)
gabcdefgabcdefgabcdefgabcdefgab
NMKQLEDKVEELLSKNYHLENEVARLKKLVG
2α1
48.8
-7.08 ± 0.02
N••••••••••••••••••••••••••••••
p2α1
47.7
-6.92 ± 0.02
0.08 ± 0.02
••N••••••••••••••••••••••••••••
2α3
39.0
-5.83 ± 0.02
••N••••••••••••••••••••••••••••
p2α3
37.1
-5.60 ± 0.03
0.12 ± 0.02
•••N•••••••••••••••••••••••••••
2α4
43.8
-6.39 ± 0.02
•••N•••••••••••••••••••••••••••
p2α4
37.1
-5.70 ± 0.02
0.35 ± 0.02
•••••N•••••••••••••••••••••••••
2α6
36.4
-5.60 ± 0.01
•••••N•••••••••••••••••••••••••
p2α6
32.8
-5.14 ± 0.03
0.23 ± 0.01
••••••N••••••••••••••••••••••••
2α7
48.1
-7.00 ± 0.02
••••••N••••••••••••••••••••••••
p2α7
43.0
-6.27 ± 0.02
0.36 ± 0.01
•••••••••N•••••••••••••••••••••
2α10
55.4
-8.06 ± 0.02
•••••••••N•••••••••••••••••••••
p2α10
46.4
-6.72 ± 0.02
0.67 ± 0.02
•••••••••••••N•••••••••••••••••
2α14
51.9
-7.65 ± 0.02
•••••••••••••N•••••••••••••••••
p2α14
52.1
-7.72 ± 0.02
-0.07 ± 0.03
•••••••••••••••••N•••••••••••••
2α18
45.8
-6.67 ± 0.01
•••••••••••••••••N•••••••••••••
p2α18
47.3
-6.90 ± 0.01
-0.11 ± 0.01
••••••••••••••••••••N••••••••••
2α21
52.6
-7.75 ± 0.02
••••••••••••••••••••N••••••••••
p2α21
49.7
-7.27 ± 0.02
0.24 ± 0.01
••••••••••••••••••••••••N••••••
2α25
47.8
-6.97 ± 0.02
••••••••••••••••••••••••N••••••
p2α25
45.6
-6.62 ± 0.02
0.17 ± 0.01
•••••••••••••••••••••••••••N•••
2α28
45.0
-6.53 ± 0.01
•••••••••••••••••••••••••••N•••
p2α28
46.6
-6.79 ± 0.02
-0.13 ± 0.01
a
Folding free energies are given ± standard error in kcal/mol at 30 µM protein concentration in 20 mM sodium
phosphate buffer (pH 7) at the average melting temperature of variants 2α1, 2α3, 2α4, 2α6, 2α7, 2α10, 2α14, 2α18,
2α21, 2α25, 2α28 and their PEGylated counterparts (318.5 K). ΔΔGf values represent the energetic contribution of a
single AsnPEGylation event to helix-bundle conformational stability.
Peptide

comprised of four ethylene oxide units; Figure 1B) at solvent exposed positions 1, 3, 4, 6, 7, 10,
14, 18, 21, 25, and 28, respectively (Figure 1A, Table 1). Qiang Xiao also prepared their Asncontaining sequence-matched non-PEGylated counterparts 2α1, 2α3, 2α4, 2α6, 2α7, 2α10, 2α14,
2α18, 2α21, 2α25, and 2α28. We used variable temperature CD experiments to obtain the apparent
melting temperatures (Tm) and folding free energies (ΔGf) of each variant listed in Table 1, along
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with the impact of PEGylation on the conformational stability of each PEGylated variant relative
to its non-PEGylated counterpart (ΔΔGf).
Asn-PEGylation has a minimal effect at positions 1, 3, 14 within GCN4-p1; is destabilizing at
positions 4, 6, 7, 10, 21, and 25; and is slightly stabilizing at positions 18 and 28 (Table 1). We
examined the structural context of each of these PEGylation sites to explore whether their
proximity to any nearby non-covalent interactions was related to the overall impact of PEGylation
on the helix bundle. Interestingly, positions 4 and 18 share a similar structural context: they each
occupy the i–4 position relative to an i to i+3 salt bridge: Lys8–Glu11 in p2α4 (Figure 1C) and
Glu22–Arg25 in p2α18 (Figure 1D). However, PEGylation has opposite effects at these positions:
p2α4 is less stable than 2α4, whereas p2α18 is more stable than 2α18. We wondered whether these
differences might be reflected in the impact of PEG on the strength of the Lys8–Glu11 salt bridge
in p2α4 vs. the Glu22–Arg25 salt bridge in p2α18.
We explored this possibility using triple mutant cycle analysis as we have done previously.13
Qiang Xiao prepared six additional variants of 2α4 and p2α4 in which we replaced Lys8 and
Glu11 with Ala, individually (2α4-ΚΑ, 2α4-AE, p2α4-ΚΑ, p2α4-AE) and in combination (2α4AΑ, p2α4-AA). For the non-PEGylated variants, comparing the impact of the Ala8 to Lys8
mutation in the presence of Ala11 (2α4-KΑ vs. 2α4-AΑ, ΔΔGf = 0.03 ± 0.02 kcal/mol) vs. Glu11
(2α4 vs. 2α4-AE, ΔΔGf = -0.03 ± 0.02 kcal/mol) reveals that the Lys8–Glu11 salt bridge does not
contribute substantially to the stability of 2α4 (ΔΔΔGf = -0.06 ± 0.02 kcal/mol). For the PEGylated
variants, comparing analogous variants (p2α4-KA vs. p2α4-AA, ΔΔGf = 0.36 ± 0.01 kcal/mol;
2α4 vs. 2α4-AE, ΔΔGf = 0.41 ± 0.01 kcal/mol) reveals that the Lys8-Glu11 salt bridge has a
similarly small impact on the stability of p2α4 (ΔΔΔGf = 0.05 ± 0.02 kcal/mol), indicating that
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PEG has a minimal impact on the strength of the Lys8–Glu11 salt bridge (ΔΔΔΔGf = 0.11 ± 0.03
kcal/mol).
Table 2. Triple mutant box analysis of the impact of PEGylation on salt-bridge strength within peptides p2α4, p2α18,
p3α1, and p3α6.a
ΔGf
ΔΔGf b
ΔΔΔGf c
ΔΔΔΔGf d
(kcal/mol)
(kcal/mol)
(kcal/mol)
(kcal/mol)
2α4
43.8
-6.80 ± 0.03
-0.06 ± 0.03
2α4-KA
39.1
-6.23 ± 0.02
2α4-AE
43.6
-6.74 ± 0.03
2α4-AA
39.6
-6.29 ± 0.03
p2α4
37.1
-6.03 ± 0.03 0.38 ± 0.02 0.04 ± 0.02 0.11 ± 0.03
p2α4-KA
39.6
-6.27 ± 0.02 -0.02 ± 0.01
p2α4-AE
44.3
-6.85 ± 0.03 -0.06 ± 0.02
p2α4-AA
45.2
-7.00 ± 0.02 -0.35 ± 0.02
2α18
45.8
-7.74 ± 0.02
-0.46 ± 0.02
2α18-EA
42.1
-7.07 ± 0.03
2α18-AR
31.1
-5.59 ± 0.02
2α18-AA
33.7
-5.84 ± 0.02
p2α18
47.3
-7.93 ± 0.02 -0.10 ± 0.01 -1.14 ± 0.03 -0.69 ± 0.03
p2α18-EA
38.3
-6.51 ± 0.04 0.28 ± 0.02
p2α18-AR
28.7
-5.30 ± 0.02 0.14 ± 0.01
p2α18-AA
35.9
-6.17 ± 0.02 -0.16 ± 0.01
3α1
77.4
-15.24 ± 0.02
-0.35 ± 0.01
3α1-EA
76.0
-14.90 ± 0.02
3α1-AK
73.2
-14.23 ± 0.02
3α1-AA
76.1
-14.92 ± 0.03
p3α1
75.4
-14.76 ± 0.02 0.16 ± 0.01 -0.40 ± 0.01 -0.05 ± 0.02
p3α1-EA
73.9
-14.40 ± 0.02 0.17 ± 0.01
p3α1-AK
71.2
-13.76 ± 0.01 0.15 ± 0.01
p3α1-AA
74.7
-14.59 ± 0.02 0.11 ± 0.01
3α6
77.2
-15.71 ± 0.02
-0.99 ± 0.01
3α6-KA
67.4
-13.48 ± 0.02
3α6-AE
72.4
-14.51 ± 0.02
3α6-AA
75.5
-15.25 ± 0.02
p3α6
73.3
-14.73 ± 0.02 0.32 ± 0.01 -1.10 ± 0.01 -0.11 ± 0.02
p3α6-KA
64.9
-13.08 ± 0.01 0.13 ± 0.01
p3α6-AE
70.7
-14.10 ± 0.01 0.14 ± 0.01
p3α6-AA
77.7
-15.76 ± 0.03 -0.17 ± 0.01
a
Variable temperature CD experiments were performed in 20 mM phosphate buffer (pH 7) at 30 μM protein
concentration except for the WW variants β18 and β23 and their derivatives, which were characterized at 50 μΜ. ΔGf
values are given ± standard error. ΔGf values for each of the eight peptides within the same triple mutant cycle were
calculated at their average melting temperature: 314.7 K for 2α4 and its derivatives; 311.0 K for 2α18 and its
derivatives; 347.9 K for 3α1 and its derivatives; 345.5 K for 3α6 and its derivatives; bImpact of PEGylation on
peptide/protein conformational stability. cStrength of salt-bridge interaction. dImpact of PEGylation on salt-bridge
strength.
Peptide

Tm (°C)
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Table 3. Triple mutant box analysis of the impact of PEGylation on salt-bridge strength within peptides pβ18 and
pβ23.a
ΔGf
ΔΔGf b
ΔΔΔGf c
ΔΔΔΔGf d
(kcal/mol)
(kcal/mol)
(kcal/mol)
(kcal/mol)
β18
77.7
-0.53 ± 0.02
-0.50 ± 0.03
β18-DA
68.7
0.37 ± 0.01
β18-SR
69.5
0.30 ± 0.01
β18-SA
65.7
0.70 ± 0.01
pβ18
80.4
-0.78 ± 0.02 -0.25 ± 0.02 -0.54 ± 0.02 -0.03 ± 0.04
pβ18-DA
71.3
0.09 ± 0.01 -0.28 ± 0.01
pβ18-SR
74.3
-0.21 ± 0.01 -0.51 ± 0.01
pβ18-SA
70.8
0.13 ± 0.01 -0.57 ± 0.02
β23
51.9
-0.35 ± 0.02
-0.35 ± 0.03
β23-EA
42.5
0.42 ± 0.01
β23-AR
48.0
-0.04 ± 0.01
β23-AA
42.8
0.38 ± 0.02
pβ23
55.6
-0.64 ± 0.02 -0.28 ± 0.03 -0.78 ± 0.03 -0.43 ± 0.04
pβ23-EA
43.4
0.31 ± 0.01 -0.11 ± 0.02
pβ23-AR
48.6
-0.09 ± 0.02 -0.05 ± 0.02
pβ23-AA
46.5
0.08 ± 0.01 -0.30 ± 0.02
a
Variable temperature CD experiments were performed in 20 mM phosphate buffer (pH 7) at 30 μM protein
concentration except for the WW variants β18 and β23 and their derivatives, which were characterized at 50 μΜ. ΔGf
values are given ± standard error. ΔGf values for each of the eight peptides within the same triple mutant cycle were
calculated at their average melting temperature 345.4 K for β18 and its derivatives; 320.6 K for β23 and its derivatives.
b
Impact of PEGylation on peptide/protein conformational stability. cStrength of salt-bridge interaction. dImpact of
PEGylation on salt-bridge strength.
Peptide

Tm (°C)

Qiang Xiao performed analogous experiments with 2α18 and p2α18 and their six sequence
mutants (2α18-EΑ, 2α18-AR, 2α18-AA, p2α18-EΑ, p2α18-AR, p2α18-AA). When Asn
occupies position 18, the Glu22–Arg25 salt bridge contributes -0.45 ± 0.02 kcal/mol to the stability
of 2α18; when AsnPEG occupies position 18, the Glu22–Arg25 salt bridge contributes -1.14 ±
0.03 kcal/mol to the stability of p2α18, indicating that PEG stabilizes the Glu22–Arg25 salt bridge
by -0.69 ± 0.03 kcal/mol. We wondered whether other stabilizing PEGylation sites might be
similarly characterized by their ability to increase the strength of nearby salt bridges. To test this
hypothesis, we explored PEGylation sites near salt bridges within a second α-helical model system
(i.e the trimeric helix bundle 1CW)13-15 and within a β-sheet model protein (the WW domain of
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the human protein Pin1).16, 17 The variants and positions we explored are summarized in Figure
1E–H and in Table 2 and 3.
Position 1 within 1CW is oriented toward a nearby i to i+4 salt bridge comprised of Glu3 and
Lys7 on an adjacent helix within the trimer (Figure 1E). Qiang Xiao generated variant 3α1 and its
PEGylated counterpart p3α1 by incorporating Gln vs. Gln-PEG (Figure 1B) at position 1 within
1CW (Table 2). We chose to use Gln vs. Gln-PEG because they more closely resemble the residue
that occupies position 1 (i.e. Glu) within the parent 1CW peptide from which these variants were
derived. Gln-PEGylation slightly destabilizes p3α1 and relative to 3α1. Comparing ΔGf values for
p3α1 and 3α1 with those of their sequence variants (3α1-EA, 3α1-AK, 3α1-AA, p3α1-EA, p3α1AK, and p3α1-AA) reveals that PEGylation at Gln1 does not substantially change the strength of
the Glu3–Lys7 salt bridge (ΔΔΔΔGf = -0.05 ± 0.02 kcal/mol), which contributes favorably to helix
bundle stability whether or not PEG is present (Table 2).
Position 6 within 1CW is oriented toward a salt bridge between Lys8 on an adjacent helix and
Glu13 within the same helix (Figure 1F). Accordingly, Qiang Xiao prepared 1CW variant 3α6 and
its PEGylated counterpart p3α6, in which we incorporated Gln vs. Gln-PEG, respectively, at
position 6; as with position 1 above, the residue that occupies this position in the parent 1CW is
Glu. Gln-PEGylation destabilizes p3α6 by 0.32 ± 0.01 kcal/mol relative to 3α6 (Table 2). Triple
mutant cycle analysis of p3α6, 3α6, and their sequence variants at positions 8 and 13 (p3α6-KA,
p3α6-AE, p3α6-AA, 3α6-KA, 3α6-AE, and 3α6-AA) indicates that the Lys8–Glu13 salt bridge
contributes strongly to helix bundle conformational stability (ΔΔΔGf = -0.99 ± 0.01 kcal/mol) with
PEGylation of Gln6 only slightly increasing salt bridge strength (ΔΔΔΔGf = -0.11 ± 0.02
kcal/mol).
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Position 18 within WW (normally occupied by Asp) occupies the same reverse turn as nearby
positions 16 and 21, which are normally occupied by Ser and Arg, respectively (Figure 1G). Side
chains at these three positions occupy the same face of the reverse turn. We envisioned that
incorporating Asn-PEG vs. Asn at position 18 and Asp at position 16 might allow PEG to stabilize
a salt bridge between Asp16 and Arg21. Accordingly, Qiang Xiao prepared WW variants β18 and
pβ18, with Asp at position 16, Asn vs. Asn-PEG at position 18, respectively, and Arg at position
21. PEGylation modestly stabilizes pβ18 relative to β18 (ΔΔGf = -0.25 ± 0.02 kcal/mol). Triple
mutant cycle analysis of pβ18, β18, and their sequence variants (pβ18-DA, pβ18-SR, pβ18-SA,
β18-DA, β18-SR, and β18-SA) indicates that the Asp16-Arg21 salt bridge is stabilizing (ΔΔΔGf
= -0.50 ± 0.03 kcal/mol), but PEGylation at position 18 does not affect its strength (ΔΔΔΔGf = 0.03 ± 0.04 kcal/mol, Table 3).
Finally, we recently found that conjugating an azido-functionalized four-unit PEG to a
propargyloxyphenylalanine residue (PrF, Figure 1B) at position 23 within WW increases the
conformational stability of the PEGylated protein (pβ23) relative to its non-PEGylated counterpart
β23 (Table 3; ΔΔGf = -0.28 ± 0.03 kcal/mol).4 Position 23 within WW (normally occupied by Tyr)
is oriented toward a salt bridge between Glu12 and Arg14 on an adjacent β-strand (Figure 1H),
and we wondered whether PEG-based stabilization of the Glu12–Arg14 salt bridge might partially
account for the increased stability of pβ23 relative to β23. Triple mutant cycle analysis of pβ23
and β23 and their sequence variants pβ23-EA, pβ23-AR, pβ23-AA, β23-EA, β23-AR, and β23AA (prepared by Steven Draper) indicates that the Glu12–Arg14 salt bridge contributes -0.35 ±
0.03 kcal/mol to WW conformational stability, with PEGylation increasing the strength of the salt
bridge by an additional -0.43 ± 0.04 kcal/mol.
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These results are summarized in
Figure 2, which plots salt bridge strength
(ΔΔΔGf) within non-PEGylated variants
2α4, 2α18, 3α1, 3α6, β18, and β23 (xaxis) vs. salt bridge strength (ΔΔΔGf)
within PEGylated variants p2α4, p2α18,
p3α1, p3α6, pβ18, and pβ23 (y-axis).
PEGylation data points for 2α4, 3α1, 3α6,
and β18 fit readily to a line with slope =
Figure 2. Plot of salt-bridge strength (ΔΔΔGf) within PEGylated
variants p2α4, p2α18, p3α1, p3α1-ER, p3α6, pβ18, and pβ23
vs. salt-bridge strength (ΔΔΔGf) within the corresponding nonPEGylated variants 2α4, 2α18, 3α1, p3α1-ER, 3α6, β18, and
β23. Data for p2α18 vs. 2α18 and pβ23 vs. β23 are highlighted
in orange; at these positions salt bridges are stronger in the
presence of PEG than without PEG. Dotted line represents linear
regression of the data for p2α4 vs. 2α4, p3α1 vs. 3α1, p3α1-ER
vs. 3α1-ER, p3α6 vs. 3α6, and pβ18 vs. β18 (points highlighted
in blue), in which PEGylation does not substantially change the
salt-bridge strength.

1.2 ± 0.01 (p = 0.001), indicating that PEG
has no substantial impact on salt bridge
strength for these variants. In contrast,
data points for 2α18 and β23 are
exceptions to this trend: the salt bridges

we investigated are stronger within PEGylated p2α18 and pβ23 than in non-PEGylated 2α18 and
β23. We wondered whether p2α18 and pβ23 had any common features that might explain this
observation. We noticed that both p2α18 and pβ23 contained a Glu–Arg salt bridge; in contrast,
p2α4, p3α1, p3α6 contain a Glu–Lys salt bridge and pβ18 contains an Asp–Arg salt bridge. To
explore whether Glu–Arg salt bridges are uniquely subject to PEG-based stabilization, we prepared
variants 3α1-ER, 3α1-AR, p3α1-ER, p3α1-AR, in which Arg occupies position 7 in 1CW rather
than Lys. Comparing folding free energies of these variants (see supporting information section
below) vs. those of previously characterized 3α1-EA, 3α1-AA, p3α1-EA, and p3α1-AA reveals
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Figure 3. (A)–(B) Ribbon diagram of α-helical coiled-coil dimers formed by GCN4-p1 variant 2α18 (PDB ID: 6O2E)
and its PEGylated counterpart p2α18 (PDB ID: 6O2F), respectively, with side chains shown as sticks. Asn18 is
highlighted in gray, with the Glu22-Arg25 salt bridge highlighted in orange. Also shown are close up views of Asn18,
Glu22, and Arg25 within a single helix (yellow) within the crystalline lattices formed by variants 2α18 and p2α18,
respectively. Gray mesh represents electron density contoured at 0.5 σ.

that PEGylation does not substantially change the strength of the Glu3-Arg7 salt bridge (although
the Glu3-Arg7 salt bridge in 3α1-ER is stronger than the corresponding Glu3-Lys7 salt bridge in
3α1). It appears from this observation that salt-bridge residue identity alone is not a sufficient
predictor of the impact of PEGylation on salt bridge strength.
To gain structural insight into how PEG affects the Glu22-Arg25 salt bridge in 2α18 vs p2α18,
Steven Draper crystallized these variants, obtained x-ray diffraction data, and solved their
structures via molecular replacement (Figure 3A-B, respectively). The structures for 2α18 (PDB
ID: 6O2E) and p2α18 (PDB ID: 6O2F) are extremely similar overall (rmsd = 0.113 Å) with
identical distances between Glu22 and Arg25, indicating that the increased strength of the Glu22Arg25 salt bridge in the presence of PEG does not come from increased proximity of these charged
groups. However, differences in the crystallographic data become more apparent upon close
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inspection of the electron density maps of 2α18 vs. p2α18: the area immediately surrounding
Asn18, Glu22 and Arg25 in PEGylated p2α18 contains substantially more electron density than
the corresponding area in non-PEGylated 2α18 (Figure 3A-B). Indeed, electron density for the
Asn18 side chain in p2α18 continues to extent outward from the side-chain amide nitrogen, which
is consistent with the presence of Asn-PEG at position 18 within p2α18 (as confirmed by mass
spectrometry; see supporting information section below). Including an explicit Asn-linked PEG at
position 18 in our crystallographic model for p2α18 allowed us to account for some of this extra
electron density and led to modest improvements in the statistical quality of the model. However,
no single conformation of PEG accounted for all of the observed extra electron density; similar
improvements in the statistical quality of the model resulted from including explicit
crystallographic water molecules in the place of PEG. Based on these observations, we speculate
that the Asn-linked PEG at position 18 in the crystalline state of p2α18 is disordered but likely
occupies the space between Asn18, Glu22 and Arg25. These observations apply specifically to the
crystalline state, but it is tempting to extrapolate them to the solution behavior of p2α18: it is
possible that PEG occupies space in the immediate vicinity of the Glu22-Arg25 salt bridge, thereby
increasing its strength through partial desolvation.
3.3 Conclusion
Here we have shown that a short PEG oligomer can increase protein conformational stability
by increasing the strength of a nearby salt bridge in two distinct secondary structural contexts,
including an i to i+4 Glu-Arg salt bridge within an α-helix and an intra-strand i to i+2 Glu-Arg salt
bridge within a β-sheet. High-resolution crystallography data supports the possibility that PEG
adopts a disordered conformation near the Glu22–Arg25 salt bridge within GCN4 variant p2α18,
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occupying space that would normally be occupied by water. It is possible that this effect is partially
responsible for the PEG-based stabilization of the Glu22-Arg25 salt bridge. However, the
structural prerequisites for this effect are not a simple function of secondary structural context,
orientation and distance of the PEGylation site with respect to the salt bridge, or of salt-bridge
residue identity. PEGylation did not increase the strength of some salt-bridges, for reasons that
remain unclear. Previous work showed that the structure of the PEG-protein linkage is a major
determinant of PEG-based stabilization at a given PEGylation site.4, 5 Moreover, a short PEG
oligomer comprised of three ethylene oxide units can almost entirely recapitulate the PEG-based
stabilization associated with a longer 45-unit PEG.1, 2 These observations suggest that the impact
of PEG-based protein stabilization derives primarily from the PEG-protein linker and the first few
atoms of the attached PEG, which perturb the microenvironment in the immediate vicinity of the
PEGylation site, including nearby side-chain and backbone groups, along with water molecules in
the first solvent shell. If so, the minimal impact of PEG on the stability of nearby salt bridges
within p2α4, p3α1, p3α6, and pβ18 could reflect our choice of suboptimal linkers at these
positions (Asn-PEG, Gln-PEG, Gln-PEG, and Asn-PEG, respectively) vs. serendipitously optimal
linkers at corresponding positions within p2α18 and pβ23 (Asn-PEG and PrF-PEG, respectively).
More broadly, our results also highlight the importance of considering the extent to which sidechain functionalization (e.g. with a fluorophore, an affinity tag, a post-translational modification,
etc.) perturbs interactions with and among water molecules and side-chain or backbone groups in
the localized microenvironment and hydration sphere of the conjugation site.
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3.4 Supporting Information

3.4.1 Protein Synthesis, Purification and Characterization: All peptide variants were
synthesized as C-terminal acids by Fmoc-based solid-phase peptide synthesis as described
previously.5 β18, pβ18, β18-SR, pβ18-SR and β23 and pβ23 were synthesized previously.5, 18
Peptides with carboxyl termini were synthesized on Fmoc-Gly-Wang resin (EMD Biosciences)
and those with amidated termini were synthesized on Rink amide resin (Advanced Chem Tech).
We used standard Fmoc-protected amino acids with acid-labile sidechain protecting groups. We
used

previously

synthesized

Fmoc-L-GlnPEG4-OH

[18-((((9H-fluoren-9-

yl)methoxy)carbonyl)amino)-15-oxo-2,5,8,11-tetraoxa-14-azanonadecan-19-oic
previously

synthesized

Fmoc-L-PrF-OH

acid],5

N-[(9H-Fluoren-9-ylmethoxy)-O-2-propyn-1yl-L-

tyrosine,19 and previously synthesized PEG-azide 13-azido-2,5,8,11-tetraoxatridecane2 for
PEGylating the PrF peptides via the copper (I) catalyzed azide-alkyne cycloaddition.5 For the
asparagine PEG peptides we used previously synthesized Fmoc-L-(AsnPEG4)2-OH [(S)-17((((9H-fluoren-9-yl)methoxy)carbonyl)amino)-15-oxo-14-(2,5,8,11-tetraoxatridecan-13-yl)2,5,8,11-tetraoxa-14-azaoctadecan-18-oic acid].5 Other reagents we used were: 2-(1Hbenzotriazole-1-yl)-1,1,3,3-tetramethyluronium

hexafluorophosphate

(HBTU)

and

N-

hydroxybenzotriazole hydrate (HOBt) from Advanced ChemTech for amino acid activation; 20%
piperidine in N,N-dimethylformamide for removal of the Fmoc protecting group from the Nterminal α- amine; a solution of a solution of phenol (0.0625 g), water (62.5 μL), thioanisole (62.5
μL), ethanedithiol (31 μL) and triisopropylsilane (12.5 μL) in trifluoroacetic acid (TFA, 1 mL) for
cleaving the protein from resin and globally removing acid-labile side-chain protecting groups.
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Proteins were precipitated from the TFA solution by addition of diethyl ether (~40 mL). Following
centrifugation, the ether was decanted, and the pellet was dissolved in ~40mL 1:1 H2O/MeCN,
then flash frozen over dry ice in acetone and lyophilized to remove volatile impurities. The
resulting powder was stored at -20°C until purification.
Proteins were purified by preparative reverse-phase high performance liquid chromatography
(HPLC) on a C18 column using a linear gradient of water in acetonitrile with 0.1% v/v TFA.
Fractions containing the desired protein product were pooled, frozen, and lyophilized. Proteins
were identified by electrospray ionization time of flight mass spectrometry (ESI-TOF); expected
and observed exact masses mass spectra appear in Table S1, S2 and S3 and spectra appear in
Figures S1-S63. Protein purity was assessed by Analytical HPLC (Figures S64-S127).
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Table S1. Sequences, molecular formulas, expected and observed m/z ratios for GCN4 variants.

Peptide

Sequence

Ac-NMKQLEDKVEELLSKNYHLENEVARLKKLVG-NH2
Ac-N••••••••••••••••••••••••••••••-NH2
Ac-RMNQLEDKVEELLSKNYHLENEVARLKKLVG -NH2
Ac-••N••••••••••••••••••••••••••••-NH2
Ac-RMKNLEDKVEELLSKNYHLENEVARLKKLVG-NH2
Ac-•••NLEDKVEA••••••••••••••••••••-NH2
Ac-•••NLEDAVEE••••••••••••••••••••-NH2
Ac-•••NLEDAVEA••••••••••••••••••••-NH2
Ac-•••NLEDKVEE••••••••••••••••••••-NH2
Ac-•••NLEDKVEA••••••••••••••••••••-NH2
Ac-•••NLEDAVEE••••••••••••••••••••-NH2
Ac-•••NLEDAVEA••••••••••••••••••••-NH2
Ac-RMKQLNDKVEELLSKNYHLENEVARLKKLVG-NH2
Ac-•••••N•••••••••••••••••••••••••-NH2
Ac-RMKQLENKVEELLSKNYHLENEVARLKKLVG-NH2
Ac-••••••N••••••••••••••••••••••••-NH2
Ac-RMKQLEDKVNELLSKNYHLENEVARLKKLVG-NH2
Ac-•••••••••N•••••••••••••••••••••-NH2
Ac-RMKQLEDKVEELLNKNYHLENEVARLKKLVG-NH2
Ac-•••••••••••••N•••••••••••••••••-NH2
Ac-RMKQLEDKVEELLSKNYNLENEVARLKKLVG-NH2
Ac-•••••••••••••••••NLENEVAA••••••-NH2
Ac-•••••••••••••••••NLENAVAR••••••-NH2
Ac-•••••••••••••••••NLENAVAA••••••-NH2
p2α18
Ac-•••••••••••••••••NLENEVAR••••••-NH2
p2α18-EA Ac-•••••••••••••••••NLENEVAA••••••-NH2
p2α18-AR Ac-•••••••••••••••••NLENAVAR••••••-NH2
p2α18-AA Ac-•••••••••••••••••NLENAVAA••••••-NH2
2α21
Ac-RMKQLEDKVEELLSKNYHLENEVARLKKLVG-NH2
p2α21
Ac-••••••••••••••••••••N••••••••••-NH2
2α25
Ac-RMKQLEDKVEELLSKNYHLENEVNRLKKLVG-NH2
p2α25
Ac-•••••••••••••••••••••••N•••••••-NH2
2α28
Ac-RMKQLEDKVEELLSKNYHLENEVARLKNLVG-NH2
p2α28
Ac-•••••••••••••••••••••••••••N•••-NH2
2α1
p2α1
2α3
p2α3
2α4
2α4-KA
2α4-AE
2α4-AA
p2α4
2α4-KA
2α4-AE
2α4-AA
2α6
p2α6
2α7
p2α7
2α10
p2α10
2α14
p2α14
2α18
2α18-EA
2α18-AR
2α18-AA

4
4
4
4
4
4
4
4

Expected
[M+z∙H]/z
928.009
975.539
935.010
982.541
935.020
920.518
920.755
906.254

Observed
[M+z∙H]/z
927.987
975.539
935.015
982.535
935.016
920.522
920.759
906.257

4
4
4
4
4
4
4
4
4
4
4
4
4
4
4
4

982.550
968.051
968.285
953.787
934.774
982.304
938.277
985.808
934.774
982.304
945.276
992.806
932.769
911.503
918.268
897.002

982.550
968.051
968.289
953.787
934.765
982.298
938.273
985.802
934.770
982.302
945.268
992.806
932.762
911.505
918.271
897.006

4
4
4
4
4
4
4
4
4
4

980.300
959.034
965.798
944.532
938.523
986.054
949.275
996.805
935.010
982.541

980.298
959.036
965.802
944.536
938.516
986.053
949.268
996.805
935.013
982.541

z
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Table S2. Sequences, molecular formulas, expected and observed m/z ratios for 1CW variants.

Name

Sequence

z

3α1
3α1-ER
3α1-EA
3α1-AK
3α1-AR
3α1-AA

Ac-QVEALEKKVAALESKVQALEKKVEALEY-NH2
Ac-QVEALER•••••••••••••••••••••-NH2
Ac-QVEALEA•••••••••••••••••••••-NH2
Ac-QVAALEK•••••••••••••••••••••-NH2
Ac-QVAALER•••••••••••••••••••••-NH2
Ac-QVAALEA•••••••••••••••••••••-NH2
Ac-QVEALEK•••••••••••••••••••••-NH2
Ac-QVEALER•••••••••••••••••••••-NH2
Ac-QVEALEA•••••••••••••••••••••-NH2
Ac-QVAALEK•••••••••••••••••••••-NH2
Ac-QVAALER•••••••••••••••••••••-NH2
Ac-QVAALEA•••••••••••••••••••••-NH2
Ac-EVEALQKKVAALESKVQALEKKVEALEY-NH2
Ac-•••••QKKVAALA•••••••••••••••-NH2
Ac-•••••QKAVAALE•••••••••••••••-NH2
Ac-•••••QKAVAALA•••••••••••••••-NH2
Ac-•••••QKKVAALA•••••••••••••••-NH2
Ac-•••••QKAVAALE•••••••••••••••-NH2
Ac-•••••QKAVAALA•••••••••••••••-NH2
Ac-•••••QKKVAALA•••••••••••••••-NH2

3
3
3
3
3
3
3
3
3
3
3
3
3
3
3
3
3
3
3
3

p3α1
p3α1-ER
p3α1-EA
p3α1-AK
p3α1-AR
p3α1-AA
3α6
3α6-KA
3α6-AE
3α6-AA
p3α6
p3α6-KA
p3α6-AE
p3α6-AA

Expected
[M+z∙H]/z

1062.267
1071.602
1043.247
1042.931
1052.267
1023.912
1125.640
1134.976
1106.621
1106.305
1115.640
1087.286
1062.267
1042.931
1043.247
1023.912
1125.640
1106.305
1106.621
1087.286

Observed
[M+z∙H]/z

1062.264
1071.615
1043.245
1042.929
1052.280
1023.908
1125.636
1134.986
1106.616
1106.301
1115.653
1087.284
1062.260
1042.933
1043.241
1023.914
1125.633
1106.290
1106.620
1087.287
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Table S3. Sequences, molecular formulas, expected and observed m/z ratios for WW variants.

Name
β18
β18-DA
β18-SR
β18-SA
pβ18
pβ18-DA
pβ18-SR
pβ18-SA
β23
β23-EA
β23-AR
β23-AA
pβ23
pβ23-EA
pβ23-AR
pβ23-AA

Sequence

z

H2N-KLPPGWEKRMDANGRVYYFNHITNASQFERPSG-OH 4
H2N-••••••••••DANGA••••••••••••••••••-OH 4
H2N-••••••••••SANGR••••••••••••••••••-OH 3
H2N-••••••••••SANGA••••••••••••••••••-OH 3
H2N-••••••••••DANGR••••••••••••••••••-OH 4
H2N-••••••••••DANGA••••••••••••••••••-OH 4
H2N-••••••••••SANGR••••••••••••••••••-OH 4
H2N-••••••••••SANGA••••••••••••••••••-OH 4

H2N-KLPPGWEKRMSRSSGRVXYFNHITNASQFERPSG-OH --H2N-••••••EKAMSRSSGRVX••••••••••••••••-OH 4
H2N-••••••AKRMSRSSGRVX••••••••••••••••-OH 4
H2N-••••••AKAMSRSSGRVX••••••••••••••••-OH 4

H2N-••••••EKRMSRSSGRVX••••••••••••••••-OH --H2N-••••••EKAMSRSSGRVX••••••••••••••••-OH 4
H2N-••••••AKRMSRSSGRVX••••••••••••••••-OH 4
H2N-••••••AKAMSRSSGRVX••••••••••••••••-OH 4

Expected
[M+z∙H]/z
967.231

Observed
[M+z∙H]/z
967.226

945.965

945.948

1279.973

1279.973

1251.619

1251.607

1014.761

1014.747

993.495

993.483

1007.762

1007.751

986.496

986.482

---

---

984.741

984.735

991.506

991.503

970.240

970.232

---

---

1043.026

1043.020

1049.790

1049.787

1028.524

1028.517

Figure S1. ESI-TOF MS data for 2α1 (QX108111). Expected [M+4H+]/4 = 928.009.
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Figure S2. ESI-TOF MS data for p2α1 (QX108111p). Expected [M+4H+]/4 = 975.539.

Figure S3. ESI-TOF MS data for 2α3 (QX108110). Expected [M+4H+]/4 = 935.010.

Figure S4. ESI-TOF MS data for p2α3 (QX108110p). Expected [M+4H+]/4 = 982.541.
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Figure S5. ESI-TOF MS data for 2α4 (QX10819). Expected [M+4H+]/4 = 935.020.

Figure S6. ESI-TOF MS data for 2α4-KA (QX11192). Expected [M+4H+]/4 = 920.518.

Figure S7. ESI-TOF MS data for 2α4-AE (QX11193). Expected [M+4H+]/4 = 920.755.
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Figure S8. ESI-TOF MS data for 2α4-AA (QX11191). Expected [M+4H+]/4 = 906.254.

Figure S9. ESI-TOF MS data for p2α4 (QX10819p). Expected [M+4H+]/4 = 982.550.

Figure S10. ESI-TOF MS data for p2α4-KA (QX11195). Expected [M+4H+]/4 = 968.051.

158

Figure S11. ESI-TOF MS data for p2α4-AE (QX11196). Expected [M+4H+]/4 = 968.285.

Figure S12. ESI-TOF MS data for p2α4-AA (QX11194). Expected [M+4H+]/4 = 953.787.

Figure S13. ESI-TOF MS data for 2α6 (QX10818). Expected [M+4H+]/4 = 934.774.
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Figure S14. ESI-TOF MS data for p2α6 (QX10818p). Expected [M+4H+]/4 = 982.304.

Figure S15. ESI-TOF MS data for 2α7 (QX10817). Expected [M+4H+]/4 = 938.277.

Figure S16. ESI-TOF MS data for p2α7 (QX10817p). Expected [M+4H+]/4 = 985.808.
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Figure S17. ESI-TOF MS data for 2α10 (QX10816). Expected [M+4H+]/4 = 934.774.

Figure S18. ESI-TOF MS data for p2α10 (QX10816p). Expected [M+4H+]/4 = 982.304.

Figure S19. ESI-TOF MS data for 2α14 (QX10815). Expected [M+4H+]/4 = 945.276.
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Figure S20. ESI-TOF MS data for p2α14 (QX10815p). Expected [M+4H+]/4 = 992.806.

Figure S21. ESI-TOF MS data for 2α18 (QX10814). Expected [M+4H+]/4 = 932.769.

Figure S22. ESI-TOF MS data for 2α18-EA (NAB10212). Expected [M+4H+]/4 = 911.503.
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Figure S23. ESI-TOF MS data for 2α18-AR (NAB10211). Expected [M+4H+]/4 = 918.268.

Figure S24. ESI-TOF MS data for 2α18-AA (NAB10213). Expected [M+4H+]/4 = 897.002.

Figure S25. ESI-TOF MS data for p2α18 (QX10814p). Expected [M+4H+]/4 = 980.300.
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Figure S26. ESI-TOF MS data for p2α18-EA (NAB10215). Expected [M+4H+]/4 = 959.034.

Figure S27. ESI-TOF MS data for p2α18-AR (NAB10214). Expected [M+4H+]/4 = 965.798.

Figure S28. ESI-TOF MS data for p2α18-AA (NAB10216). Expected [M+4H+]/4 = 944.532.

164

Figure S29. ESI-TOF MS data for 2α21 (QX10813). Expected [M+4H+]/4 = 938.523.

Figure S30. ESI-TOF MS data for p2α21 (QX10813p). Expected [M+4H+]/4 = 986.054.

Figure S31. ESI-TOF MS data for 2α25 (QX10812). Expected [M+4H+]/4 = 949.275.
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Figure S32. ESI-TOF MS data for p2α25 (QX10812p). Expected [M+4H+]/4 = 996.805.

Figure S33. ESI-TOF MS data for 2α28 (QX10811). Expected [M+4H+]/4 = 935.010.

Figure S34. ESI-TOF MS data for p2α28 (QX10811p). Expected [M+4H+]/4 = 982.541.
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Figure S35. ESI-TOF MS data for 3α1 (QX10714). Expected [M+3H+]/3 = 1062.267.

Figure S36. ESI-TOF MS data for 3α1-ER (QX21532). Expected [M+3H+]/3 =1071.602.

Figure S37. ESI-TOF MS data for 3α1-EA (QX10713). Expected [M+3H+]/3 = 1043.247.
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Figure S38. ESI-TOF MS data for 3α1-AK (QX10712). Expected [M+3H+]/3 = 1042.931.

Figure S39. ESI-TOF MS data for 3α1-AR (QX21531). Expected [M+3H+]/3 =1052.267.

Figure S40. ESI-TOF MS data for 3α1-AA (QX10711). Expected [M+3H+]/3 = 1023.912.
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Figure S41. ESI-TOF MS data for p3α1 (QX10718). Expected [M+3H+]/3 = 1125.640.

Figure S42. ESI-TOF MS data for p3α1-ER (QX21534). Expected [M+3H+]/3 =1134.976.

Figure S43. ESI-TOF MS data for p3α1-EA (QX10717). Expected [M+3H+]/3 = 1106.621.
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Figure S44. ESI-TOF MS data for p3α1-AK (QX10716). Expected [M+3H+]/3 = 1106.305.

Figure S45. ESI-TOF MS data for p3α1-AR (QX21533). Expected [M+3H+]/3 =1115.640.

Figure S46. ESI-TOF MS data for p3α1-AA (QX10715). Expected [M+3H+]/3 = 1087.286.
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Figure S47. ESI-TOF MS data for 3α6 (QX10511). Expected [M+3H+]/3 = 1062.267.

Figure S48. ESI-TOF MS data for 3α6-KA (QX10512). Expected [M+3H+]/3 = 1042.931.

Figure S49. ESI-TOF MS data for 3α6-AE (QX10513). Expected [M+3H+]/3 = 1043.247.
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Figure S50. ESI-TOF MS data for 3α6-AA (QX10514). Expected [M+3H+]/3 = 1023.912.

Figure S51. ESI-TOF MS data for p3α6 (QX10515). Expected [M+3H+]/3 = 1125.640.

Figure S52. ESI-TOF MS data for p3α6-KA (QX10516). Expected [M+3H+]/3 = 1106.305.
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Figure S53. ESI-TOF MS data for p3α6-AE (QX10517). Expected [M+3H+]/3 = 1106.621.

Figure S54. ESI-TOF MS data for p3α6-AA (QX10518). Expected [M+3H+]/3 = 1087.286.

Figure S55. ESI-TOF MS data for β18 (EL1101). Expected [M+4H+]/4 = 967.231.
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Figure S56. ESI-TOF MS data for β18-DA. Expected [M+4H+]/4 = 945.965.

Figure S57. ESI-TOF MS data for β18-SR (ML1006). Expected [M+4H+]/3 = 1279.973.

Figure S58. ESI-TOF MS data for β18-SA. Expected [M+4H+]/3 = 1251.619.
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Figure S59. ESI-TOF MS data for pβ18 (QX10492). Expected [M+4H+]/4 = 1014.747.

Figure S60. ESI-TOF MS data for pβ18-DA (QX10494). Expected [M+4H+]/4 = 993.495.

Figure S61. ESI-TOF MS data for pβ18-SR (QX10491). Expected [M+4H+]/4 = 1007.762.
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Figure S62. ESI-TOF MS data for pβ18-SA (QX10493). Expected [M+4H+]/4 = 986.496.

Figure S63. ESI-TOF MS data for β23-EA (SD2006#2). Expected [M+4H+]/4 = 984.741.

Figure S64. ESI-TOF MS data for β23-AR (SD2018). Expected [M+4H+]/4 = 991.506.
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Figure S65. ESI-TOF MS data for β23-AA (SD2006#1). Expected [M+4H+]/4 = 970.240.

Figure S66. ESI-TOF MS data for pβ23-EA (SD2006#2C). Expected [M+4H+]/4 = 1043.026.

Figure S67. ESI-TOF MS data for pβ23-AR (SD2018C). Expected [M+4H+]/4 = 1049.790.
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Figure S68. ESI-TOF MS data for pβ23-AA (SD2006#1C). Expected [M+4H+]/4 = 1028.524.
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Analytical HPLC data.
Peptide solution was injected onto a C18 analytical column and eluted with a linear gradient of 1060% B (A = H2O, 0.1% TFA; B= MeCN, 0.1% TFA) over 50 min.; 10-min. rinse (95% B); and 10-min.
column re-equilibration.

Figure S69. Analytical HPLC data for 2α1 (QX108111). Retention time = 36.042 minutes.

Figure S70. Analytical HPLC data for p2α1 (QX108111p). Retention time = 37.750 minutes.
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Figure S71. Analytical HPLC data for 2α3 (QX108110). Retention time = 36.625 minutes.

Figure S72. Analytical HPLC data for p2α3 (QX108110p). Retention time = 37.233 minutes.

Figure S73. Analytical HPLC data for 2α4 (QX10819). Retention time = 35.683 minutes.
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Figure S74. Analytical HPLC data for 2α4-KA (QX11192). Retention time = 49.983 minutes.

Figure S75. Analytical HPLC data for 2α4-AE (QX11193). Retention time = 52.491 minutes.

Figure S76. Analytical HPLC data for 2α4-AA (QX11191). Retention time = 51.358 minutes.
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Figure S77. Analytical HPLC data for p2α4 (QX10819p). Retention time = 41.625 minutes.

Figure S78. Analytical HPLC data for p2α4-KA (QX11195). Retention time = 53.067 minutes.

Figure S79. Analytical HPLC data for p2α4-AE (QX11196). Retention time = 60.617 minutes.
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Figure S80. Analytical HPLC data for p2α4-AA (QX11194). Retention time = 54.008 minutes.

Figure S81. Analytical HPLC data for 2α6 (QX10818). Retention time = 33.617 minutes.

Figure S82. Analytical HPLC data for p2α6 (QX10818p). Retention time = 34.450 minutes.
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Figure S83. Analytical HPLC data for 2α7 (QX10817). Retention time = 35.750 minutes.

Figure S84. Analytical HPLC data for p2α7 (QX10817p). Retention time = 35.900 minutes.

Figure S85. Analytical HPLC data for 2α10 (QX10816). Retention time = 34.525 minutes.
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Figure S86. Analytical HPLC data for p2α10 (QX10816p). Retention time = 41.600 minutes.

Figure S87. Analytical HPLC data for 2α14 (QX10815). Retention time = 41.525 minutes.

Figure S88. Analytical HPLC data for p2α14 (QX10815p). Retention time = 36.100 minutes.
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Figure S89. Analytical HPLC data for 2α18 (QX10814). Retention time = 42.958 minutes.

Figure S90. Analytical HPLC data for 2α18-EA (NAB10212). Retention time = 44.467 minutes.

Figure S91. Analytical HPLC data for 2α18-AR (NAB10211). Retention time = 38.275 minutes.
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Figure S92. Analytical HPLC data for 2α18-AA (NAB10213). Retention time = 39.775 minutes.

Figure S93. Analytical HPLC data for p2α18 (QX10814p). Retention time = 38.117 minutes.

Figure S94. Analytical HPLC data for p2α18-EA (NAB10215). Retention time = 45.283 minutes.
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Figure S95. Analytical HPLC data for p2α18-AR (NAB10214). Retention time = 36.842 minutes.

Figure S96. Analytical HPLC data for p2α18-AA (NAB10216). Retention time = 47.250 minutes.

Figure S97. Analytical HPLC data for 2α21 (QX10813). Retention time = 41.825 minutes.
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Figure S98. Analytical HPLC data for p2α21 (QX10813p). Retention time = 36.450 minutes.

Figure S99. Analytical HPLC data for 2α25 (QX10812). Retention time = 41.667 minutes.

Figure S100. Analytical HPLC data for p2α25 (QX10812p). Retention time = 36.300 minutes.
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Figure S101. Analytical HPLC data for 2α28 (QX10811). Retention time = 42.492 minutes.

Figure S102. Analytical HPLC data for p2α28 (QX10811p). Retention time = 36.917 minutes.

Figure S103. Analytical HPLC data for 3α1 (QX10714). Retention time = 39.442 minutes.
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Figure S104. Analytical HPLC data for 3α1-ER (QX21352). Retention time = 46.250 minutes.

Figure S105. Analytical HPLC data for 3α1-EA (QX10713). Retention time = 40.150 minutes.

Figure S106. Analytical HPLC data for 3α1-AK (QX10712). Retention time = 39.217 minutes.
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Figure S107. Analytical HPLC data for 3α1-AR (QX21531). Retention time = 45.933 minutes.

Figure S108. Analytical HPLC data for 3α1-AA (QX10711). Retention time = 39.858 minutes.
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Figure S109. Analytical HPLC data for p3α1 (QX10718). Retention time = 40.483 minutes.

Figure S110. Analytical HPLC data for p3α1-ER (QX21354). Retention time = 48.367 minutes.

Figure S111. Analytical HPLC data for p3α1-EA (QX10717). Retention time = 40.492 minutes.

Figure S112. Analytical HPLC data for p3α1-AK (QX10716). Retention time = 40.575 minutes.
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Figure S113. Analytical HPLC data for p3α1-AR (QX21353). Retention time = 47.808 minutes.

Figure S114. Analytical HPLC data for p3α1-AA (QX10715). Retention time = 41.375 minutes.

Figure S115. Analytical HPLC data for 3α6 (QX10511). Retention time = 39.725 minutes.
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Figure S116. Analytical HPLC data for 3α6-KA (QX10512). Retention time = 40.317 minutes.

Figure S117. Analytical HPLC data for 3α6-AE (QX10513). Retention time = 45.183 minutes.

Figure S118. Analytical HPLC data for 3α6-AA (QX10514). Retention time = 45.808 minutes.
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Figure S119. Analytical HPLC data for p3α6 (QX10515). Retention time = 40.425 minutes.

Figure S120. Analytical HPLC data for p3α6-KA (QX10516). Retention time = 40.267 minutes.

Figure S121. Analytical HPLC data for p3α6-AE (QX10517). Retention time = 45.517 minutes.
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Figure S122. Analytical HPLC data for p3α6-AA (QX10518). Retention time = 46.850 minutes.

Figure S123. Analytical HPLC data for β18 (EL1101). Retention time = 25.52 minutes.
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Figure S124. Analytical HPLC data for β18-DA. Retention time = 28.93 minutes.

Figure S125. Analytical HPLC data for β18-SR (ML1006). Retention time = 25.5 minutes.
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Figure S126. Analytical HPLC data for β18-SA. Retention time = 28.91 minutes.

Figure S127. Analytical HPLC data for pβ18 (QX10492). Retention time = 26.767 minutes.
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Figure S128. Analytical HPLC data for pβ18-DA (QX10494). Retention time = 30.533 minutes.

Figure S129. Analytical HPLC data for pβ18-SA (QX10491). Retention time = 26.525 minutes.

Figure S130. Analytical HPLC data for pβ18-SA (QX10493). Retention time = 30.458 minutes.
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Figure S131. HPLC data for β23-EA (SD2006#2).

Figure S132. HPLC MS data for β23-AR (SD2018).
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Figure S133. HPLC MS data for β23-AA (SD2006#1).

Figure S134. HPLC MS data for pβ23-EA (SD2006#2C).
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Figure S135. HPLC MS data for pβ23-AR (SD2018C).

Figure S136. HPLC MS data for pβ23-AA (SD2006#1C).
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3.4.2 Biophysical Characterization of Peptide Variants: Previously characterized peptide
1CW adopts a homotrimeric self-association state in solution, whereas GCN4 adopts a
homodimeric self-association state in solution. The peptides explored here (shown in
Supplementary Table 1) precluded the use of time- and resource-intensive sedimentation
equilibrium experiments to characterize their self-association properties. Consequently, we used
the higher-throughput size exclusion chromatography to characterize the self-association
properties of peptides by comparing their retention times on a size-exclusion column to the
retention times of homotrimeric 1CW, homodimeric GCN4 and monomeric α-helical PSBD36.1,
20, 21

Size exclusion chromatography (SEC) was done on a Shimadzu HPLC instrument using a
Phenomenex yarra 3u sec-3000 column (batches 1 and 2) or a Zenix-C SEC 100 column (batches
3 and 4). The columns were calibrated with internal 1CW, GCN4, and PSBD36 standards.
Previous characterization of 1CW, GCN4, and PSBD36 by sedimentation equilibrium analytical
ultracentrifugation under analogous buffer conditions demonstrates that 1CW adopts a trimeric
association state; that GCN4 adopts a dimeric state; and that PSBD36 is an α-helical monomer.
The retention times derived from SEC experiments on α3 series of peptides are very close to
that of trimeric 1CW, suggesting that these variants likewise adopt a trimeric association state.
Similarly, the retention times derived from SEC experiments on α2 series of peptides are close to
that of dimeric GCN4, suggesting that these variants likewise adopt a dimeric association state.
Variants α210, pα21 and p3α1-AR have retention time between dimer and monomer or dimer and
trimer simply because they are in an equilibrium of those two states.
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Table S4. Retention times of helical peptides on a Zenix-C SEC 100 column.
Peptide
PSBD36(monomer standard)
GCN4/2α21(dimer standard)
1CW(trimer standard)
2α28
2α25
2α18
2α14
2α10
2α7
2α6
2α4
2α3
2α1
p2α28
p2α25
p2α21
p2α18
p2α14
p2α10
p2α7
p2α6
p2α4
p2α3
p2α1
2α4-AA
2α4-KA
2α4-AE
p2α4-AA
p2α4-KA
p2α4-AE
2α18-AR
2α18-EA
2α18-AA
p2α18-AR
p2α18-EA
p2α18-AA

Batch 1
Retention Time
12.08
10.28
9.41
10.38
10.35
10.18
10.32
11.55
10.65
10.66
10.30
10.26
10.00
10.26
10.31
10.14
10.08
10.08
10.18
10.53
10.66
11.18
10.36
9.98
10.83
10.65
10.31
10.66
10.60
10.19
11.29
10.47
10.88
11.04
10.48
10.91

Inferred association state

dimer
dimer
dimer
dimer
dimer/monomer
dimer
dimer
dimer
dimer
dimer
dimer
dimer
dimer
dimer
dimer
dimer
dimer
dimer
dimer
dimer
dimer/trimer
dimer
dimer
dimer
dimer
dimer
dimer
dimer
dimer
dimer
dimer
dimer
dimer
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Peptide
3α6
3α6-KA
3α6-AE
3α6-AA
p3α6
p3α6-KA
p3α6-AE
p3α6-AA
3α1-EA
3α1
p3α1-EA
p3α1

Peptide
GCN4/2α21(dimer standard)
p2α4
3α1-AR
3α1-ER
p3α1-AR
p3α1-ER
3α1-AA
3α1-AK
p3α1-AA
p3α1-AK

Batch 1 Continued
Retention Time
9.65
9.74
9.54
9.70
9.71
9.81
9.48
9.68
9.66
9.72
9.74
9.87

Batch 2
Retention Time
12.05
11.84
10.74
10.08
11.21
10.37
10.26
10.29
10.48
10.55

Inferred association state
trimer
trimer
trimer
trimer
trimer
trimer
trimer
trimer
trimer
trimer
trimer
trimer

Inferred association state
dimer
trimer
trimer
trimer/dimer
trimer
trimer
trimer
trimer
trimer

Circular Dichroism Spectropolarimetry: Measurements were made with an Aviv 420 Circular
Dichroism Spectropolarimeter, using quartz cuvettes with a path length of 0.1 cm. Protein
solutions were prepared in 20 mM sodium phosphate buffer, pH 7, and protein concentrations were
determined spectroscopically based on tyrosine and tryptophan absorbance at 280 nm in 6 M
guanidine hydrochloride + 20 mM sodium phosphate (εTrp = 5690 M-1cm-1, εTyr = 1280 M-1cm-1).22
CD spectra of 30 μM solutions were obtained from 260 to 200 nm at 25°C. Variable temperature
CD data were obtained at least in triplicate by monitoring the molar ellipticity [θ] at 222 nm of 30
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μM solutions of each α-helical variant and at 227 nm of 50 μM solutions of each β-sheet variant
in 20 mM sodium phosphate (pH 7) from 1 to 95 °C at 2 °C intervals, with 120 s equilibration time
between data points and 30 s averaging time.
Triplicate variable temperature CD data for each peptide were fit globally to a two-state
model for thermally-induced unfolding. This approach treats the observed [θ] of a peptide solution
at a given temperature as the average of the [θ] values for the folded state and the unfolded
ensemble, weighted according to their relative concentrations at that temperature, as shown in the
following equation:
[θ] = (uo + uo T)(1 − Ffolded ) + (fo + f1 T)(Ffolded )

(S1)

In equation S1, T is the temperature in Kelvin; uo and u1 are the intercept and slope of the pretransition baseline (which represents the linear dependence of the unfolded ensemble CD signal
[θ] on temperature); fo and f1 are the intercept and slope of the pre-transition baseline (which
represents the linear dependence of the folded state CD signal [θ] on temperature); and Ffolded is
the fraction of the total protein concentration that is folded as at temperature T.
Ffit is a function of the folding equilibrium constant; its precise form depends on whether
or not the associate state of the protein changes upon folding. Folding of the GCN4-p1 variants
listed in Table S1 involves association of two unfolded monomers M into a folded dimer D with
temperature-dependent equilibrium constant K as defined below:
[𝐃𝐃]

2𝐌𝐌 ⇌ 𝐃𝐃; 𝐊𝐊 = [𝐌𝐌]2

(S2)

P = [𝐌𝐌] + 2[𝐃𝐃] = [𝐌𝐌] + 2𝐊𝐊[𝐌𝐌]2

(S3)

The constant total concentration of peptide in solution P is defined by the equation S3:
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The positive root of this quadratic equation provides an expression for [M] as a function of P and
K:
[𝐌𝐌] =

√1+8𝐊𝐊𝐊𝐊−1
4𝑲𝑲

(S4)

Substitution of [M] into the definition of Ffolded gives the following expression for the monomerdimer equilibrium:
Ffolded =

2𝐊𝐊[𝐌𝐌]2
𝐏𝐏

1

1

1

(S5)

= 1 + 4𝐊𝐊𝐊𝐊 − �16𝐊𝐊2 𝐏𝐏2 − 2𝐊𝐊𝐊𝐊

Folding of the 1CW variants listed in Table S2 involves association of three unfolded
monomers M into a folded trimer Tri with temperature-dependent equilibrium constant K as
defined below:
3𝐌𝐌 ⇌ 𝐓𝐓𝐓𝐓𝐓𝐓; 𝐊𝐊 =

[𝐓𝐓𝐓𝐓𝐓𝐓]

(S6)

[𝐌𝐌]3

The constant total concentration of peptide in solution P is defined by equation S7:
P = [𝐌𝐌] + 3[𝐃𝐃] = [𝐌𝐌] + 3𝐊𝐊[𝐌𝐌]3

(S7)

Rearranging equation S7 results in the following polynomial equation that is cubic in [M]:
0 = [𝐌𝐌]3 +

[𝐌𝐌]
3𝐊𝐊

𝐏𝐏

(S8)

− 3𝐊𝐊

Using Mathematica, we found the three roots of this polynomial, two of which are complex,
whereas the third is real. The real root of equation S8 provides an expression for [M] as a function
of P and K:
𝐏𝐏

1

𝐏𝐏 2

1
2

1
3

[𝐌𝐌] = � + �
+ 36𝐊𝐊2 � � −
6𝐊𝐊
729𝐊𝐊 3

1

9𝐊𝐊�

𝐏𝐏2

1
1 3
2

𝐏𝐏
1
�
+�
+
6𝐊𝐊
729𝐊𝐊3 36𝐊𝐊2

(S9)

�
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Substitution of [M] into the definition of Ffolded gives the following expression for the monomertrimer equilibrium:
Ffolded =

3𝐊𝐊[𝐌𝐌]3
𝐏𝐏

(S10)

Folding of the WW variants listed in Table S3 involves an equilibrium between an unfolded
monomer (U) and a folded monomer (F) temperature-dependent equilibrium constant K as defined
below:
𝐔𝐔 ⇌ 𝐅𝐅; 𝐊𝐊 =

[𝐅𝐅]

[U]

(S11)

The constant total concentration of peptide in solution P is defined by equation S11:
P = [𝐔𝐔] + [𝐅𝐅] = [𝐔𝐔] + 𝐊𝐊[𝐔𝐔]

(S12)

Ffolded of the monomer folding equilibrium is defined as follows:
𝐊𝐊

Ffolded = 1+𝐊𝐊

(S13)

In each of these cases, K is related to the change in free energy upon folding (ΔGf):
ΔGf

𝐊𝐊 = e− RT

(S14)

∆Gf = ∆Go + ∆G1 (T − To ) + ∆G2 (T − To )2

(S15)

In turn, the temperature-dependence of ΔGf for the dimer or trimer can be expressed as a second
order polynomial:

where ΔG0, ΔG1 and ΔG2 are parameters to be determined via least-squares regression (though
ΔG2 is excluded when its standard error is too high), and T0 is an arbitrary reference temperature
that should be close to the melting temperature. We used this expression for the GCN4-p1 and
1CW variants, though many of the 1CW variants did not require the use of ΔG2. For the WW
variants, we used the following expression for the temperature-dependence of ΔGf, which is a
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function of folding enthalpy at the melting temperature ΔH(Tm), folding heat capacity ΔCp, and the
melting temperature Tm (i.e., the temperature at which Ffolded = 0.5 and ΔGf = 0 kcal/mol):
∆Gf =

∆H(Tm ) ∙(Tm −T)
Tm

T

+ ΔCp ∙ (T − Tm − T ∙ ln �T �)
m

(S16)

We used least-squares regression to fit the variable temperature CD for each variant to these
equations. Far-UV CD spectra and variable temperature CD data for these compounds are shown
below in Figures S137-S200, along with the parameters of the fits (and their standard errors and
p-values) and fit statistics (including R2 and sum of the squared residuals). For the monomer-dimer
and monomer-trimer equilibria, the melting temperature Tm (defined as the temperature at which
Ffolded = 0.5) is not a parameter of the fit. In these cases, we used Mathematica to solve for Tm
numerically.

Figure S137. CD data spectra for 2α1 (QX108111).
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Figure S138. CD data for p2α1 (QX108111p).

Figure S139. CD data for 2α3 (QX108110).
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Figure S140. CD data for p2α3 (QX108110p).

Figure S141. CD data for 2α4 (QX10819).
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Figure S142. CD data for p2α4 (QX10819p).

Figure S143. CD data for 2α6 (QX10818).
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Figure S144. CD data for p2α6 (QX10818p).

Figure S145. CD data for 2α7 (QX10817).
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Figure S146. CD data for p2α7 (QX10817p).

Figure S147. CD data for 2α10 (QX10816).
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Figure S148. CD data for p2α10 (QX10816p).

Figure S149. CD data for 2α14 (QX10815).
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Figure S150. CD data for p2α14 (QX10815p).

Figure S151. CD data for 2α18 (QX10814).
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Figure S152. CD data for p2α18 (QX10814p).

Figure S153. CD data for 2α21 (QX10813).
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Figure S154. CD data for p2α21 (QX10813p).

Figure S155. Cd data for 2α25 (QX10812).
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Figure S156. CD data for p2α25 (QX10812p).

Figure S157. CD data for 2α28 (QX10811).
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Figure S158. CD data for p2α28 (QX10811p).

Figure S159. CD data for 2α4-AE (QX11193).
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Figure S160. CD data for p2α4-AE (QX11196).

Figure S161. CD data for 2α4-KA (QX11192).
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Figure S162. CD data for p2α4-KA (QX11195).

Figure S163. CD data for 2α4-AA (QX11191).
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Figure S164. CD data p2α4-AA (QX11194).

Figure S165. CD data for 2α18-AR (NAB10211).
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Figure S166. CD data for p2α18-AR (NAB10214).

Figure S167. CD data 2α18-EA (NAB10212).
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Figure S168. CD data for p2α18-EA (NAB10215).

Figure S169. CD data for 2α18-AA (NAB10213).
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Figure S170. CD data for p2α18-AA (NAB10216).

Figure S171. CD data for 3α6 (QX10511).
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Figure S172. CD data for 3α6-KA (QX10512).

Figure S173. CD data for 3α6-AE (QX10513).
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Figure S174. CD data for 3α6-AA (QX10514).

Figure S175. CD data for p3α6 (QX10515).

229

Figure S176. CD data for p3α6-KA (QX10516).

Figure S177. CD data for p3α6-AE (QX10517).
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Figure S178. CD data for p3α6-AA (QX10518).

Figure S179. CD spectra 3α1-AA (QX10711).
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Figure S180. CD spectra for 3α1-AK (QX10712).

Figure S181. CD data for 3α1-EA (QX10713).
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Figure S182. CD data for 3α1 (QX10714).

Figure S183. CD data for p3α1-AA (QX10715).
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Figure S184. CD data for p3α1-AK (QX10716).

Figure S185. CD data for p3α1-EA (QX10717).
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Figure S186. CD data for p3α1 (QX10718).

Figure S187. CD data for pβ18-SA (QX10491).
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Figure S188. CD data for pβ18-DA (QX10492).

Figure S189. CD data for β18-SA (QX10493).

236

Figure S190. CD data for β18-DA (QX10494).

Figure S191. CD data for 3α1-AR (QX21531).
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Figure S192. CD data for 3α1-ER (QX21532).

Figure S193. CD data for p3α1-AR (QX21533).

238

Figure S194. CD data for p3α1-ER (QX21534).

Figure S195. CD data for β23-EA (SD2006#2).
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Figure S196. CD data for β23-AR (SD2018).

240

Figure S197. CD data for β23-AA (SD2006#1).

241

Figure S198. CD data for pβ23-EA (SD2006#2C).

Figure S199. CD data for pβ23-AR (SD2018C).
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Figure S200. CD spectra for pβ23-AA (SD2006#1C).

Table S5. Triple mutant box analysis of the impact of PEGylation on salt-bridge strength within peptide
p3α1-ER.a
Peptide
3α1-ER
3α1-EA
3α1-AR
3α1-AA
p3α1-ER
p3α1-EA
p3α1-AR
p3α1-AA

Tm (°C)
77.9
76.0
73.0
76.1
74.7
73.9
70.7
74.7

ΔGf
(kcal/mol)
-15.38 ± 0.02
-14.90 ± 0.02
-14.18 ± 0.02
-14.92 ± 0.03
-14.61 ± 0.02
-14.40 ± 0.02
-13.68 ± 0.01
-14.59 ± 0.02

ΔΔGf b
(kcal/mol)

ΔΔΔGf c
(kcal/mol)
-0.60 ± 0.02

ΔΔΔΔGf d
(kcal/mol)

0.38 ± 0.01
0.17 ± 0.01
0.25 ± 0.01
0.11 ± 0.01

-0.56 ± 0.02

0.05 ± 0.03

Q = GlnPEG. Variable temperature CD experiments were performed in 20 mM phosphate buffer (pH 7)
at 30 μM protein concentration. ΔGf values are given ± standard error at the average melting temperature
for these variants (347.8 K). bImpact of PEGylation on peptide/protein conformational stability. cStrength
of salt-bridge interaction. dImpact of PEGylation on salt-bridge strength.
a
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3.4.3 Crystallographic Characterization of 2α18 and p2α18: 2α18 was crystalized by vapor
diffusion in sitting drops where the well solution contained 0.1 M PCTP (sodium propionate,
sodium cacodylate trihydrate, and bis-Tris Propane) and 25% w/v PEG 1500 at pH 4. Each drop
contained 0.3 μL well solution and 0.3 μL peptide (10 mg/ml in water). Crystals were looped and
cryocooled by plunging them into liquid nitrogen prior to data collection. Data were collected at
100 K with a copper rotating anode X-ray source (Bruker FR-591 Dual Source Low Temperature
X-ray Diffractometer with CCD Detector).
2α18 was crystalized by vapor diffusion in sitting drops where the well solution
contained 0.1 M sodium malonate dibasic monohydrate and 25% w/v PEG 1500 at pH 4. Each
drop contained 0.3 μL well solution and 0.3 μL peptide (10 mg/ml in water). Crystals were
looped and cryocooled by plunging them into liquid nitrogen prior to data collection. Data were
collected at 100 K with a copper rotating anode X-ray source (Bruker FR-591 Dual Source Low
Temperature X-ray Diffractometer with CCD Detector).
The data were integrated and scaled using Protium. The molecular replacement and
refinement were done in Phenix. Model building was carried out in winCOOT.
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Table S6. Crystallographic statistics
Data collection 2α18 unPEGylated

Data collection p2α18 PEGylated

Resolution (Å)
Total Observations
Unique observations

PDB ID:
6O2E
I 21 21 21
19.3, 30.0,
107.1; 90, 90,
90
28.9-1.90
15,787
2,679

Resolution (Å)
Total Observations
Unique observations

PDB ID:
6O2F
I 21 21 21
19.2, 30.0,
106.8; 90, 90,
90
28.9-1.80
33,482
3,133

Redundancy
Completeness (%)

5.9 (1.9)
99.04 (93.02)

Redundancy
Completeness (%)

9.8 (1.75)
99.74 (99.66)

I/σ

9.5 (0.76)

<I/σI>

11.9 (0.76)

Rpim

0.067

Rpim

0.047

Refinement
Resolution (Å)
Rcrystb

28.9-1.90
0.214 (0.298)

Refinement
Resolution (Å)
Rcrystb

28.9-1.80
0.180 (0.248)

Rfreec

0.248 (0.311)

Rfreec

0.235 (0.310)

Average B-factor

26.21

Average B-factor

22.48

RMSD: bonds (Å) / angles (°)

0.008 / 1.04

RMSD: bonds (Å) / angles (°)

0.12 1.26

Space Group
Unit cell dimensions (Å)

Space Group
Unit cell dimensions (Å)
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4 PEGYLATION NEAR A PATCH OF NON-POLAR SURFACE RESIDUES
INCREASES THE CONFORMATIONAL STABILITY OF THE WW DOMAIN
*Reproduced with permission from J. Org. Chem. 2020, 85, 1725–1730 Copyright 2020 American Chemical Society.

4.1 Introduction
The desolvation and burial of non-polar residues in the interior of protein tertiary and
quaternary structures provides a major driving force for protein folding, via enthalpic and entropic
contributions known collectively as the hydrophobic effect.1-5 This process allows the ordered
water molecules that surrounded the non-polar residues in the unfolded conformation to be
released to bulk solvent upon folding; it also maximizes the contact surface area between nonpolar side chains in the folded conformation. Previous observations suggest that side-chain
PEGylation similarly releases surface-bound water molecules in the immediate vicinity of the
PEGylation site, thereby increasing protein conformational stability via an entropic effect.6, 7 We
recently found that the strength of a salt bridge between Glu12 and Arg14 in the WW domain
(hereafter called WW) increases when a propargyloxyphenylalanine residue at position 23 (PrF23)
is modified with a PEG-azide via the copper-catalyzed azide-alkyne cycloaddition (compare ER
vs pER in Table 1; Figure 1).6 We chose WW as a model protein because its two-state folding
energetics have been extensively characterized;8-10 because it is relatively tolerant to amino acid
substitutions at many locations;11-13 and because its short length (34 residues) facilitates its
preparation via solid-phase peptide synthesis, making it much easier to install a short PEG
oligomer at a single well-defined location.14, 15 Presumably the PEGylated PrF residue (PrFp23) in
WW strengthens the nearby Glu12-Arg14 salt bridge by shielding it from interfering water
molecules. Based on this observation, we wondered whether PrFp23 might be similarly able to
249

shield or partially desolvate non-polar residues at positions 12 and 14, thereby increasing WW
conformational stability via the hydrophobic effect.

Figure 11. Ribbon diagram of the parent WW domain (PDB ID: 1PIN) from which the variants described here
were derived. The orange outlined box shows the non-polar residues that we incorporated at positions 12 and 14,
which are highlighted in orange space-filling spheres. Shown in parentheses are the c log P values for the
corresponding N-acetyl N-methyl amino acid amide. The black outlined box shows the PrF and PrFp residues
that we incorporated at position 23, which is highlighted in black space-filling spheres.

4.2 Results and Discussion
To test this hypothesis, we prepared WW variants LL and pLL, in which Leu occupies
positions 12 and 14, with either PrF or PrFp, respectively at position 23 (one letter code: Z for PrF,
Z for PrFp). Variable temperature circular dichroism (CD) experiments reveal that pLL is -0.89 ±
0.04 kcal/mol more stable than non-PEGylated LL (Table 1). We used triple mutant box analysis6,
16-23

to explore the origins of this stabilizing effect by replacing Leu12 and/or Leu14 with Ala to

generate variants LA, AL, and AA, along with their PEGylated counterparts pLA, pAL, and pAA.
Comparing the folding free energies of these variants reveals that Leu12 and Leu14 engage in a
favorable interaction in pLL (ΔΔΔGf = -0.44 ± 0.04 kcal/mol, Table 2), but not in non-PEGylated
LL (ΔΔΔGf = -0.06 ± 0.05 kcal/mol, Table 2). PEGylation enhances the Leu12-Leu14 interaction
by -0.38 ± 0.06 kcal/mol (ΔΔΔΔGf in Table 2), a synergistic effect that represents a substantial
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fraction of the overall difference in stability between pLL and LL (see above). Based on this result,
we wondered whether PEGylation of PrF23 would be similarly stabilizing for WW variants with
Table 1. Sequences, melting temperatures and folding free energy changes of PEGylated WW variants relative to
their non-PEGylated counterparts.a
Tm
ΔΔGf
Peptid
Sequence
(kcal/mol)
e
(⁰C)
KLPPGWEKRMSRSSGRVYYFNHITNASQFE
WW
58.0
•••••••••••••••••Z••••••••••••
ER
51.9
•••••••••••••••••Z••••••••••••
pER
55.6
-0.30 ± 0.03
••••••L•L••••••••Z••••••••••••
LL
52.0
••••••L•L••••••••Z••••••••••••
pLL
61.9
-0.89 ± 0.04
••••••L•A••••••••Z••••••••••••
LA
51.8
••••••L•A••••••••Z••••••••••••
pLA
55.3
-0.31 ± 0.02
••••••A•L••••••••Z••••••••••••
AL
42.1
••••••A•L••••••••Z••••••••••••
pAL
48.4
-0.56 ± 0.04
••••••A•A••••••••Z••••••••••••
AA
42.8
••••••A•A••••••••Z••••••••••••
pAA
46.5
-0.31 ± 0.02
••••••F•F••••••••Z••••••••••••
FF
50.7
••••••F•F••••••••Z••••••••••••
pFF
54.7
-0.33 ± 0.02
••••••F•A••••••••Z••••••••••••
FA
43.8
••••••F•A••••••••Z••••••••••••
pFA
48.5
-0.36 ± 0.02
••••••A•F••••••••Z••••••••••••
AF
51.2
••••••A•F••••••••Z••••••••••••
pAF
55.5
-0.37 ± 0.02
••••••X•X••••••••Z••••••••••••
XX
49.2
••••••X•X••••••••Z••••••••••••
pXX
63.2
-1.30 ± 0.02
••••••X•A••••••••Z••••••••••••
XA
43.2
••••••X•A••••••••Z••••••••••••
pXA
47.8
-0.40 ± 0.02
••••••A•X••••••••Z••••••••••••
AX
52.3
••••••A•X••••••••Z••••••••••••
pAX
58.4
-0.51 ± 0.02
••••••X•L••••••••Z••••••••••••
XL
49.9
••••••X•L••••••••Z••••••••••••
pXL
60.8
-0.90 ± 0.02
••••••F•L••••••••Z••••••••••••
FL
46.9
••••••F•L••••••••Z••••••••••••
pFL
55.5
-0.68 ± 0.02
••••••L•F••••••••Z••••••••••••
LF
48.2
••••••L•F••••••••Z••••••••••••
pLF
55.5
-0.56 ± 0.02
a
X = cyclohexylalanine (Cha), Z = propargyloxyphenylalanine (PrF); Z = PrFPEG. ΔΔGf value for each PEGylated
variant is given ± standard error relative to its non-PEGylated counterpart in kcal/mol at 50 µM protein concentration,
in 20 mM sodium phosphate buffer (pH 7), at the melting temperature of the non-PEGylated protein. Data for WW
are from reference 22. Data for variants ER and pER are from reference 23.

other non-polar residues at positions 12 and 14, with more non-polar WW variants experiencing
greater PEG-based stabilization.
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Table 2. Triple mutant box analysis of the impact of PEGylation the interaction between residues 12 and 14 within
variants pLL, pFF and pXX .a
ΔGf
ΔΔΔGf b
ΔΔΔΔGf c
Peptide
(kcal/mol)
(kcal/mol)
(kcal/mol)
AA
0.60 ± 0.02
LA
-0.12 ± 0.02
AL
0.61 ± 0.04
LL
-0.17 ± 0.02 -0.06 ± 0.05
pAA
0.30 ± 0.01
pLA
-0.46 ± 0.01
pAL
0.15 ± 0.02
pLL
-1.05 ± 0.02 -0.44 ± 0.03 -0.38 ± 0.06
AA
0.53 ± 0.02
FA
0.44 ± 0.02
AF
-0.16 ± 0.01
FF
-0.19 ± 0.02 0.06 ± 0.03
pAA
0.22 ± 0.01
pFA
0.05 ± 0.01
pAF
-0.53 ± 0.01
pFF
-0.46 ± 0.01 0.25 ± 0.02 0.19 ± 0.04
AA
0.63 ± 0.02
XA
0.42 ± 0.01
AX
-0.16 ± 0.02
XX
0.19 ± 0.02 0.56 ± 0.03
pAA
0.33 ± 0.01
pXA
0.23 ± 0.03
pAX
-0.67 ± 0.02
pXX
-1.18 ± 0.01 -0.41 ± 0.04 -0.97 ± 0.05
a
ΔGf, ΔΔΔGf, and ΔΔΔΔGf values are given ± standard error. ΔGf values for each of the eight peptides within the
same triple mutant box were calculated at their average melting temperature: 323.3 K for pLL and its derivatives;
322.3 K for pFF and its derivatives; 323.5 K for pXX and its derivatives; Because variants AA, AL, LA, AF, FA,
and XA and their PEGylated counterparts appear in more than one triple mutant box, their ΔGf values are necessarily
presented at more than one temperature. bStrength of interaction between residues 12 and 14. cImpact of PEGylation
on the strength of the interaction between residues 12 and 14.

To explore this possibility, we prepared and characterized additional derivatives of LL and
pLL, in which Leu12 and/or Leu14 were replaced by Phe, Ala, or cyclohexylalanine (Cha; oneletter abbreviation is X) to give variants FF, FA, AF, XX, XA, AX, XL, LX, FL, and LF, along
with their PEGylated counterparts pFF, pFA, pAF, pXX, pXA, pAX, pXL, pLX, pFL, and pLF
(Table 1). The CD spectra of these variants are generally similar to that of the parent WW protein
from which they were derived, with a maximum molar ellipticity at 227 nm that is characteristic
of its triple-stranded antiparallel β-sheet structure. Notable exceptions include XX and pXA: both
have strong minima at 210 nm and pXA lacks the characteristic maximum at 227 nm. The origin
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of these observations is unclear; both variants contain the non-proteinogenic cyclic non-polar
residue Cha at position 12, but so do variants XA and pXX, which each display the characteristic
maximum at 227 nm. It is possible that Cha modestly perturbs the secondary/tertiary structure of
XX and pXA relative to the parent WW variant from which they were derived. However, these
perturbations are not likely to be dramatic: XX and pXA each exhibit cooperative thermal
unfolding behavior when monitored at 227 nm during variable temperature CD experiments, with
melting temperatures well within the range of the other WW variants described here.
Table 3. Triple mutant box analysis of the impact of PEGylation the interaction between residues 12 and 14 within
variants pXL, pFL and pLF.a
ΔGf
ΔΔΔGf b
ΔΔΔΔGf c
Peptide
(kcal/mol)
(kcal/mol)
(kcal/mol)
AA
0.40 ± 0.02
XA
0.26 ± 0.01
AL
0.43 ± 0.03
XL
-0.24 ± 0.01 -0.53 ± 0.04
pAA
0.10 ± 0.01
pXA
-0.01 ± 0.03
pAL
-0.07 ± 0.02
pXL
-1.09 ± 0.02 -0.91 ± 0.04 -0.39 ± 0.06
AA
0.33 ± 0.02
FA
0.25 ± 0.02
AL
0.43 ± 0.03
FL
-0.01 ± 0.02 -0.28 ± 0.04
pAA
0.02 ± 0.01
pFA
-0.13 ± 0.01
pAL
-0.14 ± 0.02
pFL
-0.69 ± 0.01 -0.39 ± 0.03 -0.11 ± 0.05
AA
0.66 ± 0.02
LA
-0.06 ± 0.02
AF
-0.03 ± 0.02
LF
0.23 ± 0.01 0.99 ± 0.03
pAA
0.36 ± 0.01
pLA
-0.39 ± 0.01
pAF
-0.40 ± 0.01
pLF
-0.36 ± 0.01 0.79 ± 0.03 -0.20 ± 0.04
a
ΔGf, ΔΔΔGf, and ΔΔΔΔGf values are given ± standard error. ΔGf values for each of the eight peptides within the
same triple mutant box were calculated at their average melting temperature: 320.8 K for pXL and its derivatives;
320.0 K for pFL and its derivatives; 324.0 K for pLF and its derivatives. Because variants AA, AL, LA, AF, FA, and
XA and their PEGylated counterparts appear in more than one triple mutant box, their ΔGf values are necessarily
presented at more than one temperature. bStrength of interaction between residues 12 and 14. cImpact of PEGylation
on the strength of the interaction between residues 12 and 14.
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Figure 12. (A) Plot of the impact of PrF-PEGylation at position 23 the conformational stability of WW variants
pAA, pLA, pAL, pLL, pFA, pAF, pFF, pXA, pAX, pXX, pXL, pFL, and pLF relative to their non-PEGylated
counterparts (ΔΔGf) vs. the composite c log P for residues at positions 12 and 14. Dotted line is a fit of the data to a
linear equation with the indicated R2 value. (B) Plot of the impact of PrF-PEGylation on the synergistic interaction
between residues 12 and 14 (ΔΔΔΔGf) in variants pLL, pFF, pXX, pXL, pFL, and pLF vs. the composite c log P
values for residues at these positions. Dotted line is a fit of the date to a linear equation with the indicated R2 value.

We estimated the hydrophobicity of each residue incorporated at 12 and/or 14 by calculating
the logarithm of the water-octanol partition coefficient (c log P) of the corresponding N-acetyl
amino acid N-methyl amide in ChemDraw; we then estimated the overall hydrophobicity of
residues 12 and 14 by averaging their individual c log P values. A plot of the impact of PEGylation
on the folding free energy of each variant (ΔΔGf) vs. this composite c log P value is shown in
Figure 2A. The data in these plots fit reasonably to a linear equation with a slope of -0.37 ± 0.07
kcal/mol per log unit (R2 = 0.70), indicating that PEGylation at position 23 is more stabilizing
when the residues that occupy positions 12 and 14 are more hydrophobic.
Next, we wondered whether these observations depended similarly on PEG-based
strengthening of favorable synergistic interactions between residues at positions 12 and 14 as we
observed above for pLL. Triple mutant box analysis of variant pXX (Table 2) reveals that
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PEGylation shifts the Cha12-Cha14 interaction from unfavorable (ΔΔΔGf = 0.56 ± 0.03 kcal/mol)
to favorable (ΔΔΔGf = -0.41 ± 0.04 kcal/mol), a synergistic effect worth ΔΔΔΔGf = -0.97 ± 0.05
kcal/mol. Similarly, PEG increases the strength of already favorable interactions between Cha12
and Leu14 in pXL and between Phe12 and Leu14 in pFL (Table 3, ΔΔΔΔGf = -0.39 ± 0.06, and
-0.11 ± 0.05 kcal/mol, respectively). In contrast, PEGylation makes an unfavorable interaction in
pLF between Leu12 and Phe14 less unfavorable (Table 3, ΔΔΔΔGf = -0.20 ± 0.04 kcal/mol) and
has a destabilizing effect on the interaction between Phe12 and Phe14 in pFF (Table 2, ΔΔΔΔGf
= 0.19 ± 0.04 kcal/mol). The variability among these ΔΔΔΔGf values correlates inversely with the
composite c log P values for residues 12 and 14 (R2 = 0.77; slope = -0.67 ± 0.18 kcal/mol per log
unit), indicating that PEGylation better enhances the interaction between more hydrophobic
residues (Figure 2B).
4.3 Conclusion
In previous work, we found that increasing oligomer length beyond four ethylene oxide
residues does not substantially change the impact of PEG on conformational stability,7, 15 whereas
alterations to the PEG-protein linker have dramatic consequences;14, 24 these observations suggest
that the origin of the observed stabilization must be in the immediate vicinity of the protein surface.
Published atomistic simulations of PEGylated WW variants suggest that the conjugated PEG
oligomer is flexible and highly dynamic;7, 21 it does not appear to engage in long-lived noncovalent interactions with protein surface residues. Instead, we hypothesize the PEG occupies
space within the first solvent shell that would otherwise be occupied by water molecules. We
would expect such first shell water molecules to have reduced translational freedom in the
immediate vicinity of non-polar patch of surface residues. Presumably PEG-based displacement
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of these water molecules increases their translational freedom, thereby stabilizing the folded
conformation of the protein via an entropic effect. Many proteins have one or more surfaceexposed patches of non-polar residues;25 our observations here suggest that PEGylation near such
locations might be a useful general strategy for increasing protein conformational stability. We
also note that variants pLL, pXX and pXL (Tm = 61.9, 63.2, and 60.8 °C, respectively) are each
more stable than the parent WW domain from which they were derived (Tm = 58.0 °C),
highlighting the possibility of simultaneously engineering a PEGylation site and a nearby surfaceexposed hydrophobic patch in place of native residues to achieve superior conformational stability
relative to the native sequence. Such stabilized PEGylated WW variants have previously shown
enhanced resistance to proteolysis relative to their non-stabilized counterparts,7, 24 highlighting the
importance of PEGylation site selection in developing PEG-protein conjugates with optimal
resistance to proteolysis. It will be interesting to see whether stabilized PEG-protein conjugates
retain better function than their unstabilized or non-specifically PEGylated counterparts.
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4.4 Supporting Information

4.4.1 Protein Synthesis, Purification, and Characterization: Sequences, molecular
formulas, and expected and observed m/z ratios for each WW variant are given in Table S1. ESITOF MS spectra for each variant appear in Figures S1–S24.
Table S1. Sequences, molecular formulas, expected and observed m/z ratios for WW variants.
Protein
LL
LA
AL
AA
pLL
pLA
pAL
pAA
FF
FA
AF
pFF
pFA
pAF
XX
XA
AX
pXX
pXA
pAX
XL
FL
LF
pXL
pFL
pLF

4

Expected
[M+z∙H]/z
991.2633

Observed
[M+z∙H]/z
991.2594

H2N-••••••LKAMSRSSGRVZ••••••••••••••••-OH

4

980.7516

980.7500

4

980.7516

980.7511

H2N-••••••AKAMSRSSGRVZ••••••••••••••••-OH

---

---

---

H2N-••••••LKLMSRSSGRVZ••••••••••••••••-OH

4

1049.5477

1049.5450

H2N-••••••LKAMSRSSGRVZ••••••••••••••••-OH

4

1039.0360

1039.0326

H2N-••••••AKLMSRSSGRVZ••••••••••••••••-OH

4

1039.0360

1039.0357

H2N-••••••AKAMSRSSGRVZ••••••••••••••••-OH

---

---

---

H2N-••••••FKFMSRSSGRVZ••••••••••••••••-OH

4

1008.2555

1008.2572

H2N-••••••FKAMSRSSGRVZ••••••••••••••••-OH

4

989.2476

989.2472

H2N-••••••AKFMSRSSGRVZ••••••••••••••••-OH

4

989.2476

989.2480

H2N-••••••FKFMSRSSGRVZ••••••••••••••••-OH
H2N-••••••AKFMSRSSGRVZ••••••••••••••••-OH

Sequence

z

H2N-KLPPGWLKLMSRSSGRVZYFNHITNASQFERPSG-OH
H2N-••••••AKLMSRSSGRVZ••••••••••••••••-OH

4

1066.5399

1066.5338

H2N-••••••FKAMSRSSGRVZ••••••••••••••••-OH

4

1047.5321

1047.5375

4

1047.5321

1047.5337

H2N-••••••XKXMSRSSGRVZ••••••••••••••••-OH

4

1011.2790

1011.2825

H2N-••••••XKAMSRSSGRVZ••••••••••••••••-OH

4

990.7594

990.7580

H2N-••••••AKXMSRSSGRVZ••••••••••••••••-OH

4

990.7594

990.7629

H2N-••••••XKXMSRSSGRVZ••••••••••••••••-OH

4

1069.5634

1069.5557

H2N-••••••XKAMSRSSGRVZ••••••••••••••••-OH

4

1049.0438

1049.0425

H2N-••••••AKXMSRSSGRVZ••••••••••••••••-OH

4

1049.0438

1049.0381

H2N-••••••XKLMSRSSGRVZ••••••••••••••••-OH

4

1001.2711

1001.2705

H2N-••••••FKLMSRSSGRVZ••••••••••••••••-OH

4

999.7594

999.7586

H2N-••••••LKFMSRSSGRVZ••••••••••••••••-OH

4

999.7594

999.7577

H2N-••••••XKLMSRSSGRVZ••••••••••••••••-OH

4

1059.5555

1059.5534

H2N-••••••FKLMSRSSGRVZ••••••••••••••••-OH

4

1058.0438

1058.0419

H2N-••••••LKFMSRSSGRVZ••••••••••••••••-OH

4

1058.0438

1058.0412
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Figure S13. ESI-TOF MS data for LL (SD1075#1). Expected [M+4H+]/4 = 991.2633.

Figure S14. ESI-TOF MS data for LA (DA1018#2). Expected [M+4H+]/4 = 980.7516.

Figure S15. ESI-TOF MS data for AL (DA1018#1). Expected [M+4H+]/4 = 980.7516
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Figure S16. ESI-TOF MS data for pLL (SD1075#1C). Expected [M+4H+]/4 = 1049.5477.

Figure S17. ESI-TOF MS data for pLA (DA1018#4). Expected [M+4H+]/4 = 1039.0360.

Figure S18. ESI-TOF MS data for pAL (DA1018#3). Expected [M+4H+]/4 = 1039.0360.
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Figure S19. ESI-TOF MS data for FF (DA1037#1). Expected [M+4H+]/4 = 1008.2555.

Figure S20. ESI-TOF MS data for FA (SD2176#1). Expected [M+4H+]/4 = 989.2476.

Figure S21. ESI-TOF MS data for AF (DS2176#2). Expected [M+4H+]/4 = 989.2476.
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Figure S22. ESI-TOF MS data for pFF (DA1037#3). Expected [M+4H+]/4 = 1066.5399.

Figure S23. ESI-TOF MS data for pFA (SD2176#1p). Expected [M+4H+]/4 = 1047.5321.

Figure S24. ESI-TOF MS data for pAF (SD2176#2p). Expected [M+4H+]/4 = 1047.5321.
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Figure S25. ESI-TOF MS data for XX (DA1037#2). Expected [M+4H+]/4 = 1011.2790.

Figure S26. ESI-TOF MS data for XA (SD2184#2). Expected [M+4H+]/4 = 990.7594.

Figure S27. ESI-TOF MS data for AX (SD2184#1). Expected [M+4H+]/4 = 990.7594.
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Figure S28. ESI-TOF MS data for pXX (DA1037#4). Expected [M+4H+]/4 = 1069.5634.

Figure S29. ESI-TOF MS data for pXA (SD2184#2p). Expected [M+4H+]/4 = 1049.0438.

Figure S30. ESI-TOF MS data for pAX (SD2184#1p). Expected [M+4H+]/4 = 1049.0438.
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Figure S31. ESI-TOF MS data for XL (BC1039#1). Expected [M+4H+]/4 = 1001.2711.

Figure S32. ESI-TOF MS data for LF (BC1039#3). Expected [M+4H+]/4 = 999.7594.

Figure S33. ESI-TOF MS data for FL (BC1039#4). Expected [M+4H+]/4 = 999.7594.
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Figure S34. ESI-TOF MS data for pXL (BC1039#1p). Expected [M+4H+]/4 = 1059.5555.

Figure S35. ESI-TOF MS data for pLF (BC1039#3p). Expected [M+4H+]/4 = 1058.0438.

Figure S36. ESI-TOF MS data for pFL (BC1039#4p). Expected [M+4H+]/4 = 1058.0438.
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Analytical HPLC Chromatograms
Peptide solution was injected onto a C18 analytical column and eluted with a linear
gradient of 10–60% B (A = H2O, 0.1% TFA; B= MeCN, 0.1% TFA) over 50 min.; 10-min. rinse
(95% B); and 10-min. column re-equilibration. Chromatograms appear in Figures S25–S48.

Figure S37. Analytical HPLC data for LL (SD1075#1). Retention time = 31.658 minutes.

Figure S38. Analytical HPLC data for LA (DA1018#2). Retention time = 36.18 minutes.
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Figure S39. Analytical HPLC data for AL (DA1018#1). Retention time = 36.28 minutes.

Figure S40. Analytical HPLC data for pLL (SD1075#1C). Retention time = 28.217 minutes.
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Figure S41. Analytical HPLC data for pLA (DA1018#4). Retention time = 35.68 minutes.

Figure S42. Analytical HPLC data for pAL (DA1018#3). Retention time = 35.52 minutes.

Figure S43. Analytical HPLC data for FF (DA1037#1). Retention time = 45.98 minutes.
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Figure S44. Analytical HPLC data for FA (SD2176#1). Retention time = 40.26 minutes.

Figure S45. Analytical HPLC data for FA (SD2176#2). Retention time = 42.31 minutes.
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Figure S46. Analytical HPLC data for pFF (DA1037#3). Retention time = 30.47 minutes.

Figure S47. Analytical HPLC data for pFA (SD2176#1p). Retention time = 33.167 minutes.

Figure S48. Analytical HPLC data for pAF (SD2176#2p). Retention time = 24.408 minutes.

270

Figure S49. Analytical HPLC data for XX (DA1037#2). Retention time = 36.18 minutes.

Figure S50. Analytical HPLC data for XA (SD2184#2). Retention time = 37.70 minutes.
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Figure S51. Analytical HPLC data for AX (SD2184#1). Retention time = 37.70 minutes.

Figure S52. Analytical HPLC data for pXX (DA1037#4). Retention time = 32.78 minutes.
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Figure S53. Analytical HPLC data for pXA (SD2184#2p). Retention time = 36.81 minutes.

Figure S54. Analytical HPLC data for pAX (SD2184#1p). Retention time = 37.35 minutes.
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Figure S55. Analytical HPLC data for XL (BC1039#1). Retention time = 38.86 minutes.

Figure S56. Analytical HPLC data for FL (BC1039#4). Retention time = 37.67 minutes.

Figure S57. Analytical HPLC data for LF (BC1039#3). Retention time = 37.91 minutes.

274

Figure S58. Analytical HPLC data for pXL (BC1039#1p). Retention time = 38.26 minutes.

Figure S59. Analytical HPLC data for pFL (BC1039#4p). Retention time = 36.54 minutes.

Figure S60. Analytical HPLC data for pLF (BC1039#3p). Retention time = 37.05 minutes.
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4.4.2 Biophysical Characterization of Peptide Variants: Variable temperature CD data were
obtained at least in triplicate (one sample was made and then aliquoted into three different cuvettes)
by monitoring the molar ellipticity [θ] at 227 nm of 50 μM solutions of each WW variant in 20
mM sodium phosphate (pH 7) from 1 to 95 °C at 2 °C intervals, with 120 s equilibration time
between data points and 30 s averaging time. Triplicate variable temperature CD data for each
peptide were fit globally to a two-state model for thermally induced unfolding. This approach
treats the observed [θ] of a peptide solution at a given temperature as the average of the [θ] values
for the folded state and the unfolded ensemble, weighted according to their relative concentrations
at that temperature, as shown in the following equation:
[θ] = (a + bT)(Ffolded ) + (c + dT)(1 − Ffolded )

(S1)

In equation S1, T is the temperature in Kelvin; a and b are the intercept and slope of the pretransition baseline (which represents the linear dependence of the folded ensemble CD signal [θ]
on temperature); c and d are the intercept and slope of the post-transition baseline (which represents
the linear dependence of the unfolded ensemble CD signal [θ] on temperature); and Ffolded is the
fraction of the total protein concentration that is folded as at temperature T.
Ffit is a function of the folding equilibrium constant; folding of WW involves an equilibrium
between an unfolded monomer (U) and a folded monomer (F) with the temperature-dependent
equilibrium constant K as defined below:
𝐔𝐔 ⇌ 𝐅𝐅; 𝐊𝐊 =

[𝐅𝐅]

[U]

(S2)

The constant total concentration of peptide in solution P is defined by equation S3:
P = [𝐔𝐔] + [𝐅𝐅] = [𝐔𝐔] + 𝐊𝐊[𝐔𝐔]

(S3)
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Ffolded of the monomer folding equilibrium is defined as follows:
𝐊𝐊

Ffolded = 1+𝐊𝐊

(S4)

In each of these cases, K is related to the change in free energy upon folding (ΔGf):
ΔGf

𝐊𝐊 = e− RT

(S5)

In turn, the temperature-dependence of ΔGf for can be expressed as a polynomial expansion about
the melting temperature Tm (i.e., the temperature at which Ffolded = 0.5, K = 1, and ΔGf = 0):
∆Gf = ∆G1 (T − Tm ) + ∆G2 (T − Tm )2

(S6)

where ΔG1, ΔG2, and Tm are parameters to be determined via least-squares regression (though
ΔG2 was excluded from the fits of all the WW variants described here, because attempts to use it
resulted in corresponding parameter standard error values that were too high). We used leastsquares regression to fit the variable temperature CD for each variant to these equations. Far-UV
CD spectra and variable temperature CD data for these compounds are shown below in Figures
S49-S74, along with the parameters of the fits (and their standard errors and p-values) and fit
statistics (including R2 and sum of the squared residuals).
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Figure S61. CD data for LL (SD1075#1).

Figure S62. CD data for LA (DA1018#2).
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Figure S63. CD data for AL (DA1018#1).
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Figure S64. CD data for AA.
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Figure S65. CD data for pLL (SD1075#1C).

Figure S66. CD data for pLA (DA1018#4).
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Figure S67. CD data for pAL (DA1018#3).

Figure S68. CD data for pAA.
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Figure S69. CD Data for FF (DA1037#1).

Figure S70. CD Data for FA (SD2176#1).
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Figure S71. CD data for AF (DS2176#2).

Figure S72. CD data for pFF (DA1037#3).
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Figure S73. CD data for pFA (SD2176#1p).

Figure S74. CD data for pAF (SD2176#2p).
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Figure S75. CD data for XX (DA1037#4).

Figure S76. CD data for XA (SD2184#2).
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Figure S77. CD data for AX (SD2184#1).

Figure S78. CD data for pXX (DA1037#4).
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Figure S79. CD data for pXA (SD2184#2p).

Figure S80. CD data for pAX (SD2184#1p).
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Figure S81. CD data for XL (BC1039#1).

Figure S82. CD data for FL (BC1039#4).
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Figure S83. CD data for LF (BC1039#3).

Figure S84. CD data for pXL (BC1039#1p).
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Figure S85. CD data for pFL (BC1039#4p).

Figure S86. CD data for pLF (BC1039#3p).
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5 PEGYLATION INCREASES THE STRENGTH OF A NEARBY NH-Π HYDROGEN
BOND IN THE WW DOMAIN

5.1 Introduction
The side chains of the amino acids Phe, Tyr, and Trp each have electron-rich faces surrounded
by an electron-poor edge. This anisotropic distribution of electron density allows Phe, Tyr, and
Trp to participate in favorable noncovalent interactions within proteins, including offset face-toface or edge-to-face interactions with other arenes (π-stacking);1, 2 edgewise interactions with
anions (anion-π);3-5 and facewise interactions with cations (cation-π)6-8 or with electron-deficient
C–H and X–H bonds (CH-π9, 10 and XH-π11-16 interactions, respectively, where X=N, O, S). Some
have argued that XH-π interactions represent an additional kind of hydrogen bond.17 NH-π
interactions are particularly common: a survey of 593 high-resolution protein crystal structures
found 1311 instances of XH-π interactions; 40% of these were NH-π interactions.18 A recent study
suggested that an NH-π interaction contributes between -0.2 to -0.9 kcal/mol to the conformational
stability of the model protein GB3.19
The WW domain of the human protein Pin1 (hereafter called WW) is an extensively
characterized triple-stranded antiparallel β-sheet protein consisting of only 34 residues.20-23 The
published crystal structure of WW indicates that the side-chain amide nitrogen of Asn26 is only
3.2 Å away from the plane of the Trp11 indole (Figure 1A),24 a distance that is well within
established geometric criteria for an NH-π interaction.18 Jager et al previously showed that WW
is highly sensitive to mutation at Asn26;25 moreover, Asn is highly conserved at analogous
positions within related WW family members.26, 27 We wondered if a stabilizing NH-π interaction
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between Asn26 and Trp11 could account for the importance of Asn26 to WW folding and
conformational stability.
5.2 Results and Discussion
To explore this possibility, we replaced Asn26 in the parent WW sequence (called WN because
of Trp11 and Asn26) with Gln (variant WQ). Gln has the same side-chain amide protons as Asn
but is one methylene unit longer; we expected this increased length to move the amide protons of
Gln26 away from the center of the electron-rich face of the Trp11 indole and closer to its electronpoor edge, thereby decreasing the strength of the NH-π interaction. Consistent with this
expectation, variable temperature circular dichroism (CD) data reveal that the melting temperature
(Tm) of variant WQ is 22.5 ⁰C lower than that of previously characterized WN28 (Table 1).
However, Asn26 occupies the i-position of the type I β-turn that connects two antiparallel β-strands

in WW. In a survey of 205 nonhomologous proteins, Hutchinson and Thornton29 found that Asn
has much higher propensity for occupying the i-position of type I β-turns than does Gln. They
attribute this difference primarily to the frequent formation of an “Asx turn”, in which the sidechain carbonyl oxygen of the i-position Asn accepts a hydrogen bond from the main-chain amide
nitrogen of the i+2 amino acid. This is certainly the situation for Asn26 in WW; its carbonyl
oxygen is only 2.8 Å from the main-chain amide nitrogen of i+2-position Ile28.24 It seems likely
that disruption of this Asx turn contributes substantially to the lower stability of WQ relative to
WN, making it difficult to assess the relative contribution of changes in the strength of the putative
NH–π interaction.
We addressed this challenge by exploring the consequences of structural variations at position
11 on WW stability while keeping Asn26 unchanged. Previous structural analysis found that 7.7%
of all Trp residues within 592 high-resolution protein crystal structures were engaged in an NH-π
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Figure 1. (A) Structure of the WW domain of the human protein Pin1 (PDB: 1PIN) with Asn26 and Trp11 highlighted
in orange as space-filling spheres. (B) Calculated interaction energies for complexes of formamide with indole,
benzene, naphthalene, and phenol, calculated via the MP2 method in Gaussian 16 using the aug-cc-pVDZ basis set
and corrected for basis set superposition error (see supporting information for details). (C) Relationship between
melting temperatures (Tm) of WW variants FN, YN, WN, and ZN and the calculated interaction energies for the
corresponding formamide/arene complexes described above.

interaction; in contrast, only 3.2% of Tyr residues, 1.9% of Phe residues, and 0.7% of His residues
were similarly engaged.18 Of the 519 NH-π interactions identified in this survey, Trp accounted
for 196, Tyr for 185, and Phe for 113, and His for 25.18 Based on average expression frequencies
of Trp (1.2%), Tyr (3.0%), Phe (3.9%), and His (2.5%) in more than a half-million proteins from
38 proteomes,30 we estimate that Trp appears 3.4 times more frequently in NH-π interactions than
would be expected at random. In contrast, Tyr only appears only slightly more frequently than
expected (by a factor of 1.3), whereas Phe and His appear less frequently than expected (by factors
of 0.6 and 0.2, respectively). Together, these observations suggest the possibility that NH-π
interactions with Trp are more favorable than with Tyr, Phe, or His (note that we did not include
His in the present study out of concern that its ambiguous protonation state at pH 7 might
complicate analysis of our results). Previous computational studies support this hypothesis: OH-π
interactions are stronger for complexes of water with indole (-3.5 kcal/mol) than with phenol (-2.3
kcal/mol) or benzene (-2.1 kcal/mol).16 Similarly, MP2 calculations31 in Gaussian1632 (with the
aug-cc-pVDZ basis set,33 implicit water,34 and counterpoise correction for basis set superposition
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error)35, 36 reveal that NH-π interactions (Figure 1B) are stronger for complexes of formamide with
indole (-4.9 kcal/mol) than with phenol (-4.0 kcal/mol) or benzene (-4.1 kcal/mol).
Table 2. Sequences, Melting Temperatures, and ΔΔGf values of PEGylated WW Variants Relative to Their Non-PEGylated
Counterpartsa

Peptide

Sequence

Tm (⁰C)

ΔΔGf (kcal/mol)

WN

KLPPGWEKRMSRSSGRVYYFNHITNASQFERPSG

58.0 ± 0.3

FN

•••••F••••••••••••••N•••••••••••••

29.3 ± 0.2

YN

•••••Y••••••••••••••N•••••••••••••

28.3 ± 0.2

ZN

•••••Z••••••••••••••N•••••••••••••

55.0 ± 0.2

WNp

•••••W••••••••••••••N•••••••••••••

64.5 ± 0.1

-0.58 ± 0.03

FNp

•••••F••••••••••••••N•••••••••••••

34.7 ± 0.1

-0.34 ± 0.02

YNp

•••••Y••••••••••••••N•••••••••••••

35.2 ± 0.6

-0.47 ± 0.05

ZNp

•••••Z••••••••••••••N•••••••••••••

62.2 ± 0.2

-0.62 ± 0.03

aZ

= naphthylalanine (Nal). The ΔΔGf value for each PEGylated peptide relative to its non-PEGylated counterpart is given ±
standard error =at 50 μM protein concentration in 20 mM sodium phosphate buffer (pH 7) at the melting temperature of the nonPEGylated variant. Data for WN and WNp are from ref 44.

We wondered whether substituting Phe or Tyr for Trp11 would result in similar changes in
WW conformational stability. To explore this possibility, we prepared WW variants FN and YN,
in which Phe and Tyr, respectively, occupy position 11. We then assessed the stability of these
variants using variable temperature CD experiments (Table 1): FN (Tm = 29.3 ± 0.2 °C) and YN
(Tm = 28.3 ± 0.2 °C) are substantially less stable than WN (Tm = 58.0 ± 0.3), an observation that
agrees qualitatively with the apparent enrichment of Trp relative to Tyr and Phe in observed NHπ interactions within proteins and with the more favorable calculated NH-π interaction energies
for indole vs. phenol or benzene. Trp11 occupies a somewhat buried position within WW; we
wondered whether the smaller sizes of Tyr and Phe relative to Trp might account for some of the
observed destabilization of YN and FN relative to WN. To explore this possibility, we prepared
WW variant ZN, in which we replaced Trp11 with isosteric naphthylalanine (Nap). Variant ZN
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(Tm = 55.0 ± 0.2 °C) is only slightly less stable than WN. Similarly, MP2 calculations suggest
formamide interacts only slightly less strongly with naphthalene (-4.7 kcal/mol) than with indole.
Figure 1C plots the melting temperatures of variants WN, YN, FN, and ZN vs. the calculated NHπ interaction energies for complexes of formamide with indole, benzene, phenol, and naphthalene,
respectively. The strength of the resulting correlation (R2 = 0.98) suggests that the calculated NHπ interaction energies account for most of the variation in the melting temperatures of WN, YN,
FN, and ZN.
The strength of a noncovalent interaction within a protein is highly dependent on its
surroundings. For example, buried hydrogen bonds are strengthened by their non-polar
microenvironment37, 38 presumably due to the lower effective dielectric constant of the protein
interior vs. surface and to the absence of interfering water molecules. Similarly, a growing body
of experimental and theoretical evidence suggests that attaching polyethylene glycol to a protein
side chain (i.e., PEGylation) can strengthen nearby noncovalent interactions by localized
desolvation of the area immediately surrounding the PEGylation site.28, 39, 40 We previously found
that conjugating a four-unit PEG oligomer to the side-chain amide nitrogen of Asn26 increases the
conformational stability of the PEGylated WW variant WNp by -0.58 ± 0.06 kcal/mol relative its
non-PEGylated counterpart WN (Figure 2A).28 Analysis of solvent radial gradient distribution
functions derived from previous atomistic simulations of WN and WNp in explicit water
suggested that fewer water molecules surround Trp11 in PEGylated WNp than in non-PEGylated
WN (Figure 2A).28
We wondered whether the observed stabilization of WNp relative to WN might reflect
strengthening of the NH-π interaction between Asn26 and Trp11 due to localized PEG-based
desolvation. If so, we might expect to extent of PEG-based stabilization to depend on the strength
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Figure 2. (A) Structure of PEGylated Asn26 in variant WNp along with PEG-based stabilization of WNp relative to
its non-PEGylated counterpart WN. Also shown is the simulated radial distribution function of water around Trp11 in
WNp (red line) vs. WN (black line) along with an inset histogram of the number of water molecules within 3 Å of
Trp11 in each variant. Adapted with permission from reference 28. Copyright  2014 American Chemical Society.
(B) Relationship between the Tm of WW variants FN, YN, WN, and ZN or the calculated NH-π interaction energies
for complexes of formamide and benzene, phenol, indole, and naphthalene and the PEG-based stabilization (ΔΔG) of
FNp, YNp, WNp, and ZNp relative to their non-PEGylated counterparts. Solid green lines represent fits of these
relationships via linear least-squares regression, with the R2, F statistic, and p values shown. Horizonal dotted green
lines connect Tm values and NH-π interaction energy values for each variant.

of the NH-π interaction. To explore this possibility, we prepared PEGylated variants YNp, FNp,
and ZNp, in which a four-unit Asn-linked PEG occupies position 26, whereas Tyr, Phe, and Nap
occupy position 11, respectively (Table 1). PEGylation stabilizes variants YNp, FNp, and ZNp
relative to their non-PEGylated counterparts by -0.47 ± 0.05, -0.34 ± 0.02, and -0.62 ± 0.03
kcal/mol, respectively. The observed PEG-based stabilization is reasonably well correlated with
the melting temperatures of variants WN, YN, FN, and ZN and with the NH-π interaction energies
between formamide and indole, phenol, benzene, and naphthalene, respectively (Figure 2B),
suggesting that PEGylation of Asn26 strengthens its NH-π interaction with the arene at position
11.
We wondered what structural features of Trp and Nap vs. Tyr and Phe facilitate the stronger
NH-π interactions in WN and ZN vs. YN and FN and account for larger PEG-based stabilization
in WNp and ZNp vs. YNp and FNp. We used density functional theory (DFT) via the APFD
method41 with the 6-311+G(2d,p) basis set42, 43 to calculate the molar volume and molecular
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Figure 3. Relationship between melting temperatures (Tm; bottom row) of WW variants FN, YN, WN, and ZN or
the PEG-based stabilization (ΔΔG; top row) of FNp, YNp, WNp, and ZNp relative to their non-PEGylated
counterparts with calculated properties of benzene, phenol, indole, and naphthalene, including molar volume (yellow
circles); molecular polarizability (blue circles); the maximum electrostatic potential above the benzene centroid within
each arene (orange circles); and c log P (purple circles); Solid yellow, blue, orange, and purple lines represent fits of
these relationships via linear least-squares regression, with the R2, F statistic, and p values shown. Vertical dotted
yellow, blue, yellow, orange, and purple lines connect Tm and ΔΔG values for each variant. c log P was calculated
using ChemDraw; all other properties were calculated using Gaussian16 (see supporting information for details).

polarizability of indole, naphthalene, phenol, and benzene, along with the maximum electrostatic
potential above the centroid of the benzene ring within each arene (see the supporting information
section for details). We used ChemDraw to calculate the water-octanol partition coefficients (c log
P) for indole, naphthalene, phenol, and benzene. We plotted the melting temperatures of WN, ZN,
YN, and FN and the PEG-based stabilization (ΔΔG) of WNp, ZNp, YNp, and FNp relative to
their non-PEGylated counterparts vs. the calculated molar volume, molecular polarizability,
electrostatic potential, and c log P of indole, naphthalene, phenol, and benzene (Figure 3). We then
assessed the strength of the resulting relationships via least-squares regression. The strongest
correlations are with arene molar volume and molecular polarizability, suggesting that arene size
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and polarizability are stronger determinants of NH-π interaction strength and PEG-based
stabilization than are hydrophobicity or electrostatic potential.

5.3 Conclusion
Here we have shown that an NH-π interaction between Asn26 and Trp11 stabilizes the WW
domain. Calculated interaction energies of formamide with indole, phenol, benzene, or
naphthalene account well for observed changes in the stability of WW variants upon substitution
of Trp11 with Tyr, Phe, or Nap. Arene size and polarizability are the key structural features that
account for the increased strength of the NH-π interactions involving Trp or Nap vs. those
involving Tyr or Phe. PEGylation of Asn26 stabilizes these WW variants relative to their nonPEGylated counterparts in a way that correlates with the melting temperatures of the nonPEGylated variant and with the calculated strength of the NH-π interaction, consistent with the
growing body of evidence that PEGylation can enhance the strength of a noncovalent interaction
(in this case, an NH-π interaction) in the immediate vicinity of the PEGylation site via localized
desolvation of the protein surface. We anticipate that an increasingly detailed understanding of the
impact of PEGylation on protein structure, stability, and noncovalent interactions should facilitate
more efficient design of PEGylated protein drugs with enhanced pharmacokinetic properties that
retain full biological function.
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5.4 Supporting Information
5.4.1 Protein Synthesis, Purification and Characterization: All peptide variants were
synthesized as C-terminal acids by Fmoc-based solid-phase peptide synthesis as described
previously. WN and WNp were synthesized previously.28 Peptides were synthesized on FmocGly-Wang resin (EMD Biosciences). We used standard Fmoc-protected amino acids with acidlabile sidechain protecting groups. We used previously synthesized Asn-PEG (S)-17-((((9Hfluoren-9-yl)methoxy)carbonyl)amino)-15-oxo-2,5,8,11-tetraoxa-14-azaoctadecan-18-oic

acid

and Gln-PEG (S)-18-((((9H-fluoren-9-yl)methoxy)carbonyl)amino)-15-oxo-2,5,8,11-tetraoxa-14azanonadecan-19-oic

acid.44

Other

reagents

included

2-(1H-benzotriazole-1-yl)-1,1,3,3-

tetramethyluronium hexafluorophosphate (HBTU) and N-hydroxybenzotriazole hydrate (HOBt)
from Advanced ChemTech for amino acid activation; 20% piperidine in N,N-dimethylformamide
for removal of the Fmoc protecting group from the N-terminal α-amine; a solution of a solution of
phenol (0.0625 g), water (62.5 μL), thioanisole (62.5 μL), ethanedithiol (31 μL) and
triisopropylsilane (12.5 μL) in trifluoroacetic acid (TFA, 1 mL) for cleaving the protein from resin
and globally removing acid-labile side-chain protecting groups. Proteins were precipitated from
the TFA solution by addition of diethyl ether (~40 mL). Following centrifugation, the ether was
decanted, and the pellet was dissolved in ~4mL 1:1 H2O/MeCN, then flash frozen over dry ice in
acetone and lyophilized to remove volatile impurities. The resulting powder was dissolved in 2mL
1:1 H2O/MeCN and stored at -20°C until purification.
Proteins were purified by preparative reverse-phase high performance liquid chromatography
(HPLC) on a C18 column using a linear gradient of water in acetonitrile with 0.1% v/v TFA.
Fractions containing the desired protein product were pooled, frozen, and lyophilized. Proteins
were identified by electrospray ionization time of flight mass spectrometry (ESI-TOF); expected
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and observed exact masses mass spectra appear in Table S1 and spectra appear in Figures S1-S8.
Protein purity was assessed by Analytical HPLC (Figures S9–S16).
Table S3. Sequences, molecular formulas, expected and observed m/z rations for WW variants.

---

Expected
[M+z∙H]/z
---

Observed
[M+z∙H]/z
---

---

---

---

H2N-•••••W••••••••••••••Q•••••••••••••-OH

4

1000.0072

1000.0073

H2N-•••••W••••••••••••••Q•••••••••••••-OH

4

1047.5373

1047.5378

H2N-•••••F••••••••••••••N•••••••••••••-OH

4

986.7506

986.7407

H2N-•••••F••••••••••••••N•••••••••••••-OH

4

1034.2807

1034.2799

H2N-•••••Y••••••••••••••N•••••••••••••-OH

4

990.7493

990.7441

H2N-•••••Y••••••••••••••N•••••••••••••-OH

4

1038.2794

1038.2756

H2N-•••••Z••••••••••••••N•••••••••••••-OH

4

999.2545

999.2413

H2N-•••••Z••••••••••••••N•••••••••••••-OH

4

1046.7846

1046.7776

Variant

Sequence

z

WN

H2N-KLPPGWEKRMSRSSGRVYYFNHITNASQFERPSG-OH

WNp
WQ
WQp
FN
FNp
YN
YNp
ZN
ZNp

H2N-•••••W••••••••••••••N•••••••••••••-OH

Figure S87. ESI-TOF MS data for WQ (DA1013#2). Expected (M+4H+)/4 = 1000.0072.
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Figure S88. ESI-TOF MS data for WQp (DA1013#1). Expected (M+4H+)/4 = 1047.5373.

Figure S89. ESI-TOF MS data for FN (SE1025). Expected (M+4H+)/4 = 986.7506.

Figure S90. ESI-TOF MS data for FNp (SE1023). Expected (M+4H+)/4 = 1034.2807.
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Figure S91. ESI-TOF MS data for YN (ND1039). Expected (M+4H+)/4 = 990.7493.

Figure S92. ESI-TOF MS data for YNp (ND1040). Expected (M+4H+)/4 = 1038.2794.

Figure S93. ESI-TOF MS data for ZN (SE10331A). Expected (M+4H+)/4 = 999.2545.
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Figure S94. ESI-TOF MS data for ZNp (SE10332B). Expected (M+4H+)/4 = 1046.7846.

Analytical HPLC data.
Peptide solution was injected onto a C18 analytical column and eluted with a linear
gradient of 10-60% B (A = H2O, 0.1% TFA; B= MeCN, 0.1% TFA) over 50 min; 10-min rinse
(95% B); and 10-min column re-equilibration.

Figure S95. Analytical HPLC data for WQ (DA1013#2).
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Figure S96. Analytical HPLC data for WQp (DA1013#1).

Figure S97. Analytical HPLC data for FN (SE1025).

Figure S98. Analytical HPLC data for FNp (SE1023).
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Figure S99. Analytical HPLC data for YN (ND1039).

Figure S100. Analytical HPLC data for YNp (ND1040).

Figure S101. Analytical HPLC data for ZN (SE10331A).
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Figure S102. Analytical HPLC data for ZNp (SE10332B).

5.4.2 Biophysical characterization of peptide variants: We fit variable temperature CD data
globally to a two-state model for thermally-induced unfolding of monomeric proteins. The
observed molar ellipticity as a function of temperature [θ] is the average of the molar ellipticity of
the folded and unfolded conformations ([θf] and [θu], respectively), weighted by the fraction of
total peptide concentration P that is folded ( f = [F]/P) vs. unfolded (u = [U]/P = 1 – f ):
[𝜃𝜃] = (1– 𝑓𝑓)[𝜃𝜃𝑢𝑢 ] + 𝑓𝑓[𝜃𝜃𝑓𝑓 ]

(S1)

�𝜃𝜃𝑓𝑓 � = 𝑎𝑎 + 𝑏𝑏 ∙ 𝑇𝑇

(S2)

In general, we assume that [θf] and [θu] vary linearly with temperature (equations S2 and S3):

[𝜃𝜃𝑢𝑢 ] = 𝑐𝑐 + 𝑑𝑑 ∙ 𝑇𝑇

[𝜃𝜃] = (1 − 𝑓𝑓)(𝑐𝑐 + 𝑑𝑑 ∙ 𝑇𝑇) + 𝑓𝑓(𝑎𝑎 + 𝑏𝑏 ∙ 𝑇𝑇)

(S3)
(S4)

where a and b are the intercept and slope for [θf], whereas c and d are the intercept and slope for
[θu]. The temperature dependence of fraction folded f is derived from the equilibrium between the
unfolded and folded conformations, with the equilibrium constant K as defined in equation S5:
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[𝐹𝐹]

𝑓𝑓

(S5)

𝐾𝐾 = [𝑈𝑈] = 1−𝑓𝑓
which leads to the alternative expression for f in equation S6:
𝐾𝐾

(S6)

𝑓𝑓 = 1+𝐾𝐾

In turn, K is related to the temperature dependent free energy ΔG, enthalpy ΔH, and entropy ΔS of
folding:
−𝛥𝛥𝐺𝐺

(S7)

𝐾𝐾 = exp � 𝑅𝑅𝑅𝑅 �

(S8)

𝛥𝛥𝛥𝛥 = 𝛥𝛥𝛥𝛥 − 𝑇𝑇𝑇𝑇𝑆𝑆

𝛥𝛥𝛥𝛥 = 𝛥𝛥𝐻𝐻(𝑇𝑇𝑚𝑚) + 𝛥𝛥𝐶𝐶𝑝𝑝 ∙ (𝑇𝑇 − 𝑇𝑇𝑚𝑚 )

(S9)

𝛥𝛥𝛥𝛥 = 𝛥𝛥𝑆𝑆(𝑇𝑇𝑚𝑚) + 𝛥𝛥𝐶𝐶𝑝𝑝 ∙ ln �𝑇𝑇 �

(S10)

𝑇𝑇

𝑚𝑚

where melting temperature Tm is the temperature at which ΔG = 0, K = 1, and f = 0.5. At Tm,
𝛥𝛥𝑆𝑆(𝑇𝑇𝑚𝑚) =

𝛥𝛥𝐻𝐻(𝑇𝑇𝑚𝑚 )

(S11)

𝑇𝑇𝑚𝑚

Therefore,
𝛥𝛥𝛥𝛥 =

𝛥𝛥𝐻𝐻(𝑇𝑇𝑚𝑚 ) (𝑇𝑇−𝑇𝑇𝑚𝑚 )
𝑇𝑇𝑚𝑚

𝑇𝑇

+ 𝛥𝛥𝐶𝐶𝑝𝑝 �𝑇𝑇 − 𝑇𝑇𝑚𝑚 − 𝑇𝑇 ∙ 𝑙𝑙𝑙𝑙 �𝑇𝑇 ��
𝑚𝑚

(S12)

We fit our variable temperature CD data globally using equations S4, S6, S7 and S12, with the
parameters and standard errors shown in Figures S17–S26.
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Figure S103. CD data for WN (data from main text reference 28).

Figure S104. CD data for WNp (data from main text reference 28).
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Figure S105. CD data for WQ (DA1013#2).

Figure S106. CD data for WQp (DA1013#1).
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Figure S107. CD data for FN (SE1025).

Figure S108. CD data for FNp (SE1023).
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Figure S109. CD data YN (ND1039).

Figure S110. CD data for YNp (ND1040).
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Figure S111. CD data for ZN (SE10331A).

Figure S112. CD data for ZNp (SE10332B).
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5.4.3 Computations: We optimized the structures of formamide, benzene, phenol, indole, and
naphthalene, and the formamide-benzene complex via DFT calculations via the APFD method41
with the 6-311+G(2d,p) basis set,42, 43 followed by frequency calculations to determine molar
volume, molecular polarizability, and electrostatic potential at regular intervals above the centroid
of the benzene ring within each arene. Attempts to optimize formamide-phenol or formamideindole complexes led to hydrogen-bound complexes (involving the phenolic OH or indole NH
groups, respectively) that did not have NH-π geometry. Accepting that the NH-π geometry may
not represent the global minimum for these complexes, we fixed the location of formamide above
the phenol, indole, and naphthalene rings with geometry derived from the optimized formamidebenzene complex. We used MP2 calculations31 in Gaussian1632 (with the aug-cc-pVDZ basis set,
implicit33 water,34 and counterpoise correction for basis set superposition error)35, 36 to calculate
the complexation energies of the resulting formamide-benzene, formamide-phenol, formamideindole, and formamide-naphthalene complexes.
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6 CONCLUSIONS
In Chapter 2 of this work, we concluded that PEG-based increases in conformational stability
are dependent on both the position of conjugation and the amino acid chosen to conjugate PEG to.
We found that Gln and Aha PEGylation followed similar trends to Asn PEGylation, though they
both had decreases in their stabilization compared to Asn PEGylation. PrF PEGylation stabilized
two positions that none of the other conjugation strategies stabilized, suggesting that most
positions could be stabilized by PEG if the amino acid conjugation strategy were optimized.
In chapters 3, 4 and 5 we found that PEG can stabilize noncovalent interactions. In chapter 3
we found that PEG can stabilize proximal salt bridges, though the precise structural prerequisites
remain unclear. We concluded from the crystal structures of some of our peptide variants that PEG
occupies the space between the PEGylation site and the salt bridge residues, displacing the water
that would be there in solution. In chapter 4 we found that PEG can stabilize surface exposed
hydrophobic patches. The degree to which these are stabilized is depended on the hydrophobicity
of the residues in the hydrophobic patch. In chapter 5 we demonstrated that PEGylation of an
asparagine residue participating in an NH-π hydrogen bond increases the strength of the
interaction.
In Chapter 2 we explored the general trends of PEGylation, whereas in Chapters 3, 4 and 5 we
looked at how PEGylation affect specific interactions. It seems likely, from the results in Chapters
3, 4 and 5, that PEG-based conformational stability varies based on position and linker because
these combinations desolvate different nearby amino acid residues and noncovalent intersctions.
His27 in the WW domain is near the salt bridge between E12 and R14. PrF-PEG at is
conformationally stabilizing at both positions 23 and 27. It is likely—because of their proximity
to the interaction—that they are both stabilizing the E12 and R14 salt bridge. Similar conclusion
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can be made for other stabilizing PEGylation sites by examining the crystal structure of the WW
domain, but all are speculation without experimental data. It might be interesting to look into what
other interactions PEG stabilizes in the WW domain in attempt to explain the differences in
conformational stability between conjugation sites.
It would be interesting to explore the effect of the amino acid linker on the PEG-based
stabilization of noncovalent interactions. We know that PrF-PEG and Asn-PEG can stabilize salt
bridges, but we only used PrF-PEG to stabilize nonpolar interactions and Asn-PEG to stabilize
NH-π hydrogen bonds. It is possible that different amino acid linkers will be optimal for specific
interactions in various structural contexts. It would also be interesting to see how PEG branching
affects noncovalent interactions.
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